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Background   
Despite emerging evidence indicating the potential importance of early-life exposures for 
adult cancer risk, there is limited research investigating cancer risk factors in early-life.  
The goals of this dissertation are to 1) elucidate whether maternal adiposity influences 
epigenetic processes in the offspring relevant to obesity and carcinogenesis and 2) inform 
primary cancer prevention strategies by addressing two modifiable, early-life risk factors: 
human papillomavirus (HPV) in males and unhealthy diet in postpartum teens. 
 
Methods  
Study 1: We evaluated the association of maternal pre-pregnancy body mass index (BMI) 
and gestational weight gain (GWG) with umbilical cord blood DNA methylation in a 
prospective study of 112 black and white mothers and infants, enrolled in Baltimore, MD, 
2006-2007.  Study 2: We identified predictors of HPV vaccination using electronic 
medical record data from 14,688 males aged 11-26 years in Maryland, 2012-2013.  Study 
3: We examined associations of perceived school and home food environments with 
dietary behaviors using baseline data from 853 postpartum teens enrolled in a weight-loss 
intervention study across 27 states, 2007-2009.  Questionnaire items measuring perceived 







Study 1: Maternal pre-pregnancy BMI and GWG were significantly associated with DNA 
methylation in several CpG sites within 17 candidate genes.  A majority of these 
associations were sex-specific.  
Study 2: Approximately 15% of males initiated the HPV vaccine.  Non-Hispanic black 
males (vs. non-Hispanic white) and publicly insured males (vs. private), were more likely 
to initiate the HPV vaccine, but less likely to receive subsequent doses.  Frequent clinic 
visits (>3) were associated with increased uptake of all three doses. 
Study 3: A positive school environment was related to healthful eating behaviors such as 
fruit consumption.  In contrast, a positive home environment was associated with 
frequent consumption of a wider variety of healthful items as well as infrequent 
consumption of unhealthful food and beverages.  
 
Conclusion 
Early-life is an important, yet understudied period with respect to cancer risk.  A better 
understanding of early-life factors from both an etiologic and primary prevention 
perspective will help to inform interventions that may substantially impact current cancer 
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Current evidence suggests that more than 50% of the approximately 1.6 million 
incident cancer cases diagnosed annually in the United States (U.S) can be attributed to a 
small number of key preventable and modifiable risk factors1.  As shown in Table 1-1, 
these include tobacco use, risk factors related to energy balance such as obesity, poor 
diet, and physical inactivity2,3, alcohol, and exposure to infectious agents, such as the 
human papillomavirus4.   
Table 1-1.  The Most Common Modifiable Causes of Cancer in the United Statesa 




Tobacco Use Lung, mouth, larynx, pharynx, 
esophagus, stomach, 
colon/rectum, pancreas, kidney, 
bladder, cervix, ovary, myeloid 
leukemia 
 
18% of adults and 16% of 





colon/rectum, kidney, pancreas, 
esophagus, gallbladder, ovary, 
thyroid, possibly prostate 
 
Nearly 66% of U.S. adults 
and 33% of teens are 
overweight or obese  
20 
Poor Diet Breast, colon/rectum, possibly 
pancreas 
70% of adults and >75% of 







Breast, endometrium, colon 50% of adults and 75% of 





Alcohol  Oral cavity, pharynx, larynx, 
esophagus, liver, colon/rectum, 
and breast 
 
5% of adults are heavy 
drinkers (≥2 per day for men, 





Cervix, Oropharynx (base of 
tongue, tonsil, larynx), Vulva, 
Vagina, Penis 
69% of females and 58% of 
males received all 3 doses of 
HPV vaccine 
5 




Figures1, bAdapted from Colditz et al., 20125 
 
In 1998, the American Cancer Society (ACS) set a goal to reduce cancer 
incidence by 25% by the year 20156.  Based on trends estimated in a midpoint assessment 
in 2009, U.S. cancer incidence rates were projected to fall 50% short of the ACS 
objective7.  The most recent Annual Report to the Nation on the Status of Cancer shows 
cancer mortality rates have declined 1.8 percent per year among men and 1.4 percent per 
year among women from 2002 to 20118.  This decline can be attributed to several 
successful interventions, most notably, decreased smoking prevalence, as well as 
increased screening and early detection and decreased use of prostate specific antigen 
testing for prostate cancer screening9.  While these data are encouraging, rates for other 
cancers have increased over the past several years; many of which are associated with 
modifiable risk factors, including obesity (endometrium, esophagus, pancreas, liver, and 
thyroid) and infectious agents (liver and HPV-associated oropharyngeal cancer) (Table 1-
2).  Due to population growth and aging, it is projected that the number of people living 
with cancer will double to 2.6 million by the year 205010.   
 
Table 1-2. Estimated Number of New Cancer Cases and Deaths in 2015, Incidence 
Trends from 2007-2011 for Select Cancers 
Cancer Site Estimated Number of New Cases, 2015 
Estimated Number 
of Deaths, 2015 
Trends in Incidence 
Rates, 2007-2011 
Breast (Invasive) 231,840 40,730 Stable in white women; 
increase of 0.3% per 
year in black women  
 






Colon and Rectum 132,700 49,700 Decline of 4.5% per 
year in adults ≥50 
years; increase of 1.8% 
per year in adults < 50 
years  
 
Endometrium 54,870 10,170 Increase of 2.4% per 
year 
 
Kidney 61,650 14,080 Stable after increasing 
over past several years 
 
Liver 35,660 24,550 Increase of 3.4% per 
year 
 
Lung 221,200 158,040 Decline of 3% per year 
in men and 2.2% in 
women 
 
Oropharynx 45,780 8,650 Increase of 1.3% per 
year in white men 
(driven by HPV) and 
stable in white women; 
decline of 3% per year 
in black men and 1.4% 
per year in black 
women 
 
Ovary 21,290 14,180 Decline of 2% per year 
in white women; stable 
in black women 
 
Pancreas 48,960 40,560 Stable after increasing 
over past 10 years 
 
Prostate 220,800 27,540 Stable in men < 65 
years; decline of 2.8% 
per year in men ≥ 65 
years 
 
Thyroid 62,450 1,950 Increase of 4.4% per 
year 
 
Urinary bladder 74,000 16,000 Decline of 1.6% per 
year 
aEstimates adapted from the American Cancer Society’s Cancer Facts & Figures, 20151  
Data Source: The North American Association of Central Cancer Registries and Surveillance, 





The growing trend in incidence and mortality for cancers with known links to 
preventable risk factors underscores the need for new approaches to cancer prevention.  
These strategies must be informed with a greater understanding of cancer etiology and 
how to promote lifestyle behaviors that will achieve the greatest benefit.  To date, 
research in cancer epidemiology has primarily focused on adult populations; yet a 
growing body of evidence suggests exposures in early-life are important for adult cancer 
risk5,11.  This growing body of evidence has important implications for current cancer 
prevention strategies, suggesting a need to shift the focus to risk factors existing in earlier 
stages in the life course11.  There are significant challenges to studying early-life 
exposures including the limited availability, validity, and reliability of early-life exposure 
measurements.  In addition, the long latency periods and lack of intermediate endpoints 
associated with most cancers make it difficult to assess early-life exposures using 
traditional epidemiologic methods, particularly given the limited number of long-term 
biomarkers that have been identified11.  Because of the obvious need for more evidence, 
the National Cancer Institute convened several workshops to review opportunities for 
cancer prevention in early-life, and in 2015, released a Funding Opportunity 





Figure 1-1. Conceptual Framework. Cancer risk factors occur in all stages of 
development, and are typically initiated in early-life.  Similarly, after initiation, cancer 
typically develops over a period of several years, suggesting most of the underlying biology 
occurs earlier in life.  Thus, targeting cancer prevention efforts in early-life, before 
behaviors are fully established, is likely to achieve the greatest benefit.  
 
A life course perspective considers modifiable factors operating during different 
stages of development and the implications for cancer risk later in life12.  The conceptual 
framework for this dissertation is shown in Figure 1-1, which depicts the life course as a 
continuum of cancer risk in the context of the multistage model of carcinogenesis.  The 
underlying biology of the process from initiation to clinical detection typically occurs 




age13,14.  Likewise, several modifiable cancer risk factors are initiated during early-life, 
and become increasingly harder to change as behaviors become established in adulthood.  
By overlaying the two trajectories, it is clear that prevention strategies targeting earlier 
stages in life may achieve the greatest benefit.   
The purpose of this dissertation is to better understand known modifiable early-
life cancer risk factors, from both an etiologic and primary prevention perspective.  Even 
in the absence of cancer outcomes, important gains can be made in informing cancer 
prevention strategies15.  Overcoming the methodological challenges associated with 
studying early-life exposures requires innovative use of existing data.  This research 
leveraged data from three independent studies, each focusing on a modifiable exposure 
during a different critical period of early-life.  The goals were to 1) elucidate how early-
life risk factors, such as maternal obesity and weight gain, influence epigenetic processes 
in offspring relevant to obesity and carcinogenesis (Chapter 2) and 2) generate evidence 
that will inform primary cancer prevention strategies targeting two modifiable, early-life 
risk factors: human papillomavirus in males (Chapter 3) and unhealthy diet in a high-risk 
population of postpartum adolescents (Chapter 4).  
Background 
IN UTERO EXPOSURE TO MATERNAL ADIPOSITY: EPIGENETIC 
MECHANISMS AND IMPLICATIONS FOR CANCER RISK 
 
Obesity is a Modifiable Cancer Risk Factor 
 
It has been estimated that approximately 20% of all cancers are attributed to 




kg/m2, respectively16.  According to the American Institute for Cancer Research and the 
World Cancer Research Fund’s (AICR/WCRF) report, “Food, Nutrition, Physical 
Activity and the Prevention of Cancer: A Global Perspective”, obesity is an established 
risk factor for cancers of the breast (postmenopausal), endometrium, colon and rectum, 
kidney, pancreas, esophagus (adenocarcinoma), and a probable risk factor for cancer of 
the gallbladder17.  Since this publication, there is now convincing evidence supporting an 
association of obesity with risk of liver cancer and aggressive prostate cancer18,19, as well 
as a probable association with increased risk of ovarian cancer, leukemia, non-Hodgkin’s 
lymphoma, and multiple myeloma1.  Obesity also influences cancer progression and 
survival after diagnosis, with greater risk of death likely reflecting both biological effects 
and delays in screening and detection15.  Based on data from a landmark study of over 
900,000 U.S. adults enrolled in the early 1980’s, approximately 15–20% of all cancer 
deaths have been attributed to obesity15.  It is likely that these data now represent 
conservative estimates, as the population prevalence of obesity has nearly doubled since 
198020,21.   
 
Biological Mechanisms Linking Obesity to Cancer Risk 
 
There are several proposed biological mechanisms linking obesity to cancer risk.  
The most well studied involve pathways related to adipokine production, chronic 
inflammation, insulin resistance and signaling, and sex hormone metabolism (Figure 1-
2)22–24.  Adipose tissue is an important endocrine and metabolic organ that regulates 
energy balance and lipid metabolism by releasing free fatty acids (FFAs) and secreting a 




“adipokines”23.  Leptin is a potent hormone involved in appetite regulation and tends to 
be secreted at higher levels in obese individuals23.  Increased leptin levels have been 
associated with immune suppression, promotion of angiogenesis and inhibition of 
apoptosis in cancer cell lines25.  Additional laboratory evidence suggests that leptin 
signals through critical pathways involved in cell proliferation and differentiation (e.g., 
PI3K/Akt, MAPK, JAK/STAT)19.  Adiponectin production on the other hand, tends to be 
lower in obese individuals, and has been shown to have anti-proliferative effects26.  
Support for the protective role of adiponectin in carcinogenesis comes from 
epidemiologic studies showing consistent inverse associations of circulating adiponectin 
with risk of endometrial, breast, prostate, colorectal, renal and pancreatic cancers23.  In 
addition to adipokine regulation, expansion of adipose tissue tends to increase production 
of pro-inflammatory cytokines including tumor necrosis factor alpha (TNFα), 
interleukins IL-1β and IL-6, and the pro-inflammatory transcription factor, NF-κB, 
creating a chronic state of inflammation, which may increase cancer risk23,24 (Figure 1-2).  
In overweight and obese individuals, reduced uptake of fatty acids by adipose 
tissue combined with increased breakdown of lipids (i.e., lipolysis) leads to higher levels 
of circulating FFAs and promotion of insulin resistance and hyperinsulinemia22–24.  
Hyperinsulinemia decreases production of insulin-like growth factor binding proteins 1 
and 2 (IGFBP-1, IGFBP-2, respectively), resulting in higher levels of unbound, 
circulating IGF-127.  Activation of both the insulin and IGF-1 receptors induces signaling 
pathways that promote cell proliferation and inhibit apoptosis, two hallmarks of 






Figure 1-2. Potential Molecular Mechanisms Underlying the Association of Obesity with 
Cancer Risk. Obesity increases circulation of FFA’s, which can lead to insulin resistance and 
hyperinsulinemia.  Hyperinsulinemia decreases concentrations of IGFBP-1 and -2 as well as 
SHBG.  Decreased levels of IGFBP-1 lead to increased IGF-1 levels, which promote cellular 
proliferation and inhibit apoptosis.  Aromatase activity is enhanced in obese individuals. 
Aromatization of testosterone leads to increased levels of freely circulating E2, particularly 
when SHBG concentrations are low. Unbound E2 can bind to nuclear receptors to increase cell 
proliferation and inhibit apoptosis.  Progesterone, which typically counteracts effects of 
estrogen, can be low in obese individuals.  Increased leptin and decreased adiponectin 
concentrations associated with obesity can promote cell proliferation and inhibition of apoptosis.  
Pro-inflammatory cytokine concentrations are also increased, leading to a chronic state of low-
grade inflammation.  Abbreviations: FFAs, free fatty acids, IGFBP-1/2, insulin-like growth 
factor binding protein 1 and 2; IGF-1, insulin-like growth factor-1; SHBG, steroid hormone 
binding globulin; T, testosterone; E2, estradiol; P4, progesterone; IL, interleukin; TNFα, tumor 
necrosis factor alpha; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells 
 
Another consequence of hyperinsulinemia is reduced synthesis of sex-hormone-
binding globulin (SHBG), which binds to sex-steroid hormones, testosterone and 
estradiol22.  As an endocrine organ, adipose tissue expresses aromatase, which converts 
testosterone and Δ4-androstenedione to estradiol and estrone, respectively28,29.  The 
aromatization of androgens increases with obesity and age in both men and women and 




are low as in the case of hyperinsulinemia22,28.  In certain tissues such as breast and 
endometrium, bioavailable estrogen can bind to its receptor and stimulate cellular 
differentiation and proliferation and inhibit apoptosis30,31.  Data from prospective studies 
among postmenopausal women have demonstrated that increased levels of freely 
circulating estrogen largely explain the relationship between obesity and breast and 
endometrial cancer risk23.  Among premenopausal women, the presence of progesterone 
typically acts to counterbalance the proliferative and anti-apoptotic effects of estrogen, in 
part by increasing synthesis of IGFB-132.  However, obesity is associated with 
anovulation and decreased progesterone levels that are not sufficient to counterbalance 
the effects of estrogen31.  This is commonly referred to as the “Unopposed Estrogen 
Hypothesis”, and suggests that loss of progesterone may be the most important hormonal 
risk factor for endometrial cancer in premenopausal obese women22,23,31.    
 
Evidence for Associations of Obesity in Early-Life with Cancer Risk 
 
Nearly one-third of children aged 2-19 years are overweight or obese33.  
Overweight and obesity during childhood and adolescence have been associated with risk 
for certain cancers.  These associations may be direct, as a result of cumulative exposure 
to the physiological consequences of obesity over the life course, or indirect, as early-life 
overweight and obesity increase the risk for obesity in adulthood22.  The most compelling 
evidence supporting a direct link between early-life obesity and development of cancer in 
adulthood comes from numerous prospective studies showing that high BMI in 




later in life34.  The mechanisms underlying this association are not fully understood, but 
have been attributed to a greater frequency of anovulatory cycles in overweight and obese 
females, resulting in lower lifetime estrogen exposure35.  Aside from breast cancer, there 
have been few prospective studies assessing early-life obesity or the effect of cumulative 
obesity exposure across the life course with respect to subsequent cancer risk.  Findings 
from the NIH-AARP Diet and Health Study, a large, prospective cohort study of U.S. 
adults, suggest a significant association of obesity duration and cumulative exposure to 
obesity over a lifetime with pancreatic cancer risk36 and a significant association of 
overweight and obesity across the life course with increased risk of multiple myeloma37.   
Among women enrolled in the Nurses’ Health Study II (NHS II), early-life overweight 
and obesity and weight gain since age 18 were significantly associated with endometrial 
cancer risk later in life38.  Findings from studies on early-life BMI and risk of colorectal 
cancer have been mixed, with some reporting no association39–41 and others finding 
associations of high BMI in adolescence and/or early-adulthood with increased risk of 
colorectal cancer in men42–44 as well as a positive association of weight gain since early-
adulthood with colorectal cancer risk41.  In a series of population-based studies linking 
school health records of over 140,000 children to Danish Cancer Registry data, childhood 
BMI was associated with increased risk of liver cancer, thyroid cancer, and esophageal 
adenocarcinoma in adulthood45–47 while childhood height, but not BMI, was associated 
with future prostate cancer risk48,49.  
 





The idea that in utero exposures may increase the risk of disease later in life is 
commonly referred to as the “Developmental Origins of Health and Disease” hypothesis.  
This hypothesis was originally proposed by David Barker in the late 1980’s based on 
evidence linking low birth weight with increased risk of coronary heart disease and 
metabolic syndrome in adulthood50,51.  Barker and colleagues hypothesized that the in 
utero period was a critical window of developmental plasticity during which 
environmental exposures could lead to adaptive responses that permanently alter 
offspring development51.  While the foundation for this hypothesis is largely rooted in 
cardiovascular disease research, subsequent studies have evaluated this hypothesis in the 
context of cancer risk.  Classic, quasi-experimental studies of exposure to severe caloric 
restriction during the Dutch Winter Famine in World War II, have demonstrated an 
association of famine exposure during early gestation with subsequent breast cancer risk 
among female offspring, possibly due to rapid postnatal catch-up growth52,53.  The 
increasing prevalence of obesity among reproductive-aged women as well as children as 
young as 2 years of age21,33, has prompted studies investigating the potential harmful 
effects of maternal overweight and obesity and weight gain on fetal development.  Initial 
sibling studies among Pima Indians, a group with a very high prevalence of obesity and 
diabetes, provided strong evidence for an association of diabetes during pregnancy with 
higher offspring BMI and risk of type 2 diabetes later in life54–56.  Similarly, studies of 
siblings born before and after maternal bariatric surgery, demonstrated an increased risk 
of overweight and obesity among children who were born before surgery compared with 




obesity and gestational diabetes are independent risk factors for increased birthweight 
and body size later in life59–63.  Moreover, high birthweight, although not a perfect marker 
for the in utero environment, has been linked to adiposity later in life and increased risk 
of premenopausal breast cancer and testicular cancer34,64,65.  This cycle of obesity risk has 
important implications for subsequent cancer development, and warrants further 
investigation into the biological mechanisms underlying these associations.  
 
Maternal Metabolism During Pregnancy and the Potential Role of DNA 
Methylation in Fetal Programming 
 
During pregnancy, the maternal metabolism adapts to meet the nutritional needs 
of the growing fetus66.  In normal weight women, maternal fat accumulation primarily 
occurs during early gestation, followed by a switch to lipolysis around the third trimester, 
resulting in high levels of circulating FFAs and glycerol67.  Fatty acid transport to the 
fetus is mediated by the placenta and is maximal in late gestation68,69.  In obese women, 
the shift to lipolysis occurs earlier in gestation, thus increasing the availability of 
circulating triglycerides and FFAs that can be transported to the fetus70  Interestingly, 
maternal triglyceride levels have been shown to be independently associated with infant 
birth weight (Figure 1-3)71,72.  Lipids have the ability to activate cell-signaling pathways 
and to bind to nuclear receptors, suggesting that increased fetal lipid exposure may affect 
gene expression in pathways related to energy storage, oxidation, growth, and 
inflammation66.  Support of this hypothesis comes from a recent study of pregnant 
women with gestational or type 1 diabetes showing selective upregulation of genes 




obesity (but not in women with type 1 diabetes)73.  While the underlying biological 
mechanisms of these associations are still poorly understood, it is likely that epigenetic 
processes, such as DNA methylation, may play a role66.  
 
Figure 1-3. Maternal Metabolism During Pregnancy in Normal Weight and Obese 
Women.  In normal weight women early pregnancy (1st and 2nd trimester) is characterized by 
maternal fat accumulation and lipid storage, followed by a switch to lipolysis and lipid 
breakdown in late pregnancy (3rd trimester), resulting in adequate levels of circulating FFAs 
and glycerol molecules transported to the fetus for normal development.  In obese women, this 
switch to lipolysis happens earlier in pregnancy, resulting in increased delivery of triglycerides 
and FFA’s to the fetus.  Binding of lipids to nuclear receptors can lead to changes in gene 
expression, which are hypothesized to increase the risk of offspring adiposity. Abbreviations: 
FFAs, Free fatty acids 
 
 
DNA methylation is essential for processes involved in human embryonic 




humans, DNA methylation is facilitated by a family of DNA methyltransferase enzymes 
that catalyze the addition of a methyl group to cytosines at the 5' position of a cytosine 
and guanine dinucleotide pair termed “CpG”76.  In human diploid genomes, any specific 
CpG site in a single cell can be either methylated, partially (“hemi”) methylated, or 
unmethylated74.  The quantitative value of methylation at a given CpG site is generally 
represented as the fraction of sites that are methylated, expressed as a proportion or 
percent.  In promoter regions, binding of a methyl group can alter chromatin 
conformation and transcriptional binding site affinity, often resulting transcriptional 
silencing.  Methylation of CpG-rich stretches of DNA located in promoter regions of 
genes, termed “CpG Islands,” are essential for regulation of gene expression, while 
disruption of CpG island methylation has been documented in malignant cellular 
transformation76.  Patterns of DNA methylation are established during embryogenesis 
through a highly dynamic process in response to genetic and environmental cues77.  Upon 
fertilization, there is rapid, genome-wide DNA de-methylation, with the exception of 
imprinted genes, such as H19/IGF2, which retain their parent-of-origin marks75.  Prior to 
implantation, methylation patterns are re-established de novo and are typically stable 
throughout life77.  Collectively, this suggests that the in utero period may be a critical 
window for epigenetic programming via DNA methylation, with potential long-term 
consequences for gene expression. 
A critical step in demonstrating a role for DNA methylation as a mediator of adult 
disease is establishing an association between a prenatal exposure of interest and changes 




first step by demonstrating that prenatal conditions, such as maternal stress79, tobacco 
smoking80–82, and arsenic exposure83–85 can influence methylation patterns in cord blood 
DNA.  A growing body of evidence from both animal and human studies have provided 
meaningful insights into the role of DNA methylation in mediating the association of 
maternal nutrition with future offspring risk of obesity later in life77,86–88.  Classic, quasi-
experimental studies of exposure to severe caloric restriction during the Dutch Winter 
Famine have demonstrated an association with differences in DNA methylation in genes 
involved in growth and metabolism including IGF2, interleukin-10  (IL-10) and leptin, up 
to six decades after exposure89–91.  In a study conducted in rural Gambia, where 
nutritional status varies dramatically by season of conception, average birth weight 
among offspring conceived during the nutritionally challenged rainy season was 200–300 
grams lower than the birth weight of offspring conceived during the dry (harvest) 
season92.  In subsequent studies, season of conception was related to persistent 
differences in offspring DNA methylation patterns, evidenced in tissue from all three 
germ layers87,88.  More recent data from both animal and human studies exploring the 
effects of gestational exposure to maternal obesity and excess gestational weight gain 
(GWG) support the role of DNA methylation in the regulation of key genes involved in 
adipogenesis, inflammation, growth and signaling87,88,93–97.  In a very recent study of over 
1,000 participants, offspring born to obese mothers had differential methylation patterns 
in several CpG sites compared with offspring born to normal weight mothers.  Using 
paternal obesity as a negative control, the investigators also demonstrated a maternal-




associations were related to intrauterine mechanisms.  Interestingly, DNA methylation 
patterns associated with maternal obesity exposure tended to correlate with offspring 
adiposity, providing evidence for DNA methylation as potential mediator of the 
association of maternal obesity with offspring adiposity later in life95.   
 
 
HUMAN PAPILLOMAVIRUS VACCINATION IN MALES 
 
Infection with Carcinogenic HPV is a Modifiable Risk Factor for Cancer 
 
Infection with HPV is extremely common.  In the U.S., approximately 80 million 
people are infected with at least one HPV type, and among individuals with at least one 
opposite sex partner the lifetime probability of acquiring an HPV infection is 
approximately 85% for females and 91% for males98.  HPV infections are generally 
transmitted through sexual contact, or in some cases, through other intimate contact (e.g., 
oral-genital)99–101.  Persistent infection with one of the 13 carcinogenic HPV types is 
causally associated with nearly all cases of cervical cancer, and a substantial proportion 
of anal, oropharyngeal, vaginal, vulvar, and penile cancers4,102.  Of these 13 types, 
HPV16 is the most carcinogenic due to the activity of two oncogenes, E6 and E7, which 
interfere with tumor suppressor proteins p53 and pRb, respectively102.  HPV16 causes 
nearly all cases of cervical cancer and is responsible for a substantial proportion of other 
HPV-associated cancers in the anogenital tract and oropharynx.  HPV18 is the second 
leading carcinogenic type, and is most commonly associated with cervical 
adenocarcinomas.  Together HPV16 and HPV18 cause approximately 70% of all cervical 





Genital HPV Infection and Carcinogenesis 
 
Most of the evidence regarding HPV natural history comes from studies of 
cervical infection.  Genital HPV infections are commonly transmitted by sexual contact, 
and the likelihood of acquiring an HPV infection is highest within a few years of 
becoming sexually active.  Prevalence estimates calculated before vaccine introduction 
from National Health and Nutritional Examination Surveys (NHANES, 2003-2006) data 
suggested an overall HPV prevalence of about 42.5% among U.S. females aged 15 to 59 
years.  These estimates varied by age group, with prevalence significantly increasing 
from 32.9% in females aged 14 to 19 years to a peak prevalence of 53.8% in females 
aged 20 to 24, with subsequent declines to about 38.8% in females aged 50-59 years104.  
Regardless of the age of acquisition however, most genital HPV infections clear within 
one to two years after exposure; with the rate of clearance decreasing the longer HPV 
persists102.  For the 5-10% of carcinogenic HPV infections that persist more than two 
years, the risk of cervical precancer (i.e., cervical intraepithelial neoplasia grade 3, CIN3) 
is substantially increased105–107.  The time course for progression to CIN3 is relatively 
short, with peak incidence occurring 5 to 15 years after infection, as opposed to most 
cancers which occur over subsequent decades102.  Risk factors for progression to CIN3 
include smoking, long-term oral contraceptive use, and multiparity108–110.  Factors that 
influence the immune system, such as chronic inflammation and co-infection with HIV, 
are also associated with HPV persistence and progression to CIN3111,112.  In the U.S., 




to 65 years of age.  To lengthen screening intervals, females aged 30 to 65 years may be 
screened with a combination of cytology and HPV testing every five years113. 
Incidence rates of HPV-associated vaginal and vulvar cancers are much lower 
than those observed for cervical cancer.  In the U.S., HPV has been associated with 
approximately 69% of invasive vulvar cancers and 97% of vulvar intraepithelial 
neoplasia (VIN) grade 3, with HPV16 accounting for approximately half of vulvar 
cancers and 81% of VIN3114.  Limited data on vaginal cancers suggest HPV is associated 
with approximately 75% of all invasive cancers and approximately 90% of vaginal 
intraepithelial neoplasia (VaIN) grade 2/3, with HPV16 accounting for more than 50% of 
invasive cancers115,116.  Unlike cervical cancer, most cases of vaginal cancers occur in 
women over age 60 years116.   
Penile cancer is very rare and most commonly occurs in men aged 50 to 70 years.  
In the U.S., HPV has been associated with approximately 50% of penile cancers, with 
HPV16 accounting for approximately 45% of HPV-associated cases117.  Risk factors for 
HPV-associated penile cancer include smoking and being uncircumcised4.   
 
Anal HPV Infection and Carcinogenesis 
 
Data on the natural history of anal HPV infection is limited, particularly among 
women.  The few studies conducted among women have shown comparable prevalence 
estimates for both cervical and anal HPV infection.  In a recent study of over 2,000 
women enrolled in the Costa Rican Vaccine Trial, the prevalence of anal HPV infection 
was 32%, similar to the prevalence of cervical HPV infection in this population (37%)118.   




positive men who have sex with men (MSM).  Limited data from heterosexual males 
without HIV infection, suggest an anal HPV prevalence of approximately 12%.  In 
contrast, a pooled meta-analysis of 53 studies estimated a prevalence of anal infection 
with any HPV type to be approximately 93% among HIV-positive MSM and nearly 64% 
in HIV-negative MSM119.  Similar to cervical histopathology, anal intraepithelial 
neoplasia (AIN) grade 2/3 is the precursor lesion of anal cancer4.  In the U.S. the 
prevalence of HPV infection is 91% in anal cancers, with a majority (77%) positive for 
HPV16120.  In one of the largest studies involving 34,189 HIV-positive and 114,260 HIV-
negative participants, the incidence of anal cancer was 131 per 100,000 person-years 
among MSM compared with 46 per 100,000 person years among HIV-positive men, and 
2 per 100,000 person-years among HIV-negative men121.  Screening for anal cancer is not 
currently recommended in the U.S., although some clinics perform anal cytology in high-
risk patients such as HIV-infected and uninfected MSM.  Rates of AIN3 and invasive 
anal cancer have been increasing at a steady rate in almost all racial and ethnic groups 
and particularly among men (see Figure 1-4 below)122,123. 
 
Oral HPV Infection and Carcinogenesis 
 
The prevalence of oral HPV infection is substantially lower than that of cervical 
HPV infection.  Estimates from the most recent NHANES data (2009-2012) indicate a 
prevalence of approximately 7% in men and 1.5% in women aged 14-69 years.  The 
prevalence curve of oral HPV infection by age appears to have a bimodal distribution, 
peaking at ages 25–30 years and again at 55–65 years.  Risk factors for oral HPV 




HPV infections at other anatomical sites, the rate of oral HPV acquisition among males 
tends to remain high regardless of age, and infections are less likely to clear as men get 
older125,126.  The prevalence of HPV16 is very high with respect to other HPV types, and 
accounts for over 80% of all oral HPV infections124 and causes more than 85% of HPV 
positive oropharyngeal cancers127.  Limited data on oral HPV natural history suggest 
similar rates of persistence to genital HPV infections, with most infections clearing 
within one year128,129.  Screening for HPV-associated oropharyngeal cancer is not 
currently recommended.  Challenges to implementing a screening program include a lack 
of clinically validated oral HPV DNA-based tests, a lack of known oral HPV-associated 
precursor lesions, and the absence of a non-invasive intervention for reducing incidence 
and mortality130,131.  
 
Trends in HPV-Associated Cancers 
 
In 2012, the Annual Report to the Nation on the Status of Cancer featured data on 
HPV-associated cancer incidence rates and short-term trends.  Based on the most recent 
data available (2009), HPV-associated cancers were estimated to account for 3.3% of all 
cancer cases among females and 2.0% among males122.  Figure 1-4 has been adapted to 
show trends in incidence of select HPV-associated cancers in the U.S. from 2000 to 2009.  
Due in large part to ongoing successful screening programs in the U.S., incidence rates of 
cervical cancer have significantly decreased among women in all racial and ethnic 
groups, with the exception of American Indian/Alaskan Native females, who experienced 




HPV-associated anal cancer have increased for all racial and ethnic groups, with 
significant increases observed among white and black males and females.  Interestingly, 
rates of HPV-associated oropharyngeal cancer were significantly increased among white 
males and females, but significantly decreased among black males122.  In countries like 
the U.S. with ongoing cervical cancer screening programs, the incidence of both anal and 
oropharyngeal cancers are clearly on the rise, with the number of cases projected to 











Primary Prevention of HPV-Associated Cancers 
 
A bivalent (Cervarix, GlaxoSmithKline, Rixensart, Belgium) and quadrivalent 
(Gardasil, Merck and Co, Inc., Whitehouse Station, New Jersey) HPV vaccine were 
originally licensed for the protection against HPV-related disease4.  The Cervarix vaccine 
protects against HPV16 and HPV18 and is licensed for use in females aged 9 to 26 years.  
The Gardasil vaccine protects against types HPV16 and HPV18, plus two low-risk types, 
HPV6 and HPV11, that are responsible for more than 90% of anogenital warts133,134.  
Data from phase III clinical trials suggest both vaccines are highly efficacious against 
HPV16- and HPV18-associated CIN 2/3 (primary endpoints) and persistent infection 
 
 
Figure 1-4. Trends in Incidence of Select HPV-Associated Cancers in the U.S., 2000-2009.  
For classifying HPV-associated cancers, the average annual number of HPV-associated cancers 
was multiplied by the percentage of each cancer type found attributable to HPV based on 
genotyping studies.  For cervical cancers, all squamous cell carcinomas were selected. 
*Statistically significant trend in incidence rate (p<0.05).  Data Source: The National Program 
of Cancer Registries (NPCR) and/or the NCI’s Surveillance, Epidemiology, and End Results 
(SEER) program. Adapted from Jemal et al., 2012119 




with HPV16 and HPV18 (secondary endpoints)135–137.  High efficacy was also observed 
for protection against HPV16 and HPV18 related VIN 2/3 and VaIN 2/3138.  Very 
recently, Merck and Co., Inc released a nonavalent HPV vaccine (Gardasil 9) that 
protects against the four HPV types included in Gardasil, plus five other carcinogenic 
types that cause an additional 20% of HPV-associated cancers (HPV types 31, 33, 45, 52, 
and 58).  In a phase III efficacy trial in approximately 14,000 females aged 16 to 26 
years, efficacy for the prevention of CIN2 or worse associated with HPV types 31, 33, 
45, 52, and 58 was over 95%, and 96% for persistent (6 month) infection with these 
types139.  
One large clinical trial was conducted to assess the efficacy of Gardasil in over 
4,000 males aged 16 to 26 years.  This study found high per-protocol efficacy for 
prevention of HPV6-, HPV11-, HPV16-, and HPV18-associated incident genital warts.  
In a subanalysis restricted to 602 MSM, per-protocol efficacy for prevention of AIN 2/3 
associated with vaccine types was close to 75% and nearly 100% for anogenital warts 
associated with vaccine types.  These findings led to FDA approval of Gardasil for the 
prevention of AIN and anal cancer for both males and females.  
Safety data from both females and males aged 9 to 26 years indicate a larger 
proportion of injection-site adverse events among HPV-vaccinated groups compared with 
placebo groups.  The most common adverse events included swelling, pain, and erythema 
(i.e., redness of the skin).  There were no significant differences in serious adverse events 




The duration of protection for the HPV vaccine has not yet been established, 
though follow-up data from a phase III Gardasil trial conducted in Nordic countries 
suggest sustained antibody titers up to 9 years after vaccination140.  Protection from 
cervical HPV infection by less than three doses of Cervarix was evaluated in two phase 
III trials.  A very recent combined analysis of these data suggest similar protection 
against HPV16 and HPV18 infection for one or two doses of the HPV vaccine compared 
with receiving all three doses in females aged 15 to 25 years141.  Based on these data and 
cost-effectiveness analyses, the World Health Organization’s Strategic Advisory Group 
of Experts on Immunization now recommends two doses of the HPV vaccine for females 
aged 9 to 14 years142.  Following these recommendations, several countries have switched 
to two-dose regimens (at 0 and 6 months), including Switzerland, the Netherlands, 
Mexico, the United Kingdom, and parts of Canada (Quebec)143.   
Due in large part to the limited data on oral HPV natural history and the lack of a 
precursor lesion associated with oral HPV infection, vaccine efficacy against oral HPV 
and related disease is unknown.  Recognizing this limitation, the WHO recently 
recommended that incident and persistent HPV infections could be used as surrogate 
endpoints for risk of HPV-positive oropharyngeal cancers in HPV vaccine trials124.  
Recent data from the Costa Rican Vaccine trial demonstrate high vaccine efficacy against 
oral HPV16144–146, and in a recent analysis, vaccine efficacy for multisite infections was 
observed in females who had been previously exposed to HPV16/HPV18144.  These data 
have important implications for future vaccine efficacy trials for the prevention of HPV-





HPV Vaccine Recommendations in the U.S. 
 
Gardasil was first licensed for females in 2006 and was recommended by the 
Advisory Committee on Immunization Practices (ACIP) for routine use in females aged 
11 to 12 years with catch-up vaccination for females aged 13 to 26 years who had not 
been previously vaccinated4.  Cervarix was subsequently approved in 2009 and both 
vaccines are now recommended by ACIP for use in females.  Gardasil was licensed for 
males in 2009 and subsequently recommended by ACIP in 2011 for routine use in males 
aged 11 or 12 years with catch-up vaccination for males aged 13 to 21 years who had not 
been previously vaccinated.  Males aged 22 to 26 years may also be vaccinated and HPV 
vaccination is recommended for MSM up to 26 years of age, including those who are 
HIV-positive4.  In 2014, Gardasil 9 was licensed by the FDA for both females and males, 
and approved for routine use by ACIP in 2015147.  Each of these vaccines is administered 
as a 3-dose series, with the second and third doses administered at two and six months 
after the first dose, respectively4.  Vaccinating children at age 11 or 12, prior to sexual 
debut, ensures maximum benefit for prevention of HPV-associated disease.  
The HPV vaccine is most commonly administered by primary care providers or 
by health clinics and should be administered at the same visit as other age-appropriate 
vaccines such as tetanus, diphtheria, and pertussis (i.e., Tdap) and meningococcal 
conjugate vaccines.  The Vaccines for Children Program (VFC) provides access to the 
HPV vaccine for Medicaid and underinsured children less than 18 years of age.  Under 




to cover the HPV vaccine at no cost to patients up to 18 years of age148.  Three 
jurisdictions currently require HPV vaccines for school attendance, including Rhode 
Island, Virginia, and Washington D.C.  In 2007, lawmakers in the state of Maryland 
attempted to pass legislation that would require all girls entering the sixth grade to be 
vaccinated effective in 2008; however this bill was withdrawn and has not since been 
reintroduced149.  
 
Barriers to HPV Vaccine Uptake  
 
While the vaccine offers considerable promise for protection against HPV-
associated cancers, uptake has been suboptimal in the U.S, with only 39.7% of females 
and 21.6% of males receiving all three doses in 2014150.  These estimates fall short of the 
Healthy People 2020 goal, which targets 80% coverage for females, and recently 
extended this goal to include 80% coverage for males151.  Barriers to HPV vaccination 
among U.S. adolescents were recently summarized in a systematic review152.  A majority 
of studies included in this review focused on vaccine initiation, and were conducted 
among females.  Most studies regarding males were conducted prior to the ACIP 
recommendation in 2011.  Findings from this review suggest that among parents and 
caregivers, the most important barriers to HPV vaccine initiation included not receiving a 
recommendation from a healthcare provider, lack of information/knowledge, concerns 
about side effects, and a perception that their child was too young to get vaccinated for 
HPV.  Among healthcare providers, the most important barriers to HPV vaccine initiation 
were parents’ attitudes and concerns, financial concerns including inadequate insurance 




preference for vaccinating girls vs. boys152.  Additional barriers cited for vaccine 
completion included lack of insurance coverage, lack of a regular “medical home”, and 
infrequent contact with the healthcare system152.  Important disparities have also been 
observed with respect to HPV vaccination.  Among underserved and minority 
populations, the available data in both males and females suggest that African Americans 
and Hispanics as well as those living below the poverty line, are more likely to initiate 
the vaccine, but less likely to complete the three dose series150,152.  In one large study of 
MSM aged 18 to 26 years, a group at high risk for HPV infection and related disease, 
vaccine uptake in 2011 was only 4.9%.  Predictors of HPV vaccination in this study 
included visiting a healthcare provider in the past year, disclosure of MSM status, being 
HIV-positive, and receipt of the hepatitis vaccine.  Of the 3,000 males who were 
unvaccinated, 76% had visited a healthcare provider within the past year153.   
 
Efforts to Increase HPV Vaccine Uptake  
 
In 2012, the President’s Cancer Panel declared increasing HPV vaccine coverage  
an urgent national priority and defined three critical goals that must be achieved in order 
to increase uptake, including 1) reduce missed clinical opportunities, 2) increase 
acceptance of HPV vaccines, and 3) maximize access to HPV vaccination services154.  In 
the state of Maryland, the Health Department recently launched a coordinated effort to 
increase the percent of Maryland children that are fully vaccinated against HPV155.  
Studies have shown that the most successful strategies for improving vaccine uptake 




campaigns, patient/provider reminder systems, clinician education sessions and 
assessments, practice-level interventions to educate staff, and educating parents about the 
importance of HPV vaccination for their children150. 
 
ENVIRONMENTAL INFLUENCES OF UNHEALTHY DIET IN HIGH RISK 
ADOLESCENTS 
 
Diet is a Modifiable Risk Factor for Cancer  
 
Diet is believed to play an important, yet not fully understood role in cancer risk.  
The lack of definitive evidence is largely due to the methodological challenges associated 
with measuring dietary exposures in epidemiologic studies.  For example, a majority of 
observational studies typically rely on self-reported dietary intakes from tools such as the 
Food Frequency Questionnaire (FFQ), which measures average daily intakes of foods and 
nutrients over the past several months156.  Data collected from the FFQ and other self-
report dietary assessments are often subject to measurement error due to the inherent 
difficulty in recalling average dietary intakes over a long period of time, and in 
estimating consumption patterns and portion sizes.  Retrospective assessment of diet in 
case control studies has been shown to introduce bias in the association of dietary factors 
with cancer risk157,158.  Prospective studies of diet and cancer risk tend to mitigate this 
bias and have been more successful in providing valid associations, particularly when 
statistical methods such as regression calibration and error correction techniques are 
applied156.  Despite these challenges, the body of scientific evidence has yielded some 




quality and cancer risk, dietary recommendations from agencies such as the 
AICR/WCRF, ACS, and International Agency for Research on Cancer (IARC), 
emphasize high intake of fruit, vegetables, and unprocessed whole grains, and low intake 
of red and processed meats, and alcohol.  Dietary guidelines for obesity prevention also 
have relevance to cancer risk, and emphasize low intake of energy-dense foods, refined 
sugars, and sugar sweetened beverages159.  In 2007 the AICR/WCRF published a report 
titled, “Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global 
Perspective”, based on a thorough review of the existing literature on diet, physical 
activity and cancer by an international panel of experts17.  Since the publication of this 
report, evidence is kept up to date through the Continuous Update Project, which is an 
ongoing review that synthesizes new research as studies are published160.  The project 
collects evidence from randomized controlled trials and cohort studies for 17 cancer 
types.  Probable and convincing evidence relating dietary exposures to selected cancers 
from this project are summarized below, with particular focus on dietary exposures that 
are common in the U.S. 
 
Dairy Intake 
The 2007 AICR/WCRF report suggested a probable association of milk and 
calcium intake with decreased risk of colorectal cancer17.  Since the publication of this 
report, a meta-analysis including data from six additional studies investigating milk and 
ten additional studies investigating dietary calcium was published in 2012161.  The 




cancer risk associated with milk intake that was not statistically significant and a 6% 
decrease in colorectal cancer risk associated with dietary calcium that was statistically 
significant.  These findings support the original conclusions in the 2007 report, and 
suggest milk probably protects against colorectal cancer161.  It is hypothesized that the 
association of milk intake with reduced colorectal cancer risk is mediated by calcium, 
which has demonstrated anti-proliferative effects in colon epithelial cells and is involved 
in processes that promote differentiation of normal cells and apoptosis of transformed 
cells162. 
 
Red and Processed Meat  
The 2007 AICR/WCRF report cites convincing evidence for an association of red 
and processed meat (e.g., bacon, sausage, lunch meat, hot dogs) intake with risk of 
colorectal cancer17.  Since the report, six additional prospective studies have been 
conducted.  Collectively, these data suggest a 16% increased risk of colorectal cancer for 
every 100 grams (g) per day of total red and processed meats161.  Recently, IARC 
released a summary of the evidence on consumption of red and processed meat and 
cancer risk.  More than 800 studies were reviewed, with the majority focused on 
colorectal cancer risk.  For red meat, a total of 14 cohort and 15 high-quality population-
based case-control studies were considered and for processed meat, a total of 18 cohort 
and nine high-quality, population-based case-controls studies were considered.  Based on 
their review of this evidence, IARC classified red meat as a Group 2A carcinogen (i.e., 




“carcinogenic to humans”)163.  The relative risk for colorectal cancer was estimated to be 
about 18% for every 50 g daily serving of processed meat and about 17% for every 100 g 
daily serving of red meat163.  Potential mechanisms underlying this association include 
the high levels of heme, a component of hemoglobin, found in red meat which promotes 
the formation of potentially carcinogenic N-nitroso compounds, the production of 
polycyclic aromatic hydrocarbons and heterocyclic amines when meat is cooked at high 
temperatures, and the elevated levels of nitrates and nitrites added to preserve processed 
meat161,163.  
 
Fruits and Vegetables 
Evidence from the 2007 AICR/WCRF report supports a probable risk reduction 
associated with vegetable and fruit consumption for cancers of the lung, mouth, pharynx, 
larynx, stomach, and esophagus17.  An updated systematic literature review for lung 
cancer was published recently as part of the Continuous Update Project.  This meta-
analysis included an additional 11 studies assessing the relationship of fruit and vegetable 
intake with reduced lung cancer risk164.  Overall, there was a significant association of 
fruit and vegetable intake with a 14% reduction in lung cancer risk.  Relative risk 
reduction estimates ranged from 8% to 18%, depending on the type of vegetable or fruit 
assessed, with the highest risk reduction observed for fruit intake164.  Results from this 
analysis also provided evidence for a modest dose-response relationship of fruit and 
vegetable consumption with reduced lung cancer risk (up to 400 g per day)164.  In 




tended to only remain significant among current smokers164.  With regard to other 
cancers, evidence from the original AICR/WCRF report suggests a probable protective 
association of consumption of non-starchy vegetables, fruit, and dietary carotenoids with 
risk of cancers of the mouth, pharynx, and larynx and a probable protective association of 
consumption of non-starchy vegetables, fruit, foods containing beta-carotene, and foods 
containing vitamin C with cancer of the esophagus17.   With respect to stomach cancer, 
the report suggests a probable protective effect of consumption of non-starchy vegetables, 
allium vegetables (e.g., garlic, onions), and fruit17.  For each cancer type, most studies 
were suggestive of a dose-response relationship; however the majority of those included 
in the review were case-control studies, which limited the certainty of these findings.  
The observed protective effect associated with fruit and vegetable intake is likely due to 
specific nutrients such as carotenoids, polyphenols, and other vitamins and minerals 
found in fruits and vegetables17.  Carotenoids and polyphenols for example, can act as 
potent antioxidants, trapping free radicals produced by oxidative stress and thus 
protecting against DNA damage17.  Vitamin C has antioxidant activity, and may also 
have anti-inflammatory effects.  Allium vegetables, such as garlic, have been shown to 
have antibiotic activity, which may modify the risk of stomach cancers caused by H. 
pylori17.  In addition to the action of specific nutrients, high fruit and vegetable intake 







The 2007 AICR/WCRF report’s conclusion for a protective association of dietary 
fiber intake with colorectal cancer risk was upgraded from probable to convincing after a 
systematic review of 11 additional studies was published in 2011165.  Evidence from this 
review suggested a significant risk reduction of about 10% for each 10 g daily serving of 
dietary fiber.  This review also considered specific dietary sources of fiber and concluded 
a protective effect for cereal fiber and whole grains, but not fiber from fruit, vegetable, or 
legume sources165.  The mechanisms underlying this protective association are not 
completely understood, but likely involve fiber’s ability to reduce stool transit time in the 
gastrointestinal tract and to dilute carcinogens present in stool17,165.  Fermentation of fiber 
by gut flora produces short chain fatty acids, which may have anti-proliferative and 
apoptotic effects in the colon165.  High fiber intake may also indirectly influence 
colorectal cancer risk by protecting against weight gain165.   
 
 
Evidence for Associations of Poor Diet in Early-Life with Cancer Risk 
 
Prospective studies of diet in early-life and cancer risk in adulthood are very 
limited largely due to the methodological challenges previously discussed.  Most studies 
assessing the relationship between childhood and adolescent diet and cancer rely on data 
obtained retrospectively from adults, typically before disease onset166.  Most of the 
research has been conducted in breast cancer, although evidence for other cancers is 
emerging.  With respect to breast cancer, a study conducted among Chinese immigrant 
women demonstrated an association of red meat intake in adolescence, but not adulthood, 




Similarly, findings from an NHS II study revealed a positive association of red meat 
intake during adolescence, but not in adulthood, with premenopausal breast cancer 
risk168,169.  Additionally, among women enrolled in NHS II, consumption of vegetable 
protein at age 14 was associated with lower risk of benign breast disease in early 
adulthood, and poultry intake and replacement of red meat with a diet consisting of 
poultry, fish, legumes and nuts in adolescence was also associated with lower breast 
cancer risk later in life168,170.  In the Growing Up Today Study (GUTS), a prospective 
study of over 9,000 daughters of women enrolled in NHS II, sugar sweetened beverage 
consumption in adolescence (>1.5 servings per day) was associated with earlier age of 
menarche, a risk factor for breast cancer, even after adjusting for total energy intake, 
height and BMI171.  
The relationship between adolescent diet and colorectal cancer risk has also been 
explored in some studies.  In the NHS II for example, recalled adolescent intake of 
poultry and replacement of red meat with either poultry or fish was associated with 
reduced risk of colorectal adenomas in adulthood172.  In the NIH–AARP Diet and Health 
Study cohort, a lower risk of colon cancer was observed for those with higher intakes of 
vegetables and vitamin A during adolescence, but not in adulthood, based on recalled 
adolescent and baseline adult diets173.  This study also found that for certain foods such as 
fruit and nutrients such as calcium, the protective effect was strongest when consumed in 
both adolescence and adulthood.  Similarly, the risk of colorectal cancer was strongest for 
individuals who consumed high amounts of red and processed meat in both adolescence 




course may be important173.  A very recent analysis from the NIH-AARP study 
investigated the association of adolescent and mid-life diet and risk of thyroid cancer.  
Results from this large prospective study suggested greater intake of poultry, tuna 
(among men), sweet baked goods and vitamin C and reduced intake of butter/margarine 
were positively associated with risk of thyroid cancer later in life.  Mid-life diet appeared 
to be less important for risk of thyroid cancer, although broccoli intake in mid-life was 
associated with reduced risk among men174.  
 
Adolescent Diets in Relation to Cancer Prevention Recommendations 
 
Dietary patterns that are established in childhood and adolescence often persist 
into adulthood, and thus have important implications for diet- and obesity-related cancers 
later in life175.  In general, prominent organizations such as the ACS, AICR, and the 
WCRF issue similar dietary guidelines with respect to cancer prevention.  These 
guidelines include increasing consumption of fruits, vegetables, and whole grains, and 
decreasing intake of red and processed meats, as well as high-energy foods with low 
nutritional value, commonly referred to as “empty calories”159,176.  The 2010 U.S. Dietary 
Guidelines, intended for Americans aged 2 years and older, emphasize maintaining 
energy balance so as to sustain a healthy weight and promote consumption of nutrient-
dense foods and beverages.  These guidelines also stress the importance of maintaining 
an appropriate energy balance during each stage of the life course, including childhood, 
adolescence, adulthood, and pregnancy177.  To assess adherence to the U.S. Dietary 




Index (HEI), with the most recent guidelines released in 2010 (HEI-2010)178.  The HEI 
measures diet quality using 12 different dietary components, each associated with a score 
ranging from 0 to 20 (higher scores associated with higher quality), with a total score 
ranging from 0 to 100 representing intake per 1,000 kilocalories178.  A recent study of 
NHANES data used HEI scores as a metric to assess diet quality among over 8,000 
children and adolescents aged 4 to 18 years in the U.S. from 2005 to 2008179–181.  Overall 
diet quality in this study was poor, and fell below U.S. guidelines, which target a total 
HEI score of 80179.  Consistent with the current literature, dietary quality seemed to 
decline from childhood to adolescence: children ages 4 to 8 years had a total HEI score of 
52.1, while children ages 9 to 13 years and 14 to 18 years had a total HEI score of 46.9 
and 43.6, respectively.  In regards to specific foods related to cancer risk, adolescents in 
both age groups were not meeting recommended intakes for fruits, vegetables, and whole 
grains, and were consuming excess calories from refined grains and empty calories 
(Figure 1-5)179.  These results are in line with recent data from the Youth Behavioral Risk 
Factor Surveillance Study, which indicate that only 21.9% and 15.7% of adolescents in 
9th through 12th grade are consuming three or more fruits and vegetables per day, 





Figure 1-5.  Mean Healthy Eating Index Scores for Select Foods Among U.S. Adolescents, 
2005 to 2010.  Select dietary components were chosen based on relevance to cancer prevention 
guidelines.  Healthy Eating Index Scores for each component were calculated by estimating the 
intake per 1,000 kilocalories.  Each component has a maximum score and higher values 
correspond to better adherence to U.S. Dietary Guidelines for Americans.   Data is shown for 
male and female adolescents aged 9 to 13 years and 14 to 18 years, respectively.  Data Source: 
National Health and Nutrition Examination Survey (NHANES) 2005-2006, 2007-2008, and 








Determinants of Unhealthy Diet Among Adolescents 
 
Dietary behaviors among adolescents are influenced by a number of factors 
operating at different levels of influence181.  At the individual level, food preferences, 
taste and appearance of foods are important determinants of what adolescents choose to 
eat.  Additionally, many adolescents prioritize time and convenience over health and 
nutrition when it comes to choosing foods, and report taste, availability, convenience, and 
cost as significant barriers to eating healthy181.  Although children transition to greater 
independence and autonomy in making food decisions as they get older, many aspects of 
the family and home environment are important influences on adolescents’ eating 
behaviors181.  Engaging in a family meal, for example, is associated with healthy dietary 
behaviors, including greater fruit and vegetable consumption, and lower consumption of 
sugar-sweetened beverages and high-fat foods183.  Other factors associated with the home 
environment include parent modeling and parental influence over what foods are 
available and accessible in the home181.  Demographic characteristics, such as 
socioeconomic status, influence food choices among adolescents and their families.  For 
individuals living in poverty, the price of fresh fruits and vegetables compared with low 
cost fast food options creates a significant barrier to healthy eating184.  Packaged foods 
that tend to last longer and cost less are often a major source of refined grains, added 
sugars, and fats.  In underserved, low-income neighborhoods, grocery store options are 
typically very limited; these neighborhoods are instead often populated with convenience 




In addition to the family and home environment, the school environment plays an 
important role in shaping dietary behaviors of adolescents.  Data suggest that adolescents 
consume approximately 35 to 50% of their daily calories at school186.  This is particularly 
true for the more than 30 million children participating in federally assisted meal 
programs in the U.S., such as the National School Lunch Program and the School 
Breakfast Program187.  Schools participating in these programs are required to offer meals 
that adhere to nutrition standards implemented by the USDA.  Emerging evidence 
suggests that these policies are having an impact on the nutritional content of school 
meals and have reduced disparities in healthy food access187.  However, school meal 
programs only represent one aspect of the school food environment.  Schools also offer a 
wide range of foods and beverages outside of school meal programs that tend to be high 
in fat and sugar188.  These foods are typically sold in school cafeterias, vending machines, 
school stores, and during fundraisers and are collectively referred to as “competitive 
foods and beverages” because they displace healthy alternatives188.  As part of the 
Healthy, Hunger-Free Kids Act of 2010, the USDA implemented new “Smart Snacks in 
School” nutrition standards for competitive foods and beverages sold outside of the 
school meals program during the school day189.  These standards limit the amount of 
calories, salt, sugar, and fats in foods and beverages and promote whole grains, low fat 
dairy, fruits, and vegetables as healthy snack choices188.  Emerging evidence suggests 
that these policies may be effective in changing school food environments, but future 
studies are needed to determine the impact on adolescent eating behaviors and the 









Postpartum Adolescents: A Group at High Risk for Unhealthy Diets 
 
Nearly 300,000 adolescents become pregnant each year in the U.S., representing a 
significant, yet understudied population at high risk for obesity and related chronic 
diseases, such as cancer, later in life191.  Indeed, adolescents who become pregnant tend 
to gain excessive weight during pregnancy and retain more weight postpartum compared 
with their adult counterparts192–196.  In a recent study of NHANES data, women aged 20 
to 59 years who gave birth during adolescence were significantly more likely to be 
overweight or obese later in life compared with women who gave birth in adulthood197.  
The burden of teenage pregnancy falls disproportionately on minority and 
socioeconomically disadvantaged populations, underscoring the need for targeted 
interventions among this particularly high-risk group198.  The limited evidence on dietary 
behaviors in this population suggest that postpartum adolescents have diets low in fruits 
and vegetables, and consume excess calories from high-fat, sugary snacks199,200.  Given 
the aforementioned importance of the family, home, and school food environments for 
shaping dietary behaviors among adolescents, interventions that focus on the food 
environment may be a particularly effective strategy for preventing unhealthy diets in 
postpartum adolescents, as they require fewer individual-level resources to be 
effective201.   To date, very little is known about how the environment influences dietary 




high-risk population will be important for informing intervention strategies and 
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Introduction: In utero exposure to maternal obesity has been associated with offspring 
adiposity later in life. This association is hypothesized to involve DNA methylation.  
Using a candidate gene approach, we assessed maternal pre-pregnancy body mass index 
(BMI) and gestational weight gain (GWG) in relation to umbilical cord blood DNA 
methylation.  
 
Methods: We quantified DNA methylation in 112 cord blood leukocyte samples using 
high-throughput, microfluidic PCR and next-generation, bisulfite sequencing.  
Generalized linear models with a binomial distribution were fit to assess associations of 
DNA methylation with pre-pregnancy BMI and GWG.  From the sequencing data, we 
identified patterns of DNA methylation haplotypes and used Fisher’s Exact chi-square 
and logistic regression models with generalized estimating equations to evaluate 
associations of the most common haplotype patterns with pre-pregnancy BMI and GWG.  
All analyses were stratified by infant sex and were adjusted for false discovery rate 
(FDR).  
 
Results: A total of 29 CpG sites within 14 genes were differentially methylated with 
respect to maternal pre-pregnancy BMI (FDR-adjusted p-value ≤0.05).  A total of 30 
CpG sites within 15 genes were differentially methylated with respect to maternal GWG.  
A majority of these associations were sex-specific.  Common methylation haplotype 




overweight/obese mothers were significantly less likely to have H19 methylation 
haplotypes with all CpG sites methylated compared with females born to normal weight 
mothers.  
 
Discussion: Our findings suggest maternal overweight/obesity and excess GWG may 
influence DNA methylation within offspring genes, in a sex-specific manner.  These 







Adverse nutritional exposures in utero have been shown to influence the risk of 
chronic diseases, including certain cancers, later in life51,202.  Although studies have 
historically focused on maternal nutritional deprivation52,86–88,203,204, the rising prevalence 
of obesity among reproductive-aged women over the past several decades has 
necessitated research investigating the influence of maternal overnutrition and adiposity 
on offspring health.  A growing body of evidence suggests that infants born to obese and 
overweight mothers are at increased risk of obesity and metabolic disease later in life, 
both of which are risk factors for certain cancers59–62.  While the underlying biological 
mechanisms of these associations are not well understood, evidence from animal 
models205 and quasi-experimental human studies of prenatal nutritional deprivation89,91 
suggests that epigenetic processes, such as DNA methylation may play an important 
role66.   
DNA methylation is essential for processes involved in human development, such 
as genomic imprinting and X chromosome inactivation74,75, and aberrant DNA 
methylation patterns have been associated with diseases such as cancer206.  In humans, 
DNA methylation most commonly occurs at cytosines at the 5' position of a cytosine and 
guanine dinucleotide pair termed “CpG”.  Clusters of CpG sites in small stretches of 
DNA termed, “CpG islands”, are commonly located in promoter regions of genes76.  
DNA methylation plays a critical role in regulating gene expression by influencing 




regulate transcription74.  Patterns of DNA methylation are established during 
embryogenesis through a highly dynamic process77 and tend to be relatively stable in 
differentiated cells and tissues over time207.  Collectively, this suggests that the in utero 
period may be a critical window for epigenetic programming in response to 
environmental signals, with potential long-term consequences for gene expression.  
Very few studies have investigated the association of maternal adiposity and 
gestational weight gain (GWG) with offspring DNA methylation levels.  Findings thus 
far have been inconsistent, with studies often reporting small differences (~5%) in 
methylation levels at specific CpG sites within different genes, including sites within 
peroxisome proliferator-activated receptor gamma (PPARG), zinc finger, CCH10 domain 
containing 10 (ZCCHC10), matrix metalloproteinase-7 (MMP7) and the retinoic X 
receptor alpha (RXRA)87,89,90,93–97,208,209.  Possible reasons for discrepancies between 
studies include technical differences in the array-based platforms used to quantify DNA 
methylation levels210, potential misclassification of self-reported pre-pregnancy BMI and 
variable adjustment for confounders, and the difficulty in obtaining well-characterized 
samples of cord blood DNA.   
Thus, we evaluated the association between maternal obesity, GWG and DNA 
methylation patterns in previously identified candidate genes in 112 cord blood leukocyte 
samples with clinically-measured maternal and child characteristics.  We prioritized 
genes with known functional roles, particularly those related to obesity and cancer (i.e., 
involved in processes such as apoptosis and cell cycle regulation).  We quantitatively 




platform for target enrichment and gold standard bisulfite sequencing technology211,212.  
This method provides high-resolution CpG methylation information and allows for the 
characterization of methylation patterns of multiple, contiguous CpG sites on single DNA 
molecules (termed “methylation haplotypes”)212.  In addition, we leveraged this 
technology to assess common patterns of DNA methylation haplotypes and evaluate the 
distribution of these haplotype patterns with respect to maternal BMI and GWG 
categories.   
METHODS 
Study Population 
This study consists of black and white neonates who were part of the Hormones in 
Umbilical Cord Blood Extended Study (eHUB), a prospective study of pregnant women 
designed to determine how racial differences in the hormonal and growth factor milieu in 
utero contribute to the racial disparity in prostate and breast cancers.  The eHUB study 
was approved by the Institutional Review Board at the Johns Hopkins Bloomberg School 
of Public Health.  
This prospective cohort study included 185 black and white pregnant women 
enrolled in 2006 – 2007 from a prenatal clinic in Baltimore, MD.  Umbilical cord blood 
samples were collected by the nurse at delivery in EDTA Vacutainer tubes and samples 
were processed within 24 hours and stored at -70oC.  For the current study, inclusion 
criteria for the infants were full term birth (≥37 weeks), no major birth defects, and 
singleton birth.  Cord blood samples were available for 122 eligible infants, and a total of 





Maternal Pre-Pregnancy Body Mass Index and Gestational Weight Gain 
Pre-pregnancy body mass index (BMI) (kg/m2) was calculated using the women’s 
self-reported weight before pregnancy and height at their first questionnaire assessment.  
Self-reported BMI was highly correlated with clinically measured BMI at the first 
prenatal visit (~12 weeks) (Pearson correlation coefficient =0.93; see Appendix Figure 
A5), indicating high accuracy of self-reported weight.  Pre-pregnancy BMI was 
categorized as normal weight (<25.0 kg/m2), overweight (25.0 to <30.0 kg/m2) or obese 
(≥30 kg/m2).  Gestational weight gain (GWG) was calculated as the difference between 
the measured weight at the last obstetrics visit before delivery and the measured weight at 
the first obstetrics visit.  Within the three BMI categories, GWG was categorized 
according to the Institute of Medicine’s (IOM) recommendations213 (i.e., normal: 28-40 
lbs, overweight: 25-35 lbs, and obese: 11-20 lbs) as less than recommended, within 
recommendation, or more than recommended. 
 
Other Variables  
Women were administered a questionnaire at their first visit (~12 weeks) and at 
the postpartum visit, with questions pertaining to demographic characteristics and 
lifestyle behaviors before and during their current pregnancy, respectively.  For this 
study, we categorized education as less than a college degree vs. college or graduate 
degree, and smoking status as never, former, or current.  Additional maternal 




weight at start of pregnancy, weight at each maternity visit and at delivery, and 
pregnancy complications, and infant characteristics including sex and birth weight, were 
abstracted from the medical record.   
 
Candidate Gene Selection  
Candidate genes were chosen based on literature review (Supplementary Table 2-
S1).  We prioritized genes with known functional roles, particularly those related to 
obesity and cancer (i.e., involved in processes such as apoptosis and cell cycle 
regulation).  We selected 20 genes that were previously shown to be associated with 
maternal pre-pregnancy BMI in a recent study of African-American newborns96, 3 genes 
that showed differential methylation patterns in cord blood with respect to body 
composition in childhood93, and 2 genes that were found to be differentially methylated 
with respect to infant birthweight214.  An additional 4 genes were selected based on their 
hypothesized role in fetal programming of adiposity, with supporting evidence from 
animal studies20–23.  When possible, we designed primers to target specific CpG sites 
reported in the literature.  After testing bisulfite primers for 29 candidate genes, we 
selected 48 primer pairs that performed robustly, interrogating a total of 24 genes.  We 
will refer to each CpG site by the last four digits of its genomic position (determined by 
Genome Browser Build 36).  
 




Cord blood leukocyte DNA was isolated and re-purified to remove potential 
residual PCR inhibitors using the DNeasy Blood and Tissue kit (Qiagen).  DNA 
concentrations were determined by Qubit (Thermo Scientific, Wilmington, DE).  Sodium 
bisulfite conversion of 120 ng genomic DNA extracted from cord blood was carried out 
using the EZ DNA Methylation-Gold kit (Zymo, Irvine, CA) according to the 
manufacture’s instruction.   
 
Bisulfite Sequencing  
Targeted sequences for each candidate gene were obtained from the UCSC 
genome browser (https://genome.ucsc.edu).  The target-specific bisulfite sequencing 
primers were manually designed by the laboratory technician (D.E.) and using the online 
tool, Methprimer (http://www.urogene.org/methprimer/), when necessary.  A total of 63 
amplicons were designed for the 29 genes and covered an average of 16 CpG sites per 
amplicon (range 1 to 35) with amplicon sizes of no more than 316 bases.  Universal 
sequencing tags were added to the 5’ end of the forward and reverse primers according to 
the User Guide of the Access Array System for Illumina Sequencing Systems.  All 
primers were ordered from Integrated DNA Technologies (Coralville, IA) and validated 
in conventional bisulfite PCR reactions using JumpStart Taq DNA Polymerase (Sigma 
Aldrich, St. Louis, MO) and human male DNA (EMD, Chicago, IL) that was converted 
with the EZ DNA Methylation-Gold kit.  Each 50 µL reaction contained 60 ng of 
converted DNA, 1X JumpStart Buffer, 200 µM each dNTPs, 1X Access Array Loading 




Polymerase.  Cycling conditions are as follows: 1) 50˚C for 2 minutes; 2) 70˚C for 20 
minutes; 3) 94˚C for 1 minute; 4) 5 cycles of 94˚C for 30 seconds, 57˚C for 30 seconds, 
and 72˚C for 90 seconds, with the annealing temperature decreasing by 1˚C each cycle; 
5) 30 cycles of 94˚C for 30 seconds, 50˚C for 30 seconds, and 72˚C for 90 seconds; 6) 
72˚C for 5 minutes; 7) a 10˚C hold step until further analysis.  Reactions were then run 
out on a 1% agarose gel and visualized using GelStar (Lonza, Walkersville, MD). 
Sequencing libraries were prepared using the microfluidic Access Array system 
(Fluidigm, San Francisco, CA) as has been described elsewhere219.  In brief, following 
bisulfite conversion, cord blood DNA was eluted from the columns in 7 µL water, of 
which 3 µL eluate was amplified on the Access Array as per the manufacturer’s 
instructions.  Cycling conditions were identical to those used for conventional PCR 
validation of the bisulfite primers.  The amplified material was then subjected to a second 
round of PCR, which incorporated barcoded primers to uniquely label each sample 
library.  For this barcoding PCR, 1 µL of microfluidic PCR reaction was amplified in 20 
µL reactions containing 1X NEBNext High-Fidelity PCR Master Mix (NEB, Ipswich, 
MA) and 4 µL Access Array Barcode primers (Fluidigm).  Cycling conditions are as 
follows: 1) 98˚C for 3 minutes; 2) 15 cycles of 98˚C for 30 seconds, 60˚C for 30 seconds, 
and 72˚C for 90 seconds; 3) 72˚C for 5 minutes; 4) a 10˚C hold until further processing. 
Barcoded PCR products were pooled and purified using AMPure magnetic beads.  
The quality of PCR products was assessed using the Agilent Bioanalyzer system to 




Qubit dsDNA HS Assay kit (Life Technologies, CA) and sequenced on the Illumina 
HiSeq 2500 platform using a sequencing-by-synthesis approach. 
Methylation status was determined using a bioinformatics pipeline that included 
demultiplexing based on the unique barcoded sequences.  For each CpG site, the 
methylation ratio was calculated by dividing the number of C reads by the sum of C and 
T reads at each CpG site.  CpG site methylation patterns for each single molecule and 
counts of each pattern were determined for each amplicon, per individual sample.   
 
Quality Control 
A detailed description of the quality control analyses is provided in the Appendix.  
Briefly, we included 11 technical replicate samples for quality control purposes220.  
Concordance correlation coefficient estimates for each pair of replicates were fair to 
good, with an average of approximately 0.70 (range 0.42 – 0.82).  
 
Statistical Methods 
Descriptive statistics were used to determine means and proportions of maternal 
and infant characteristics.  We fit a generalized linear model with a binomial distribution 
and robust variance estimation to determine associations of DNA methylation at each 
CpG site with pre-pregnancy BMI and GWG respectively, adjusting for maternal age, 
parity, maternal smoking status, infant sex, maternal race, and gestational age.  To 
increase statistical power, we collapsed BMI and GWG categories into binary variables, 




and more than recommended (n=63, “excess”) vs. less than recommended or within 
recommended (n=12 and 37, respectively).  We corrected for multiple testing by 
controlling for the false-discovery rate (FDR), the expected proportion of false positive 
findings (0.05), using the Benjamini-Hochberg method221.  Because early exposures have 
been shown to influence DNA methylation patterns differentially by sex, we stratified all 
analyses of significant CpG sites by infant sex. 
From the bisulfite sequencing data we determined methylation haplotypes, 
represented as a combination of the methylation statuses of contiguous CpG sites in a 
single DNA molecule.  For simplicity, we will refer to unmethylated CpG sites as “|” and 
methylated CpG sites as “M”.  For example, a gene with 5 CpG sites that were all 
unmethylated would be represented as “|||||”, whereas if all 5 CpG sites were methylated, 
the haplotype would be represented as “MMMMM”.  We determined the prevalence of 
each unique methylation haplotype by counting the number of times a particular 
haplotype pattern was observed for each gene, for each infant sample.  As an exploratory 
analysis, we assigned each infant the most common haplotype pattern observed for each 
gene, and evaluated the distribution of methylation haplotype patterns by pre-pregnancy 
BMI and GWG.  For genes with an adequate distribution of different haplotype patterns 
across infants, we categorized each infant as having all CpG sites methylated 
(“completely methylated”, e.g., MMMMM), some CpG sites methylated (“partially 
methylated”, e.g., |MM||) or none of the CpG sites methylated (“completely 
unmethylated”, e.g., |||||) for their most common haplotype pattern.  We used Fisher’s 




distribution of the most common haplotype pattern by categories of pre-pregnancy BMI 
and GWG and where appropriate.  We also used logistic regression models with 
generalized estimating equations (GEE) to determine if methylation haplotype categories 
were significantly associated with pre-pregnancy BMI and/or GWG, accounting for 
clustering within infant.  All significant associations were further stratified by infant sex, 
and we tested for statistical interaction using GEE logistic regression models.  All 
analyses were conducted using Stata v.13.1 (StataCorp, College Station, TX). 
RESULTS 
Characteristics of Study Population 
 The characteristics of 112 mothers and infants included in this study are shown in 
Table 2-1.  The mean age of mothers was 29.5 years (range 18 to 40 years) and about 
60% were white.  Approximately 60% of mothers had a normal BMI before pregnancy 
and about 20% were overweight or obese, respectively.  A majority of mothers had a 
college or graduate degree (67%) and were never smokers (63%).  More than 50% of 
mothers gained more weight than recommended during pregnancy according to the IOM 
guidelines. With respect to infant characteristics, 50% were female and mean birth weight 
was approximately 3,411 grams (± 470 grams).  
 
Maternal Pre-Pregnancy BMI and Cord Blood DNA Methylation Levels 
 Maternal pre-pregnancy BMI was significantly associated with cord blood DNA 
methylation levels in 29 CpG sites within 14 candidate genes (FDR adjusted p-value 




associated with decreased DNA methylation levels in 12 CpG sites within 9 genes, 
including Adenylate cyclase 3 (ADCY3, 5895); Anaphase promoting complex subunit 7 
(ANAPC7, 5793, 5833); Butyrophilin, subfamily 3, member A1 (BTN3A1, 0680); 
Calcium binding protein 39 (CAB39, 5747, 5820, 5831); G protein-coupled receptor, 
family C, group 5, member B (GPRC5B, 3915); Insulin-like growth factor 2 (IGF2, 
9059); Proline rich 16 (PRR16, 7885); X-ray repair complementing defective repair in 
Chinese hamster cells 3 (XRCC3, 1137, 1148); Zinc finger with KRAB and SCAN 
domains 5 (ZKSCAN5, 0185).  Maternal pre-pregnancy overweight/obesity (vs. normal 
weight) was associated with increased DNA methylation levels in the remaining 17 CpG 
sites within 11 genes, including ADCY3 (6027), ANAPC7 (5902, 5905), Hes-Related 
Family BHLH Transcription Factor With YRPW Motif-Like (HEYL, 7781); IGF2, 
Insulin Receptor (INSR, 4660); Peroxisome proliferator-activated receptor gamma 
(PPARG, 5208); PRR16 (7848); Suppressor APC domain containing 2 (SAPCD2, 4655, 
4747); XRCC3 (1162, 1326, 1335), Zinc finger, CCHC domain containing 10 
(ZCCHC10, 0150); ZKSCAN5 (0240, 0280).   
 To determine whether the observed DNA methylation differences were sex-
dependent with respect to maternal pre-pregnancy BMI, we stratified our analyses by 
infant sex (Supplementary Table 2-S2).  Only 3 CpG sites remained significantly 
associated with pre-pregnancy BMI in both sexes (FDR adjusted p-value ≤0.05), with 2 
sites showing decreased methylation with respect to pre-pregnancy overweight/obese 
BMI (CAB39 5820, 5831) and 1 site showing increased methylation with respect to pre-




remained significantly associated with maternal pre-pregnancy BMI (FDR adjusted p-
value ≤0.05), with 3 CpG sites showing decreased methylation (CAB39 5747, IGF2 
9059, and PRR16 7885), and 4 CpG sites showing increased methylation with respect to 
maternal overweight/obese pre-pregnancy BMI (INSR 4660, SAPCD2 4747, XRCC3 
1162, and ZCCHC10 0150).  Among males only, 9 CpG sites remained significantly 
associated with maternal pre-pregnancy BMI (FDR adjusted p-value ≤0.05), with a 
majority of sites (n=8) showing increased methylation with respect to maternal 
overweight/obese pre-pregnancy BMI (ADCY3 6027, ANAPC7 5902, IGF2 8982, 
PPARG 5208, SAPCD2 4655, XRCC3 1335, and ZKSCAN5 0240, 0280) and one CpG 
site showing decreased methylation with respect to maternal overweight/obese pre-
pregnancy BMI (ANAPC7 5833).  
 
Maternal Gestational Weight Gain and Cord Blood DNA Methylation Levels 
 Maternal GWG was significantly associated with cord blood DNA methylation 
levels in 30 CpG sites within 15 candidate genes (FDR adjusted p-value ≤0.05) (Table 2-
3).  Excess maternal GWG (more than recommended vs. within/below recommended) 
was associated with decreased DNA methylation levels in 12 CpG sites within 9 genes, 
including ANAPC7 (5833), CAB39 (5693, 5747, 5762, 5780); Docking protein 2 
(DOK2, 7072); GPRC5B (4040); PRR16 (7763); XRCC3 (1162, 1272); ZCCHC10 
(0146); ZKSCAN5 (0157).  Excess maternal GWG (vs. within/below recommended) was 
associated with increased DNA methylation levels in the remaining 18 CpG sites within 




BTN3A1 (0498); CAB39 (5733, 5743, 5863); HEYL (7781); Integrin, alpha E (ITGAE, 
3436); INSR (4466, 4560); PPARG (5246); PRR16 (7721); SAPCD2 (4655, 4708, 
4780); XRCC3 (1242, 1276); ZKSCAN5 (0185).   
 To determine whether the observed DNA methylation differences were sex-
dependent with respect to maternal GWG, we stratified our analyses by infant sex 
(Supplementary Table 2-S3).  No CpG sites remained significantly associated with GWG 
in both sexes.  Among females only, 4 CpG sites remained significantly associated with 
maternal GWG (FDR adjusted p-value ≤0.05), with 2 CpG sites showing decreased 
methylation (GPRC5B 4040 and PRR16 7763), and 2 CpG sites showing increased 
methylation with respect to excess maternal GWG (ANAPC7 5831 and PPARG 5246).  
Among males only, 8 CpG sites remained significantly associated with maternal GWG 
(FDR adjusted p-value ≤0.05), with a majority of sites (n=6) showing increased 
methylation with respect to maternal excess GWG (PXYLP1 2624, CAB39 5733, HEYL 
7781, INSR 4466, 4560, and SAPCD2 4780) and 2 sites showing decreased methylation 
with respect to excess maternal GWG (ANAPC7 5833 and CAB39 5762).  
 
Methylation Haplotypes 
 As an exploratory analysis, we assessed the distribution of methylation haplotypes 
for each gene and assigned each infant the most common haplotype pattern observed for 
each gene.  The unmethylated haplotype (i.e., no methylation at all contiguous CpG sites 
for a given amplicon) was observed as the most common haplotype (≥ 50% of infants) 




amplicons), H19 (4 amplicons), IGF2, INSR, and PLAC1.  For these genes, we 
categorized each infant’s most common haplotype pattern as completely methylated, 
partially methylated, or completely unmethylated.  For H19 (amplicon 3), infants born to 
mothers who were overweight/obese pre-pregnancy were significantly less likely to have 
haplotypes with all CpG sites methylated compared with infants born to mothers who 
were normal weight pre-pregnancy (Fisher’s exact p-value = 0.023; Table 4).  Across all 
H19 amplicons, taking into account clustering by infant and adjusting for maternal age, 
we observed a significant decrease in odds of maternal pre-pregnancy overweight/obesity 
for infants with completely methylated H19 haplotype patterns (GEE OR 0.62; 95% CI 
0.39 – 0.97).  We did not observe any significant associations between common 
haplotype patterns and maternal GWG.  
To determine whether the associations between H19 methylation haplotype 
categories and maternal pre-pregnancy BMI were sex-specific, we stratified our analyses 
by sex and tested for statistical interaction using logistic regression models.  Among 
females, we observed statistically significant associations for H19 (amplicons 1 and 3) 
such that female infants born to mothers who were overweight/obese pre-pregnancy were 
significantly less likely to have haplotypes with all sites methylated compared with 
infants born to mothers who were normal weight pre-pregnancy (Fisher’s exact p-value = 
0.001 and 0.018, respectively).  Among males, methylation haplotype categories were not 
significantly associated with maternal pre-pregnancy BMI.  Across all H19 amplicons, 
taking into account clustering by infant and adjusting for maternal age, we observed a 




categories in H19 such that overweight/obese pre-pregnancy BMI was significantly 
inversely associated with having a haplotype with all sites methylated in females, but not 
in males (p-value for interaction = 0.0162). 
DISCUSSION 
 We studied the methylation levels of CpG sites within 24 candidate genes, using a 
novel next-generation, targeted bisulfite sequencing approach.  Overall we observed 
significant associations of DNA methylation levels with maternal pre-pregnancy BMI 
and with GWG in several CpG sites within 17 candidate genes.  A majority of these CpG 
sites exhibited sex-specific associations.  Differences in methylation included both 
increases and decreases with respect to maternal exposures, and in some cases within the 
same gene.  Of note, 4 CpG sites were significantly differentially methylated in the same 
direction with respect to both maternal pre-pregnancy BMI and GWG (ANAPC7 5833 
and CAB39 5747, HEYL 7781 and SAPCD2 4655).  Our findings suggest exposure to 
maternal adiposity and excess weight gain may influence DNA methylation levels within 
offspring genes, in particular ANAPC7, CAB39, HEYL and SAPCD2.  The functional 
significance of these changes is unknown; however these genes have important roles in 
cell signaling and cell division processes.  Taken together, our analyses support the 
hypothesis that associations of in utero exposures and DNA methylation levels may be 
different with respect to infant sex85,89.  In general, the influence of maternal adiposity 
and excess weight gain on DNA methylation levels appeared to be more pronounced for 
males, with increases in DNA methylation levels observed for a majority of the 




may be more susceptible to in utero exposures such as maternal adiposity and weight 
gain, and may provide insights into understanding sex-specific differences in obesity and 
cancer risk observed later in life222.  
 In exploratory analyses, we utilized the high-resolution bisulfite sequencing data 
to investigate the distribution of DNA methylation haplotype patterns within each gene, 
with respect to maternal pre-pregnancy BMI and GWG.  Interestingly, we found an 
association between methylation haplotypes and pre-pregnancy BMI within the H19 gene 
overall, and specifically among females, such that female infants born to mothers with an 
overweight/obese pre-pregnancy BMI were significantly less likely to have H19 
methylation haplotypes with all CpG sites methylated, compared with female infants born 
to mothers with normal pre-pregnancy BMI.  To our knowledge, this is one of the first 
studies to explore methylation haplotype patterns in cord blood DNA. H19 is a paternally 
imprinted gene, known to have important roles embryogenesis and fetal growth223.  
Previous studies have shown increased methylation at H19 to be associated with 
upregulation of paternally-expressed IGF2, an imprinted gene that also plays a critical 
role in fetal growth and development208.  Our findings are in line with evidence linking 
maternal adiposity to methylation patterns at the IGF2/H19 imprinting region, and 
suggest in studies of cord blood DNA, patterns of contiguous CpG site methylation in 
single DNA molecules might be more informative than individual CpG site methylation 
levels.  
 Although we did not conduct a formal replication analysis, we quantitatively 




studies, we found small differences in DNA methylation levels with respect to maternal 
pre-pregnancy BMI and GWG, though our findings did not consistently replicate the 
direction or magnitude of all previously reported associations.  We observed similar 
direction of effect for several CpG sites within certain genes (ADCY3, ANAPC7, 
BTN3A1, IGF2, PRR16, SAPCD2, and ZKSCAN5)96; however, we also found sites within 
some of these genes with significant effects in the opposite direction.  Possible reasons 
for these discrepancies include differences in study population, variability in adjustment 
for potentially important confounders, and the different assays used to assess DNA 
methylation levels.  Indeed, the majority of previous studies in the literature have used 
array-based approaches to measure associations of maternal pre-pregnancy BMI and 
GWG with DNA methylation90,94–97,208,209,214, therefore technical differences in DNA 
methylation assessment (array versus next-generation sequencing) could contribute to the 
observed discrepancies.  In addition, next-generation sequencing tends to have higher 
sensitivity for detecting very low levels of methylation, when coverage is adequately high 
(i.e., >30x)224,225    
 To our knowledge, this study is the first to use targeted, next-generation bisulfite 
sequencing to quantify DNA methylation patterns in cord blood DNA.  Next-generation 
bisulfite sequencing often considered the “gold standard” in DNA methylation studies as 
it yields quantitative methylation data with single base pair resolution and produces 
unambiguous methylation information for haplotypes of DNA molecules in a qualitative 




prospective study design with well-characterized cord blood DNA samples that enabled 
us to take important confounders into account.   
 Some important limitations of our study should be noted.  First, we measured 
methylation levels in DNA from cord blood leukocytes, which may not reflect patterns in 
relevant tissue.  Further, we did not have information on cell count distributions so we 
were not able to account for cellular heterogeneity in our analyses.  Although we 
observed small differences in DNA methylation levels, there is evidence to suggest that 
even small changes in DNA methylation can influence gene expression74.  Finally the 
limited samples size and lack of replication with previous studies limits our ability to 
draw conclusions, and suggests more research investigating changes in DNA methylation 
patterns with respect to maternal adiposity and gestational weight gain exposures.  
 In summary we have identified several CpG sites within obesity-and cancer-
related genes that are differentially methylated in cord blood DNA of offspring with 
respect to maternal overweight/obesity and GWG.  In utero exposure to maternal 
adiposity has been shown to increase risk of obesity and metabolic disease later in life, 
both of which are risk factors for certain cancers59–62.  Our findings provide evidence to 
support the hypothesis that DNA methylation may underlie this risk.  These findings 
should be considered preliminary, and further replication studies in large, prospective 








Table 2-1. Characteristics of 112 Mothers and Infants in the eHUB Study, 2006-
2007 
Age (years), mean (SD) 29.5 (5.1) 
Race, n (%)  
Black 43 (38.4) 
White 69 (61.6) 
Pre-Pregnancy BMI, n (%)  
Normal 69 (61.6) 
Overweight 22 (19.6) 
Obese  21 (18.8) 
Education, n (%)  
Less than College degree 37 (33.3) 
College or Graduate degree 74 (66.7) 
Smoking Status, n (%)  
Never 68 (63.0) 
Former 34 (31.5) 
Current 6 (5.6) 
Parity, n (%)  
Nulliparous  62 (55.4) 
Parous 50 (44.6) 
  
IOM Categories for Gestational Weight Gain, n (%)  
Less than recommended range 12 (10.7) 
Within recommended range 37 (33.0) 
More than recommended range 63 (56.2) 
Gestational Age (weeks), n (%) 39.10 (7.1) 
  
  
Infant Sex, n (%)  
Female 57 (50.9) 
Male 55 (49.1) 
  
Infant Birth Weight (grams), mean (SD) 3,411.3 (470.9) 
Abbreviations: eHUB, Hormones in Umbilical Cord Blood Extended Study; BMI, 
Body Mass Index; IOM, Institute of Medicine 
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Table 2-2. Significant Associations of Methylation Proportions at CpG Sites with Pre-Pregnancy BMI in Cord Blood DNA in the eHUB Study (n=112) 




Adjusted Mean  
(95%CI)b 




   Normal Weight Overweight/Obese   
2 ADCY3 24995895 0.2232 (0.150, 0.297) 0.0781 (0.033, 0.123) -0.1452 (-0.232, -0.058) 0.032 
24996027 0.0040 (0.000, 0.008) 0.0213 (0.011, 0.031) 0.0173 (0.007, 0.028) 0.043 
12 ANAPC7 109325793 0.0031 (0.001, 0.005) 0.0009 (0.000, 0.002) -0.0023 (-0.004, -0.000) 0.032 
109325833 0.0197 (-0.003, 0.043) 0.0005 (0.000, 0.001) -0.0192 (-0.043, 0.004) 0.011 
109325902 0.0012 (0.001, 0.002) 0.0061 (0.001, 0.011) 0.0049 (-0.000, 0.010) 0.021 
109325905 0.0008 (0.000, 0.001) 0.0066 (0.002, 0.011) 0.0057 (0.001, 0.011) 0.011 
6 BTN3A1 26510680 0.0139 (-0.005, 0.032) 0.0002 (0.000, 0.000) -0.0137 (-0.032, 0.005) 7.7 x 10-4 
2 CAB39 231285747 0.0076 (-0.005, 0.020) 0.0002 (0.000, 0.000) -0.0074 (-0.020, 0.005) 0.031 
231285820 0.0310 (-0.004, 0.066) 0.0013 (0.000, 0.002) -0.0297 (-0.065, 0.005) 0.004 
231285831 0.0776 (0.015, 0.140) 0.0006 (0.000, 0.001) -0.0770 (-0.140, -0.014) 1.6 x 10-5 
16 GPRC5B 19803915 0.0028 (0.000, 0.005) 0.0004 (0.000, 0.001) -0.0025 (-0.005, -0.000) 0.025 
1 HEYL 39877781 0.0012 (0.001, 0.002) 0.0764 (-0.013, 0.166) 0.0752 (-0.015, 0.165) 1.1 x 10-4 
11 IGF2 2118982 0.0021 (0.000, 0.004) 0.0336 (0.005, 0.063) 0.0316 (0.002, 0.061) 0.003 
2119059 0.0307 (-0.001, 0.062) 0.0008 (0.000, 0.001) -0.0299 (-0.062, 0.002) 2.7 x 10-4 
19 INSR 7244660 0.0012 (0.001, 0.001) 0.0132 (0.002, 0.025) 0.0120 (0.000, 0.024) 4.3 x 10-4 
3 PPARG 12305208 0.0014 (0.001, 0.002) 0.0097 (0.001, 0.018) 0.0083 (0.000, 0.016) 0.010 
5 PRR16 119827848 0.0018 (0.001, 0.003) 0.0323 (-0.004, 0.069) 0.0305 (-0.006, 0.067) 0.011 
119827885 0.0048 (0.002, 0.008) 0.0014 (0.001, 0.002) -0.0034 (-0.007, -0.000) 0.030 
9 SAPCD2 139084655 0.0031 (0.001, 0.005) 0.0273 (0.006, 0.048) 0.0242 (0.003, 0.045) 0.004 
139084747 0.0021 (0.000, 0.004) 0.0304 (-0.011, 0.072) 0.0283 (-0.013, 0.070) 0.033 
14 XRCC3 103251137 0.0358 (0.004, 0.067) 0.0040 (-0.000, 0.008) -0.0319 (-0.063, -0.001) 0.024 
103251148 0.0619 (-0.004, 0.128) 0.0022 (-0.000, 0.005) -0.0597 (-0.126, 0.007) 0.010 
103251162 0.0015 (0.000, 0.003) 0.0118 (0.003, 0.021) 0.0103 (0.001, 0.020) 0.011 
103251326 0.0011 (0.001, 0.002) 0.0140 (-0.004, 0.032) 0.0128 (-0.005, 0.031) 0.022 
103251335 0.0011 (0.000, 0.002) 0.0265 (0.011, 0.042) 0.0254 (0.010, 0.041) 2.3 x 10-7 
5 ZCCHC10 132390150 0.0016 (0.001, 0.002) 0.0084 (0.002, 0.015) 0.0068 (0.000, 0.014) 0.012 
7 ZKSCAN5 98940185 0.0083 (-0.004, 0.021) 0.0002 (-0.000, 0.001) -0.0081 (-0.021, 0.004) 0.050 
98940240 0.0020 (0.000, 0.004) 0.0129 (0.004, 0.022) 0.0110 (0.002, 0.020) 0.032 
98940280 0.0014 (0.001, 0.002) 0.0145 (-0.001, 0.030) 0.0131 (-0.002, 0.029) 0.025 
Abbreviations: BMI, Body Mass Index; Chr, Chromosome; CI, Confidence Interval; FDR, False Discovery Rate; aBased on NCBI Build 36; bAdjusted for 
maternal age, race, smoking status, parity, gestational age, and infant sex; cAdjusted using Benjamini-Hochberg False Discovery Method, alpha =0.05 
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Table 2-3. Significant Associations of Methylation Proportions at CpG Sites with Maternal GWG in Cord Blood DNA in the eHUB Study (n=112) 




Adjusted Mean  
(95% CI) 




   Less Than/Within 
Recommended 




3 PXYLP1 142432624 0.0009 (0.001, 0.001) 0.0150 (0.005, 0.025) 0.0141 (0.004, 0.024) 1.2 x 10-8 
12 ANAPC7 109325831 0.0031 (-0.000, 0.006) 0.0295 (0.005, 0.054) 0.0264 (0.003, 0.050) 0.014 
109325833 0.0292 (-0.006, 0.064) 0.0006 (0.000, 0.001) -0.0286 (-0.063, 0.006) 0.009 
6 BTN3A1 26510498 0.0011 (-0.000, 0.002) 0.0191 (0.006, 0.033) 0.0180 (0.004, 0.032) 0.009 
2 CAB39 231285693 0.0080 (-0.001, 0.017) 0.0008 (0.000, 0.001) -0.0072 (-0.017, 0.002) 0.038 
231285733 0.0014 (0.001, 0.002) 0.0274 (0.010, 0.045) 0.0260 (0.008, 0.044) 6.9 x 10-7 
231285743 0.0012 (0.000, 0.002) 0.0152 (-0.003, 0.034) 0.0140 (-0.005, 0.033) 0.040 
231285747 0.0084 (-0.003, 0.020) 0.0004 (0.000, 0.001) -0.0079 (-0.019, 0.004) 0.016 
  231285762 0.0247 (0.008, 0.041) 0.0042 (0.001, 0.007) -0.0205 (-0.038, -0.003) 0.034 
  231285780 0.0170 (0.008, 0.027) 0.0028 (0.000, 0.006) -0.0142 (-0.024, -0.004) 0.037 
  231285863 0.0012 (0.000, 0.002) 0.0062 (0.001, 0.012) 0.0050 (-0.001, 0.011) 0.038 
8 DOK2 21827072 0.0366 (0.025, 0.049) 0.0029 (0.001, 0.005) -0.0337 (-0.047, -0.021) 8.3 x 10-5 
16 GPRC5B 19804040 0.0450 (0.032, 0.058) 0.0006 (-0.000, 0.002) -0.0444 (-0.058, -0.031) 0.010 
1 HEYL 39877781 0.0015 (0.001, 0.002) 0.0488 (-0.006, 0.103) 0.0474 (-0.007, 0.102) 1.4 x 10-4 
17 ITGAE 3573436 0.0014 (0.001, 0.002) 0.0231 (0.008, 0.039) 0.0217 (0.006, 0.037) 4.2 x 10-7 
19 INSR 7244466 0.0050 (0.001, 0.009) 0.0384 (0.007, 0.070) 0.0334 (0.001, 0.065) 0.038 
  7244560 0.0003 (0.000, 0.001) 0.0792 (0.054, 0.104) 0.0790 (0.054, 0.104) 1.2 x 10-6 
3 PPARG 12305246 0.0041 (0.000, 0.008) 0.0486 (0.008, 0.089) 0.0445 (0.003, 0.086) 0.017 
5 PRR16 119827721 0.0016 (0.000, 0.003) 0.0099 (0.001, 0.019) 0.0083 (-0.001, 0.018) 2.7 x 10-3 
119827763 0.0108 (-0.001, 0.023) 0.0009 (0.000, 0.001) -0.0099 (-0.022, 0.002) 0.050 
9 SAPCD2 139084655 0.0017 (0.000, 0.003) 0.0204 (0.002, 0.039) 0.0186 (0.000, 0.037) 0.014 
139084708 0.0005 (0.000, 0.001) 0.0044 (-0.000, 0.009) 0.0039 (-0.001, 0.009) 0.015 
  139084780 0.0011 (0.000, 0.002) 0.0110 (-0.001, 0.023) 0.0099 (-0.002, 0.022) 0.051 
14 XRCC3 103251162 0.0118 (0.003, 0.021) 0.0018 (-0.000, 0.004) -0.0100 (-0.019, -0.001) 0.052 
103251242 0.0017 (-0.000, 0.004) 0.0171 (-0.008, 0.042) 0.0154 (-0.009, 0.039) 0.047 
103251272 0.0428 (-0.005, 0.091) 0.0015 (0.000, 0.003) -0.0413 (-0.090, 0.007) 0.023 
103251276 0.0017 (0.001, 0.003) 0.0123 (-0.002, 0.027) 0.0106 (-0.004, 0.025) 0.050 
5 ZCCHC10 132390146 0.0183 (0.012, 0.024) 0.0065 (0.003, 0.010) -0.0118 (-0.018, -0.005) 0.011 
7 ZKSCAN5 98940157 0.0056 (0.001, 0.010) 0.0009 (0.001, 0.001) -0.0047 (-0.009, -0.000) 0.007 
98940185 0.0012 (0.000, 0.002) 0.0099 (0.002, 0.018) 0.0087 (0.001, 0.017) 0.013 
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Abbreviations: GWG, Gestational Weight Gain; eHUB, Hormones in Umbilical Cord Blood Extended Study; Chr, Chromosome; CI, Confidence Interval; FDR, 
False Discovery Rate; aBased on NCBI Build 36 
bAdjusted for maternal age, race, smoking status, parity, gestational age, and infant sex; cAdjusted for multiple testing using the Benjamini-Hochberg False 
Discovery Method, alpha =0.05 
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Table 2-4. Distribution of Common Methylation Haplotypes for H19 by Pre-Pregnancy BMI in the 
eHUB Study (n=112) 
Amplicon 1 (chr11: 1977937 – 1977819) 
Haplotype, n (%) Normal (n=63) Overweight/Obese (n=39) 
MMMMMM 42 (66.7) 18 (46.2) 
MMMMM| 0 (0.0) 2 (5.1) 
MM|MMM 0 (0.0) 1 (2.6) 
M|MMMM 1 (1.6) 0 (0.0) 
|||MMM 1 (1.6) 0 (0.0) 
|||||| 19 (30.2) 18 (46.1) 
Completely Methylated 42 (66.7) 18 (46.15) 
Partially Methylated  2 (3.2) 3 (7.7) 
Completely Unmethylated 19 (30.2) 18 (46.15) 
Fisher’s Exact p-value 0.10  
Amplicon 2 (chr11: 1977841 – 1977679)  
Haplotype, n (%) Normal (n=62) Overweight/Obese (n=40) 
MMMMMMMMMMMMMMMMMM 11 (17.7) 4 (10.3) 
MMMMMMMMMMMMMMMMM| 0 (0.0) 1 (2.6) 
MMMMMMMMMMMMMMM|MM 1 (1.6) 0 (0.0) 
MMMMMMMMMMMMMM|MM| 0 (0.0) 1 (2.6) 
MMMMMMMM|MMMMMMMMM 1 (1.6) 0 (0.0) 
MMMMMMMM|||||||||| 1 (1.6) 0 (0.0) 
MMMMMM|MMMMMMMMMMM 11 (17.7) 4 (10.3) 
MMMMMM|MMMMMMMMMM| 0 (0.0) 1 (2.6) 
MMMMMM|MMMM|MMMMMM 0 (0.0) 1 (2.6) 
MMMMMM|MM|MMMMMMMM 0 (0.0) 1 (2.6) 
MMMMM|MMM|MMMMMMMM 0 (0.0) 1 (2.6) 
MMMM|MMM|MMMMMMMMM 0 (0.0) 1 (2.6) 
M|MMMM|MMMMMMMMMMM 1 (1.6) 0 (0.0) 
|||||||||||||||||| 36 (58.1) 24 (61.5) 
Completely Methylated  11 (17.7) 4 (10.3) 
Partially Methylated 15 (24.2) 11 (28.2) 
Completely Unmethylated 36 (58.1) 24 (61.5) 
Fisher’s Exact p-value 0.60  
Amplicon 3 (chr11: 1977750 – 1977587) 
Haplotype, n (%) Normal (n=63) Overweight/Obese (n=40) 
MMMMMMMMMMMMMMM 33 (50.8) 14 (35.0) 
MMMMMMMMMMMMMM| 1 (1.6) 0 (0.0) 
MMMMMMMMMMM|MMM 0 (0.0) 1 (2.5) 
MMMMMMMMMMM||MM 1 (1.6) 0 (0.0) 
MMMMMMMMMM|MMMM 0 (0.0) 1 (2.5) 
MMMMMMMMMM||||| 0 (0.0) 1 (2.5) 
MMMMMMMMM|MMMMM 2 (3.2) 1 (2.5) 
MMMMMMMMM|MMM|M 0 (0.0) 1 (2.5) 
MMMMMM||||MMMMM 1 (1.6) 0 (0.0) 
|M||M|||||||||| 1 (1.6) 0 (0.0) 
|||M||||||||||| 0 (0.0) 1 (2.5) 
||||||||||||MMM 2 (3.2) 2 (5.0) 
||||||||||||M|| 0 (0.0) 1 (2.5) 
|||||||||||||MM 3 (4.8) 7 (17.5) 
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|||||||||||||M| 2 (3.2) 0 (0.0) 
||||||||||||||M 3 (4.8) 5 (12.5) 
||||||||||||||| 14 (22.2) 5 (12.5) 
Completely Methylated 33 (52.4) 14 (35.0) 
Partially Methylated 16 (25.4) 21 (52.5) 
Completely Unmethylated 14 (22.2) 5 (12.5) 
Fisher’s Exact p-value  0.023  
Amplicon 4 (chr11: 1977679 – 1977841) 
Haplotype, n (%) Normal (n=57) Overweight/Obese (n=34) 
MMMMMMMMMMMMMMMMMM 1 (1.7) 0 (0.0) 
MMMMMMMMMMMMMM|MMM 1 (1.7) 2 (5.9) 
MMMMMMMMMMM|MMMMMM 15 (26.3) 4 (11.8) 
MMMMMMMM|MMMMMMMMM 1 (1.7) 0 (0.0) 
MMMMM|MMMMM|MMMMMM 0 (0.0) 1 (2.9) 
MMMM|MMMMMM|MMMMMM 1 (1.7) 0 (0.0) 
M|||MMMMMMMMMM|MM| 0 (0.0) 1 (2.9) 
|MMMMMMMMMMMMM|MMM 0 (0.0) 1 (2.9) 
|MMMMMMMMMM|MM|||| 1 (1.7) 0 (0.0) 
|MMMM|MMMMMMMM|MMM 0 (0.0) 1 (2.8) 
||||||||||M||||||| 1 (1.7) 0 (0.0) 
|||||||||||||||||| 36 (63.2) 24 (70.6) 
Completely Methylated 1 (1.7) 0 (0.0) 
Partially Methylated 20 (35.1) 10 (29.4) 
Completely Unmethylated 36 (63.2) 24 (70.6) 
Fisher’s Exact p-value 0.80  
Abbreviations: BMI, Body Mass Index; eHUB, Hormones in Umbilical Cord Blood Extended study 
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Table 2-S1. List of Candidate Genes and CpG Sites Included in this Study of Cord Blood DNA Methylation 
Chr. Gene Name Gene 
Symbol 
Genomic 
Start Site – 
End Sitea 
# of  
Unique  
CpG Sites 
Previously Published CpG Siteb and Relationship 
with in Utero Exposure of Interest, Corresponding 
CpG Site in Current Study (if applicable) 
Relationship to Obesity/Cancerc 




PXYLP1 142432505 - 
142432710 
8 Liu et al., 2014: cg00400028 – positive association 
with maternal pre-pregnancy BMI.   





ADCY3 24995866 - 
24996048 
9 Liu et al., 2014: cg17644208 – positive association 
with maternal pre-pregnancy BMI  







ANAPC7 109325732 - 
109325955 
20 Liu et al., 2014: cg04062907 – negative association 
with pre-pregnancy BMI (males only).   
Corresponding CpG site position: 109325928 
 








5 Liu et al., 2014: cg11213150 – negative association 
with pre-pregnancy BMI  
Corresponding CpG site position: 128924278 
 
Member of vascular endothelial 











7 Liu et al., 2014: cg01840268 – negative association 
with pre-pregnancy BMI (males only).   





CAB39 231285655 - 
231285888 
35 Liu et al., 2014: cg06874144 – positive association 
with pre-pregnancy BMI (males only).   
 
Related to insulin receptor 
signaling 




CASP10 201756214 - 
201756490 
4 Relton et al., 2012: cg13782463 – negative 
association of methylation at birth with childhood 
BMI at age 9 
 
Apoptosis 










13 Relton et al., 2012: cg17511511 – positive 
association of methylation at birth with childhood 
BMI at age 9 
 
Negative regulator of cell cycle 
and cell proliferation 
8 Docking 
protein 2 
DOK2 21826811 - 
21827097 
5 Liu et al., 2014: cg06874144 – negative association 
with pre-pregnancy BMI (males only).   
Corresponding CpG site position: 21827005 
May modulate cellular 






ERBB2 35097895 - 
35098036 
8 Liu et al., 2014: cg19752722 – negative association 
with pre-pregnancy BMI (males only).   
Member of the epidermal growth 















19 Liu et al., 2014: cg20312475 – negative association 
with pre-pregnancy BMI (males only).   
Corresponding CpG site position: 19803962 
 
May modulate insulin secretion, 
increased expression associated 
with Type 2 diabetes 

















26 Perkins et al., 2012: - positive association with H19 
DMR (chr11:2109500 – 2109519, NCBI Build 
37.1) methylation at birth and weight-for-age at 
year 1.  
Paternally imprinted gene 










27 Liu et al., 2014: cg25462291 – negative association 
with pre-pregnancy BMI (males only).   
Corresponding CpG site position: 39877643 
Involved in Notch signaling and 
may be a regulator of cell fate 
decisions 






17 Integrin, alpha 
E 






13 Liu et al., 2014: cg19585196 – negative association 
with pre-pregnancy BMI (males only).   
Corresponding CpG site position: 3573509 
Inflammation, cell adhesion 
11 Insulin-like 
growth factor 2 










48 Heijmans et al., 2008: - prenatal famine exposure 
negatively associated with DNA methylation in 
IGF2 DMR (chr11:2126035-2126372)  
Insulin receptor signaling 








36 Tobi et al., 2014: prenatal famine exposure 
positively associated with DNA methylation in 
INSR (chr19: 7110011-7111334) 
Insulin receptor signaling cascade 
X Placenta-
specific 1 
PLAC1 133619876 - 
133620051 
3 Liu et al., 2014: cg14674582 – negative association 
with pre-pregnancy BMI (females only).  
Corresponding CpG site position: 133619948 
 






PPARG 12305182 - 
12305361 
 
15 Gemma et al., 2009: positive association with 
peroxisome proliferator-activated receptor-gamma 
co-activator 1alpha gene (PPARGC1A) methylation 
and maternal pre-pregnancy BMI. 
Regulates adipocyte 
differentiation, implicated in 
obesity, diabetes, and certain 
cancers 
5 Proline rich 16 PRR16 119827677 - 
119827915 
32 Liu et al., 2014: cg25584626 – negative association 
with pre-pregnancy BMI (males only).   
Regulator of cell size and 
promotes cell size enlargement 
9 Suppressor 
APC domain 
SAPCD2 139084637 - 
139084851 
29 Liu et al., 2014: cg15785720 – negative association 
with pre-pregnancy BMI.   
Associated with certain cancers 
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WNT16 120751156 - 
120751344 
1 Liu et al., 2014: cg24849648 – positive association 
with pre-pregnancy BMI.  
Corresponding CpG site position: 120751255 
Involved in oncogenesis and 
patterning during embryogenesis. 





hamster cells 3 
XRCC3 103251106 - 
103251360 
34 Engel et al., 2014: cg02194129, cg12798040, 
cg14172849, cg23369670 – positive association 
with infant birth weight  
Involved in maintaining 
chromosome stability and 
repairing DNA damage. 












26 Liu et al., 2014: cg01422136 – positive association 
with pre-pregnancy BMI.  
Corresponding CpG site position: 132390123 
None identified 












19 Liu et al., 2014: cg01422136 – negative association 
with pre-pregnancy BMI (males only).  
Corresponding CpG site position: 98940249 
None identified 
Abbreviations: Chr, Chromosome; BMI, Body Mass Index; DMR, Differentially methylated region 
aBased on NCBI Build 36 
bCpG probe ID according to Illumina HumanMethylation27 BeadChip (Liu et al., 2014), Illumina GoldenGate Methylation Cancer Panel I (Relton et al., 
2009), Infinium HumanMethylation450 BeadChip (Engel et al., 2014), otherwise labeled according to genome position based on NCBI Build 36 
cDetermined from www.ncbi.nlm.nih.gov/gene/ 
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Table 2-S2. Significant Associations of Methylation Levels at CpG Sites with Pre-Pregnancy BMI in Cord Blood DNA in the eHUB Study, 
Stratified by Infant Sex (n=112) 
   All Females (n=57) Males (n=55) 
















2 ADCY3 24995895 -1.28  
(-2.1, -0.5) 
0.032 -1.39  
(-2.5, -0.3) 0.310 
-0.77  
(-1.9, 0.4) 0.999 
 24996027 1.71  
(0.6, 2.8) 
0.043 0.89  




12 ANAPC7 109325793 -1.3 
(-2.1, -0.5) 
0.032 -1.59  
(-2.6, -0.6) 0.067 
-0.21  
(-1.3, 0.8) 0.210 
 109325833 -3.75  
(-5.7, -1.8) 
0.011 -6.23  
(-11.1, -1.4) 0.296 
-3.19  
(-4.7, -1.7) 0.002 
 109325902 1.66  
(0.7, 2.6) 
0.021 0.30  
(-0.5, 1.1) 0.999 
2.25  
(1.2, 3.3) 0.002 
 109325905 2.12  
(1.0, 3.3) 
0.011 1.07  
(-0.0, 2.1) 0.892 
1.84  
(0.5, 3.2) 0.210 
6 BTN3A1 26510680 -4.50  
(-6.5, -2.5) 
7.7 x 10-4 -3.75  
(-5.7, -1.8) 0.73 
-2.74  
(-4.8, -0.7) 0.275 
2 CAB39 231285747 -3.64  
(-5.9, -1.4)  
0.031 -9.19  
(-14.1, -4.3) 0.018 
-1.41  
(-2.8, -0.1) 0.758 
 231285820 -3.29  
(-4.9, -1.7) 
0.004 -5.75  
(-7.9, -3.6) 7.1x10
-5 -4.09  (-6.6, -1.6) 0.050 
 231285831 -5.34  
(-7.3, -3.4) 
1.6 x 10-5 -4.05  
(-5.7, -2.4) 3.3x10
-4 -4.01  (-6.0, -2.1) 0.003 
16 GPRC5B 19803915 -2.02  
(-3.2, -0.8) 
0.025 -1.93  
(-3.3, -0.5) 0.185 
-1.45  
(-2.7, -0.2) 0.515 
1 HEYL 39877781 4.24  
(2.6, 5.9) 
1.1 x 10-5 4.09  
(1.8, 6.4) 0.022 
8.61  
(3.7, 13.5) 0.025 
11 IGF2 2118982 2.89  
(1.5, 4.3) 
0.003 3.86  
(1.2, 6.5) 0.144 
3.00  
(1.6, 4.4) 0.002 
 2119059 -3.74  
(-5.3, -2.2) 
2.7 x 10-4 -2.47  
(-3.8, -1.1) 0.022 
-4.19  
(-8.3, -0.0) 0.850 
19 INSR 7244660 2.42  
(1.4, 3.4) 
4.3 x 10-4 2.98  
(1.3, 4.6) 0.019 
1.24  
(0.3, 2.1) 0.216 
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   3 PPARG 12305208 2.00  
(1.0, 3.0) 
0.010 -0.53  
(-0.9, -0.1) 0.240 
2.62  
(1.4, 3.8) 0.002 
5 PRR16 119827848 3.00  
(1.4, 4.6) 
0.011 3.97  
(2.3, 5.6) 0.086 
0.83  
(0.0, 1.6) 0.735 
 119827885 -1.26  
(-2.0, -0.5) 
0.030 -0.90  
(-1.5, -0.3) 2.8x10
-4 -1.06  (-2.0, -0.1) 0.693 
9 SAPCD2 139084655 2.40  
(1.2, 3.6) 
0.004 -0.38  




 139084747 2.79  
(1.1, 4.5) 
0.033 3.87  
(1.9, 5.8) 0.009 
-1.86  
(-3.2, -0.5) 0.230 
14 XRCC3 103251137 -2.28  
(-3.6, -0.9) 
0.024 -3.70  
(-6.8, -0.6) 0.393 
-1.90  
(-3.7, -0.1) 0.718 
 103251148 -3.42  
(-5.3, -1.6) 
0.010 -4.04  
(-7.3, -0.8) 0.354 
-5.27  
(-10.1, -0.4) 0.715 
 103251162 2.16  
(1.0, 3.3) 
0.011 2.72  
(1.3, 4.2) 0.017 
-0.52  
(-1.0, -0.0) 0.722 
 103251326 2.55  
(1.1, 4.0) 
0.022 1.80  
(0.2, 3.4) 0.457 
2.49  
(1.0, 4.0) 0.051 
 103251335 3.42  
(2.3, 4.5) 
2.3 x 10-7 -0.67  




5 ZCCHC10 132390150 1.70  
(0.8, 2.6) 
0.012 2.11  
(0.9, 3.3) 0.017 
0.43  
(-0.2, 1.0) 0.999 
7 ZKSCAN5 98940185 -2.61  
(-4.3, -0.9) 
0.050 -2.76  
(-4.8, -0.7) 0.197 
-1.07  
(-1.9, -0.2) 0.301 
 98940240 2.39  
(0.9, 3.9) 
0.032 1.55  
(0.3, 2.8) 0.352 
2.98  
(1.3, 4.7) 0.025 
 98940280 1.96  
(0.8, 3.1) 
0.025 2.23  
(0.4, 4.1) 0.367 
2.46  
(1.3, 3.6) 0.002 
Abbreviations: BMI, Body, Mass Index; eHUB, Hormones in Umbilical Cord Blood Extended Study; Chr, Chromosome; CI, Confidence Interval; FDR, 
False Discovery Rate 
aBased on NCBI Build 36 
bAdjusted for maternal age, race, smoking status, parity, gestational age, and infant sex 
cAdjusted for multiple testing using the Benjamini-Hochberg False Discovery Method, alpha =0.05, significant p-values are shown in bold.  
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Table 2-S3. Significant Association of Methylation Levels at CpG Sites with Maternal GWG in Cord Blood DNA in the eHUB Study, Stratified by 
Infant Sex (n=112) 



















3 PXYLP1 142432624 2.87  
(2.0, 3.7) 
1.2 x 10-8 1.46  
(-0.4, 3.3) 
0.999 3.06  
(2.1, 4.0) 
2.1x10-8 
12 ANAPC7 109325831 2.45  
(1.1, 3.8) 
0.014 4.09  
(1.9, 6.3) 
0.034 1.68  
(-0.7, 4.1) 
0.999 
 109325833 -4.10  
(-6.2, -2.0) 
0.009 -3.44  
(-5.7, -1.2) 
0.138 -3.06  
(-4.3, -1.9) 
1.5x10-4 
6 BTN3A1 26510498 3.08  
(1.5, 4.7) 
0.009 0.32  
(-1.1, 1.7) 
0.999 3.72  
(2.0, 5.5) 
0.007 
2 CAB39 231285693 -2.28  
(-3.7, -0.9) 
0.038 -2.57  
(-4.4, -0.7) 
0.252 -1.62  
(-3.3, 0.0) 
0.999 
 231285733 3.62  
(2.4, 4.8) 
6.9 x 10-7 2.89  
(1.0, 4.8) 
0.141 3.89  
(2.3, 5.5) 
7.1x10-4 
 231285743 2.55  
(1.0, 4.1) 
0.040 1.17  
(-0.3, 2.6) 
0.999 3.17  
(1.3, 5.0) 
0.212 
 231285747 -2.97  
(-4.6, -1.3) 
0.016 -3.90  
(-6.2, -1.6) 
0.085 -1.55  
(-3.1, -0.0) 
0.999 
 231285762 -2.05  
(-3.3, -0.8) 
0.034 1.08  
(0.2, 1.9) 
0.348 -4.15  
(-6.1, -2.2) 
0.006 
 231285780 -2.00  
(-3.2, -0.8) 
0.037 -1.12  
(-2.3, 0.1) 
0.999 -0.43  
(-0.9, 0.1) 
0.999 
 231285863 1.68  
(0.6, 2.7) 
0.038 1.60  
(-0.1, 3.3) 
0.999 1.65  
(-0.1, 3.4) 
0.999 
8 DOK2 21827072 -4.51  
(-6.3, -2.7) 
8.3 x 10-5 -0.71  
(-1.5, 0.1) 
0.999 0.03  
(-0.8, 0.8) 
0.999 
16 GPRC5B 19804040 -9.37  
(-14.3, -4.5) 
0.010 -11.13  
(-16.8, -5.5) 
0.020 -0.32  
(-1.3, 0.7) 
0.999 
1 HEYL 39877781 3.57  
(2.1, 5.0) 
4.2 x 10-7 3.46  
(1.3, 5.7) 
0.135 6.48  
(3.2, 9.8) 
0.028 
17 ITGAE 3573436 2.88  
(1.9, 3.8) 
1.4 x 10-4 2.35  
(1.0, 3.7) 
0.057 3.73  
(1.6, 5.9) 
0.184 
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19 INSR 7244466 2.11 






 7244560 7.62 
(5.0, 10.2) 












5 PRR16 119827721 1.89 
(0.7, 3.1) 


















































































Abbreviations: GWG, Gestational Weight Gain; eHUB, Hormones in Umbilical Cord Blood Extended Study; Chr, Chromosome; CI, Confidence Interval; 
FDR, False Discovery Rate 
aBased on NCBI Build 36 
bAdjusted for maternal age, race, smoking status, parity, gestational age, and infant sex 
cAdjusted for multiple testing using the Benjamini-Hochberg False Discovery Method, alpha =0.05, significant p-values are shown in bold. 
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Chapter 3 
Predictors of Human Papillomavirus Vaccination in a Large 
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Background: Despite the recommendation for routine human papillomavirus (HPV) 
vaccination in males, coverage estimates remain low.  We sought to identify predictors of 
receiving each HPV vaccine dose among a large clinical population of males.   
 
Methods: We conducted a cross-sectional analysis of electronic medical records for 
14,688 males aged 11-26 years attending 26 outpatient clinics (January 2012 –April 
2013) in Maryland to identify predictors of each HPV vaccine dose using multivariate 
logistic regression models with generalized estimating equations.  All analyses were 
stratified in accordance with vaccine age recommendations: 11-12 years, 13-21 years, 
and 22-26 years. Analyses of predictors of receipt of subsequent HPV doses were also 
stratified by number of clinic visits (≤3, >3). 
 
Results: Approximately 15% of males initiated the HPV vaccine. Less than half of males 
eligible received the second and third dose, 49% and 47%, respectively. Non-Hispanic 
black males (vs. non-Hispanic white) aged 11-12 and 13-21 years and males with public 
insurance (vs. private) aged 13-21 years, had significantly greater odds of vaccine 
initiation, but significantly decreased odds of receiving subsequent doses, respectively. 
Attendance to >3 clinic visits attenuated the inverse association between public insurance 





Conclusion: Overall, rates of HPV vaccine initiation and of subsequent doses were low.  
While non-Hispanic black and publicly insured males were more likely to initiate the 
HPV vaccine, they were less likely to receive subsequent doses.  
 
Impact: Tailoring different intervention strategies for increasing HPV vaccine initiation 







































Vaccination against human papillomavirus (HPV) in males is substantially lower 
compared to other adolescent vaccines.  As of 2014, approximately 42% of males aged 
13-17 years in the U.S. initiated the HPV vaccine series, as compared with approximately 
79% coverage for meningococcal conjugate and 88% coverage for tetanus, diphtheria, 
and pertussis150.  Completion rates for the HPV vaccine are even lower, with 21.6% of 
males receiving all three doses in 2014150.  The HPV vaccine was originally licensed for 
males in 2009226.  In October 2011, the Advisory Committee on Immunization Practices 
(ACIP) recommended routine HPV vaccination for males aged 11-12 years, with catch-
up vaccination for males aged 13-21 years, and permissive vaccination up to 26 years of 
age227.  Although HPV vaccination coverage among U.S. males has increased, more than 
half of the target population still remains unvaccinated150. 
The quadrivalent HPV vaccine (Gardasil, Merck and Co, Inc.) is administered as 
a 3-dose series, with the second and third doses administered at 2 and 6 months after the 
first dose, respectively227.  The vaccine protects against high-risk HPV types 16 and 18 
and low-risk HPV types 6 and 11, and is most effective when administered prior to HPV 
exposure before sexual debut135,228.  Persistent infection with HPV types 16 and 18 is 
causally associated with a significant proportion of anal, penile and oropharyngeal 




nearly all cases of genital warts133.  In females, nearly 70% of all cervical cancers are 
caused by HPV types 16 and 18229.   
Data on determinants of HPV vaccination among males are limited, but suggest a 
health care provider’s recommendation as one of the most important predictors of HPV 
vaccine initiation230.  Additionally, rates of vaccine initiation are generally higher among 
non-Hispanic black and Hispanic males (vs. non-Hispanic whites) and among males 
living below the poverty level (vs. at or above the poverty level)150,152,230.  Less is known 
about factors related to HPV vaccine completion among males; however a few studies 
have shown that rates are lower among non-Hispanic black and Hispanic males and 
among uninsured/underinsured male adolescents150,152,230.  Frequent contact with the 
healthcare system has also been cited as an important predictor of completion, 
particularly among low-income and minority males152,231.  Most of the evidence on 
predictors of HPV vaccine initiation and completion among males was generated before 
the ACIP recommendation in 2011 with a majority of studies focusing on vaccine 
acceptability232–239.  More recent studies, such as the National Immunization Survey-Teen 
(NIS-Teen), include limited age ranges (13 – 17 years) and do not include males in the 
target age range (11-12 years)150,230,237,240.  To our knowledge, no recent studies have 
examined predictors of the second dose of the HPV vaccine, despite growing interest in 
reduced dosing schedules of the HPV vaccine series141,241,242.  To this end, the purpose of 
our study was to identify predictors of each dose of the HPV vaccine series among a 
large, clinical population of males aged 11 to 26 years after the ACIP recommendation, 









We evaluated EMR data from 15,996 males aged 11 to 26 years attending Johns 
Hopkins Community Physicians (JHCP) clinics from January 2012 through April 2013.  
JHCP is a university-affiliated practice comprised of 26 primary care outpatient sites in 
11 counties in Maryland.  Our study population was drawn from the Family Practice, 
Internal Medicine/Pediatrics (IM/Peds), Internal Medicine, and Pediatrics practice 
specialties at these facilities.  Males who received an HPV vaccine dose outside of a 
JHCP clinic (n=101) and those who initiated the HPV vaccine series prior to the start of 
our study (n=1,207, 7.6%) were excluded.  We created three analytic cohorts to evaluate 
HPV vaccine initiation, receipt of the second dose of the HPV vaccine, and HPV vaccine 
completion. Therefore, the analytic cohort for HPV vaccine initiation included 14,688 
males who had not received an HPV vaccine dose as of 2012.  Dates in the EMR data 
included only visit year (vs. month and year).  As such, we could not determine whether 
males who initiated in 2013 (n=346) or those who received the second dose in 2013 
(n=202) had enough time (i.e., 6 months) to complete the series; these males were 
excluded from the second dose and completion analytic cohorts, respectively.  Thus, the 
analytic cohort for the second dose of the HPV vaccine included the 1,834 males who 
initiated the HPV vaccine in 2012, and the analytic cohort for the completion analysis 
included the 702 males who received the second dose in 2012.  This study protocol was 





HPV Vaccination Outcome Definitions 
Information on HPV vaccination status was available from the EMR.  HPV 
vaccine “initiation” was defined as receipt of at least one dose of the HPV vaccine, the 
second dose was defined as receipt of two doses of the HPV vaccine, and HPV vaccine 
“completion” was defined as receipt of all three doses of the HPV vaccine series.   
 
Demographic and Clinical Predictors of HPV Vaccination 
Demographic and clinical characteristics were available from the EMR.  We 
evaluated age at the first clinic visit during the study period (i.e., “baseline”) as a 
continuous variable and also categorized baseline age according to the ACIP 
recommendations: 11-12 years (target age range for vaccination, “Target”), 13-21 years 
(catch-up age range for vaccination, “Catch-Up”, and 22-26 years (permissive age for 
vaccination, “Permissive”).  Race/ethnicity was self-identified in the registration files of 
the EMR and defined as non-Hispanic white, non-Hispanic black, Hispanic, Asian, or 
other race/ethnicity.  Insurance was categorized as private, public, or military.  The 
number of clinic visits during the study period was categorized as ≤3 visits (the minimum 
number of visits required to complete the HPV vaccine series) vs. >3 visits.  JHCP clinic 
location was defined as urban or suburban using U.S. census data and JHCP practice 
specialty was categorized as Family Practice, IM/Peds, Internal Medicine, or Pediatrics.  
Because males could visit more than one practice specialty type during the study period, 




unable to identify the most common practice specialty because a male attended an equal 
numbers of different specialties (n=602, 3.8%), we used the practice specialty at the 
male’s first visit.  Among males who were vaccinated, agreement between the assigned 
practice specialty and the specialty associated with the vaccine visit was 95%. 
 
Statistical Analysis 
In this cross-sectional analysis, we calculated means and proportions for 
demographic and clinical predictors, using descriptive statistics with t-tests and Pearson’s 
chi-square tests to assess differences by uptake of each HPV vaccine dose.  Multivariable 
logistic regression models using generalized estimating equations (GEE) were used to 
calculate adjusted odds ratios (aORs) and 95% confidence intervals of associations of 
demographic and clinical predictors with each HPV vaccine dose, accounting for 
clustering within JHCP clinics.  All models were stratified by baseline age group and 
mutually adjusted for continuous baseline age, race/ethnicity, insurance type, number of 
clinic visits, JHCP clinic location, and JHCP practice specialty.  Since additional clinic 
visits are required for receipt of subsequent doses of the HPV vaccine, we conducted a 
sub-analysis to explore whether the number of clinic visits modifies any potential 
association of race/ethnicity and insurance type with receipt of the second and third dose 
of the HPV vaccine, respectively.  In this analysis we focused on race/ethnicity and 
insurance because these factors are known to be differentially associated with healthcare 
utilization patterns (14).  To increase statistical power and adequately test for interaction, 




Hispanic white, non-Hispanic black and other (Hispanic, Asian/Pacific Islander, and 
other race/ethnicity).  We stratified our models by number of clinic visits (≤3 and >3), 
and tested for statistical interaction using the Wald test.  All analyses were conducted 
using Stata v.13.1 (StataCorp, College Station, TX). All tests were 2-sided and results 
were considered statistically significant if p<0.05.  
RESULTS 
 
HPV Vaccine Initiation 
Of the 14,688 males eligible for the first dose of the HPV vaccine, a total of 2,180 
(14.8%) initiated the series.  The average baseline age of males eligible for the first dose 
of the HPV vaccine was 18.0 ± 4.7 years, and the majority were non-Hispanic white 
(50.6%), followed by non-Hispanic black (35.1%; Table 3-1).  More than half of all 
males were privately insured (Table 3-1).  The majority of males attended ≤3 clinic visits 
during the study period, visited JHCP clinics in suburban locations and practices with a 
Family Practice or Pediatrics specialty (Table 3-1).   
Multivariable aORs for HPV vaccine initiation by age group are shown in Table 
3-2.  In the target age group, non-Hispanic black males had 39% greater odds of initiating 
the HPV vaccine compared with non-Hispanic white males (p=0.02); and males with 
public insurance had 45% greater odds of HPV vaccine initiation compared with males 
with private insurance (p=0.02).  Attending >3 clinic visits during the study period was 
associated with over a two-fold increase in odds of HPV vaccine initiation compared with 
≤3 visits during the study period (p<0.001), and visiting a clinic in an urban location was 




with clinics in a suburban location (p<0.01).  Baseline age and JHCP practice specialty 
were not significantly associated with odds of HPV vaccine initiation in this target age 
group.  
In the catch-up age group, similar to males in the target age group, non-Hispanic 
black race/ethnicity, public insurance, attending >3 clinic visits during the study period, 
and urban clinic location were significantly associated with increased odds of HPV 
vaccine initiation (p<0.01, respectively).  Additionally in the catch-up age group, older 
age at baseline was significantly associated with a 14% decrease in odds of HPV vaccine 
initiation (p<0.001) and Internal Medicine practice specialty was significantly associated 
with a 73% decrease in odds of HPV vaccine initiation compared with Family Medicine 
practice specialty (p<0.001).  
Similar to males in both the target and catch-up age groups, non-Hispanic black 
race/ethnicity in the permissive age group and attending >3 clinic visits during the study 
period were significantly associated with increased odds of HPV vaccine initiation 
(p<0.001, respectively).  Like males in the catch-up age group, older age at baseline and 
Internal Medicine practice specialty were significantly associated with decreased odds of 
HPV vaccine initiation (p=0.05 and p=0.02, respectively).  Additionally in the permissive 
age group, males with military insurance had nearly two-and-a-half times the odds of 
initiating the HPV vaccine compared to males with private insurance (p=0.04).  JCHP 
clinic location was not significantly associated with odds of HPV vaccine initiation in 





Second Dose of the HPV Vaccine  
Of the 1,834 eligible males (those who received their first HPV vaccine dose in 
2012), a total of 904 (49.1%) received the second dose of the HPV vaccine.  Males 
eligible for the second dose of the HPV vaccine tended to be younger than those eligible 
for initiation, with a mean baseline age of 14.9 ± 3.2 years (Table 3-1).  A majority of 
these males were non-Hispanic black (57.9%), publicly insured (43.5%), and attended ≤3 
clinic visits during the study period (70.7%; Table 3-1).  Approximately half attended 
JHCP clinics in suburban locations and the most common JHCP practice specialty was 
Pediatrics (62.9%; Table 3-1). 
Multivariable aORs for the second dose of the HPV vaccine by age group are 
shown in Table 3-3.  Results for the permissive age group are not shown due to limited 
statistical power.  In the target age group, non-Hispanic black males, Hispanic males, and 
males who identified as other race/ethnicity had 27%, 61%, and 74% decreased odds, 
respectively, of receiving the second dose of the HPV vaccine compared with non-
Hispanic white males (p≤0.05, respectively).  Attending >3 clinic visits during the study 
period was significantly associated with a four-fold increase in odds of receiving the 
second dose compared with ≤3 visits (p<0.001).  Baseline age, insurance type, JHCP 
clinic location, and JHCP practice specialty were not significantly associated with odds 
of receiving the second dose of the HPV vaccine in this age group.  
In the catch-up age group, similar to males in the target age group, non-Hispanic 
black race/ethnicity was significantly associated with decreased odds of receiving the 




period was associated with nearly a six-fold increase in odds of receiving the second dose 
of the HPV vaccine in the catch-up age group (p<0.001).  Additionally, males with public 
insurance had 27% decreased odds of receiving the second dose of the HPV vaccine 
compared with males with private insurance (p=0.02) and IM/Peds practice specialty was 
significantly associated with a 48% decrease in odds of receiving the second dose of the 
HPV vaccine compared with Family Practice specialty (p=0.04).  Baseline age and JHCP 
clinic location were not significantly associated with odds of receiving the second dose of 
the HPV vaccine in this age group.  
In the target and catch-up age groups, non-Hispanic black males with ≤3 visits 
had lower odds (aOR 0.62, 95% CI 0.4 – 0.9) of receiving the second dose of the HPV 
vaccine compared to their non-Hispanic white male counterparts.  This association was 
nearly equivalent for non-Hispanic black males with >3 visits (aOR 0.66, 95% CI 0.4 – 
1.1).  Similar patterns were observed for males in the combined “Other” race/ethnicity 
category (data not shown).  Number of clinic visits did not modify the association 
between race/ethnicity and receipt of the second dose of the HPV vaccine (p-interaction = 
0.07).  In contrast, in the target and catch-up age groups, publicly insured males with ≤3 
visits had significantly lower odds of receiving the second dose of the HPV vaccine (aOR 
0.67, 95% CI 0.5 – 0.9) compared to their privately insured counterparts; however, this 
association was attenuated for publicly insured males with >3 visits (aOR 1.05, 95% 0.7 
– 1.6).  There was no significant difference in the odds of receipt of the second dose of 
the HPV vaccine when comparing males with military insurance to their privately insured 




1.2 vs. >3 visits: aOR 0.81, 95% CI 0.3 – 1.9).  Number of clinic visits modified the 
association between insurance type and receipt of the second dose of the HPV vaccine (p-
interaction = 0.001).  
 
HPV Vaccine Completion  
Of the 702 eligible males (those who received their second HPV vaccine dose in 
2012), a total of 331 (47.2%) completed the series during the study timeframe.  Males 
eligible for the third dose of the HPV vaccine tended to be younger than those eligible for 
initiation, with a mean baseline age of 14.7 ± 3.2 years (Table 3-1).  A majority of these 
males were non-Hispanic black (46.7%) and privately insured (44.2%; Table 3-1).  About 
half attended ≤3 clinic visits during the study period, the majority attended JHCP clinics 
in suburban locations (61.1%) and the most common JHCP practice specialty was 
Pediatrics (57.3%; Table 3-1).   
Multivariable aORs for HPV vaccine completion by age group are shown in Table 
3-4.  Results for the permissive age group are not shown due to limited statistical power.  
In the target age group, attending >3 clinic visits during the study period was 
significantly associated with over a three-and-a-half-fold increase in odds of HPV 
vaccine completion compared with ≤3 visits (p<0.001) and visiting a clinic in an urban 
location was significantly associated with a 43% decrease in odds of HPV vaccine 
completion compared with suburban locations (p<0.01).  Baseline age, race/ethnicity, 
insurance type, and JHCP practice specialty were not significantly associated with odds 




In the catch-up age group, similar to males in the target age group, attending >3 
clinic visits during the study period was significantly associated with over a three-and-a-
half-fold increase in odds of HPV vaccine completion (p<0.001).  Additionally, males 
with public insurance had 50% decreased odds of HPV vaccine completion compared 
with males with private insurance (p=0.05).  Baseline age, race/ethnicity, JHCP clinic 
location, and JCHP practice specialty were not significantly associated with odds of HPV 
vaccine completion in this age group.   
In the target and catch-up age groups, non-Hispanic black males with ≤3 visits 
had lower odds (aOR 0.53, 95% CI 0.2 – 1.3) of completing the HPV vaccine compared 
to their non-Hispanic white male counterparts.  This association was nearly equivalent for 
non-Hispanic black males with >3 visits (aOR 0.69, 95% CI 0.3 – 1.5).  Similar patterns 
were observed for males in the combined “Other” race/ethnicity category (data not 
shown).  Number of clinic visits did not modify the association between race/ethnicity 
and completing the HPV vaccine (p-interaction = 0.14).  In contrast, in the target and 
catch-up age groups, publicly insured males with ≤3 visits had significantly lower odds of 
completing the HPV vaccine (aOR 0.46, 95% CI 0.3 – 0.6) compared to their privately 
insured counterparts; however, this association was attenuated for publicly insured males 
with >3 visits (aOR 0.72, 95% 0.3 – 1.7).  There was no significant difference in the odds 
of completing the HPV vaccine when comparing males with military insurance to their 
privately insured counterparts, irrespective of number of clinic visits (≤3 visits: aOR 




visits modified the association between insurance type and completing the HPV vaccine 




In this large clinical population of over 14,500 males aged 11 to 26 years, the 
overall proportion of HPV vaccine initiation was low, with approximately 15% of males 
receiving at least one dose of the vaccine between January 2012 and April 2013.  We 
observed differences in rates of initiation by age group; approximately 25% of males in 
the target age group initiated the HPV vaccine, while 18.5% and 2% of males in the 
catch-up and permissive age groups initiated the HPV vaccine, respectively.  Our rates of 
initiation were lower than those reported from the NIS-Teen, which estimated that 35% 
of males aged 13-17 years initiated the HPV vaccine in the U.S. in 2013 (21% in 
2012230).  In our study, among all males who initiated the HPV vaccine in 2012, 49% 
received the second dose, and among those who received the second dose in 2012, 47% 
completed the HPV vaccine series.  Our rates of completion were comparable with those 
reported for the general U.S. male population in the NIS-Teen study, which estimated 
that 48% of males who initiated the HPV vaccine (45.1% in 2012230) completed the series 
in 2013.    
Among all age groups, we found that non-Hispanic black males were more likely 
to initiate the HPV vaccine compared with non-Hispanic white males.  Irrespective of 
race/ethnicity, males in the target and catch-up age groups who were publicly insured 




previous studies among both males and females suggesting higher HPV vaccine initiation 
rates among non-Hispanic black and publicly insured populations150,152,230.  Although cost 
has been previously cited as a barrier to HPV vaccination243–245, efforts over the past 
several years have focused on improving HPV vaccine reimbursement246.  For low-
income children, the Vaccine For Children (VFC) program provides access to the HPV 
vaccine for Medicaid and underinsured children less than 18 years of age247.  In the 
private sector, the Affordable Care Act requires most private insurance plans to cover the 
HPV vaccine at no cost to patients up to 18 years of age248.  We also observed that males 
in the permissive age group with military insurance were more likely to initiate the HPV 
vaccine compared with males with private insurance.  HPV vaccination is a covered 
benefit for males aged 11 to 26 years under military insurance plans249.  Given that cost 
should not be a barrier going forward, interventions targeting parents and/or providers to 
increase HPV vaccine initiation may be warranted.  
In contrast to our findings for HPV vaccine initiation, we found that non-Hispanic 
black males (vs. non-Hispanic white) in both the target and catch-up age groups and 
males with public insurance (vs. private insurance) in the catch-up age group were less 
likely to receive subsequent doses of the HPV vaccine.  These findings are comparable 
with previous studies reporting lower completion rates among non-Hispanic black and 
publicly insured/underinsured populations152.  It is unclear why the same males who are 
more likely to initiate the vaccine series are less likely to receive subsequent doses.  Our 
data indicated that for non-Hispanic black males, returning for additional clinic visits did 




clinic visits during the study period were equally likely to complete the HPV vaccine 
series compared to males with private insurance.  These findings suggest provider alerts 
and/or patient reminder systems may facilitate HPV series completion for all males, and 
could be particularly effective among minority and publicly insured male patients.  
We also found important clinical predictors associated with HPV vaccination in 
our study.  Among all age groups, attending >3 clinic visits was associated with increased 
odds of HPV vaccine initiation and with receipt of subsequent doses.  These findings are 
similar to other studies reporting that males require more primary care visits to complete 
HPV vaccine series231,250.  We also found that males in the catch-up and permissive age 
groups who primarily attended Internal Medicine clinics (vs. Family Practice) were less 
likely to initiate the HPV vaccine, however once they initiated, they were equally likely 
to receive subsequent doses.  Together these findings have important implications for 
clinical intervention strategies.  For example, broad interventions encouraging routine 
healthcare visits may promote HPV vaccine initiation and completion among all age-
eligible males, whereas more targeted interventions focused on increasing vaccine 
initiation among patients of Internal Medicine physicians may be needed for increasing 
coverage in males who require catch-up HPV vaccination. 
To our knowledge, this is one of the first and largest studies of demographic and 
clinical predictors of HPV vaccination among age-eligible males after the ACIP began 
routinely recommending the vaccine in 2011152.  Our study is unique in that we assessed 
independent predictors of each dose of the HPV vaccine, and contributes to the literature 




our diverse study population in terms of patient age, race/ethnicity, insurance, and 
practice specialties.  However, some important limitations are worth noting.  First, our 
study was limited to clinics affiliated with a single academic-institution in Maryland, and 
therefore our results might not be generalizable to non-academic practice settings or other 
geographic regions.  Second, because we assigned each male a practice specialty type 
based on his most common visit or first visit (if most common was not available), it is 
possible that we misclassified practice specialty type; however we would expect such 
misclassification to be non-differential by vaccine status.  Third, we did not have exact 
visit date, and therefore were limited in our ability to assess timing of each vaccine dose.  
Finally, we used data obtained from the medical record, which is subject to the 
limitations of databases that were not designed for research purposes (e.g., lack of data on 
potential confounders such as parent perceptions, provider recommendation to vaccinate, 
etc.). 
In conclusion, our study indicates that a substantial proportion of age-eligible 
males attending primary care clinics did not receive the HPV vaccine during visits with 
their healthcare provider.  Consistent with the literature, we found important disparities in 
HPV vaccine completion by race/ethnicity and insurance status.  Moreover, we provide 
new evidence demonstrating that these disparities are as equally important for receipt of 
the second dose of the HPV vaccine.  These findings point toward a need for 
understanding barriers to receiving subsequent doses of the HPV vaccine and focused 
interventions among minority and publicly insured males to ensure HPV vaccine series 




provider specialty, and warrant future research on provider-level factors associated with 
HPV vaccination.  
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Table 3-1. Demographic and Clinical Characteristics of Males Aged 11-26 Years 
Attending JHCP Clinics from 2012-2013 by HPV Vaccine Dose Eligibility 
 HPV Vaccine Dose Eligibility 






Total  N 14,688 1,834 702 
Total Vaccinated n (%) 2,180 (14.8) 904 (49.1) 331 (47.2) 
Mean Baseline Age (SD) 18.0 (4.7) 14.9 (3.2) 14.7 (3.2) 
Age Group n (%)    
Target 2,471 (16.8) 493 (26.9) 197 (28.1) 
Catch-Up 8,011 (54.5) 1,270 (69.2) 472 (67.2) 
Permissive 4,206 (28.6) 71 (3.9) 33 (4.7) 
Race/Ethnicity  n (%)    
White 7,432 (50.6) 585 (31.9) 291 (41.4) 
Black 5,163 (35.1) 1,062 (57.9) 328 (46.7) 
Hispanic 684 (4.7) 66 (3.6) 32 (4.6) 
Asian/Pacific Is. 454 (3.1) 29 (1.6) 13 (1.9) 
Other 955 (6.5) 92 (5.0) 38 (5.4) 
Insurance Type  n (%)    
Private 8,688 (59.1) 709 (38.7) 310 (44.2) 
Public 3,114 (21.2) 797 (43.5) 226 (32.2) 
Military 2,494 (17.0) 318 (17.3) 162 (23.1) 
Missing 392 (2.7) 10 (0.5) 4 (0.5) 
Number of Clinic Visits  n (%)    
1-3 Visits 12,325 (83.9) 1,296 (70.7) 346 (49.3) 
>3 Visits 2,363 (16.1) 538 (29.3) 356 (50.7) 
JHCP Clinic Location  n (%)    
Suburban 10,955 (74.6) 939 (51.2) 436 (61.1) 
Urban 3,730 (25.4) 895 (48.8) 266 (37.9) 
JHCP Practice Specialty  n (%)    
Family Practice 5,643 (38.4) 494 (26.9) 230 (32.8) 
IM/Peds 1,021 (7.0) 115 (6.3) 41 (5.8) 
Internal Med 3,553 (24.2) 72 (3.9) 29 (4.1) 
Pediatrics 4,471 (30.4) 1,153 (62.9) 402 (57.3) 
Abbreviations: Asian/Pacific Is., Asian/Pacific Islander; IM/Peds, Internal 
Medicine/Pediatrics; Internal Med, Internal Medicine 
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Table 3-2. Associations of Demographic and Clinical Characteristics with HPV Vaccine Initiation by Age Group 
Among 14,688 Males Attending JHCP Clinics from 2012-2013 
 Target (11-12 years) Catch-Up (13-21 years) Permissive (22-26 years) 
 HPV Vaccine 
Initiation  
 HPV Vaccine 
Initiation  






































(0.72 – 0.97) 
Race/Ethnicity n          
White 187 943 1.0 
(Reference) 
469 3,400 1.0 
(Reference) 
39 2,394 1.0 
(Reference) 
Black 368 660 1.39 
(1.06 - 1.84) 
866 2,165 1.39  
(1.12 - 1.74) 
32 1,072 1.93  
(1.20 - 3.09) 
Hispanic 20 65 1.36  
(0.79 - 2.35) 
54 312 1.04  
(0.76 - 1.42) 
5 228 1.58  
(0.42 - 5.89) 
Asian 11 57 1.15 
(0.69 - 1.90) 
21 198 0.85  
(0.46 - 1.57) 
2 165 0.76  
(0.18 - 3.26) 
Other 31 129 1.16  
(0.77 - 1.75) 
73 453 1.01  
(0.76 - 1.33) 
2 267 0.50  
(0.12 - 2.11) 
Insurance Type n          
Private 193 896 1.0 
(Reference) 
588 3,692 1.0 
(Reference) 
59 3,260 1.0 
(Reference) 
Public 312 457 1.45  
(1.07 - 1.96) 
625 1,237 1.21  
(1.05 - 1.39) 
9 474 0.61 
(0.28 - 1.37) 
Military 112 493 1.25  
(1.03 - 1.51) 
261 1,466 1.06  
(0.91 - 1.25) 
10 152 2.46  
(1.06 - 5.71) 
Number of Clinic Visits n          
1-3 Visits 429 1,528 1.0 
(Reference) 
1,103 5,562 1.0 
(Reference) 
51 3,652 1.0 
(Reference) 
>3 Visits 188 326 2.39 
(1.84 - 3.11) 
380 966 2.19 
(1.76 – 2.73) 
29 474 4.08 
(2.20 –7.56) 
JHCP Clinic Location n          
Suburban  299 1,474 1.0 765 5,298 1.0 63 3,056 1.0 
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(Reference) (Reference) (Reference) 
Urban 318 380 3.27 
(1.53 - 6.99) 
718 1,229 3.84 
(2.23 – 6.61) 
17 1,068 0.98 
(0.35 – 2.76) 
JHCP Specialty n          
Family Practice 120 613 1.0 
(Reference) 
423 2,873 1.0 
(Reference) 
43 1,571 1.0 
(Reference) 
IM/Peds 39 125 1.17  
(0.73 - 1.88) 
86 515 1.00  
(0.74 - 1.34) 
7 249 0.97 
(0.35 - 2.66) 
Internal Med 5 4 1.43  
(0.78 - 2.63) 
55 1,187 0.27  
(0.15 - 0.47) 
29 2,273 0.47  
(0.22 - 0.98) 
Pediatrics 455 1,112 0.81  
(0.51 - 1.28) 
919 1,953 1.28  
(0.95 - 1.73) 
1 33 1.77  
(0.23 - 13.37) 
All models mutually adjusted for all variables listed in the table. Abbreviations: aOR – Adjusted Odds Ratio; CI, Confidence Interval; Asian/Pacific 
Is., Asian/Pacific Islander; IM/Peds, Internal Medicine/Pediatrics; Internal Med, Internal Medicine 
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Table 3-3. Associations of Demographic and Clinical Characteristics with 2nd 
Dose of the HPV Vaccine by Age Group Among 1,834 Males Attending JHCP 
Clinics from 2012-2013 
 Target (11-12 years) Catch-Up (13-21 years) 


























(0.88 - 1.02) 
Race/Ethnicity n       
White 104 43 1.0 
(Reference) 
257 147 1.0 
(Reference) 
Black 132 160 0.63  
(0.40 - 1.00) 
283 458 0.65  
(0.46 - 0.92) 
Hispanic 8 10 0.39  
(0.17 - 0.89) 
21 23 0.72  
(0.33 - 1.54) 
Asian 6 4 0.50  
(0.17 - 1.46) 
10 7 1.11  
(0.52 - 2.40) 
Other 11 15 0.26  
(0.09 - 0.81) 
32 32 0.71  
(0.37 - 1.37) 
Insurance Type n       
Private 100 61 1.0 
(Reference) 
266 230 1.0 
(Reference) 
Public 104 142 0.77  
(0.43 - 1.39) 
195 347 0.73  
(0.56 - 0.96) 
Military 57 29 1.03  
(0.60 - 1.79) 
138 86 0.78  
(0.52 - 1.16) 
Number of Clinic 
Visits n       
1-3 Visits 136 194 1.0 
(Reference) 
326 596 1.0 
(Reference) 
>3 Visits 125 38 4.01  
(3.22 - 4.99) 
277 71 5.82  
(4.13 - 8.20) 
JHCP Clinic 
Location n       
Suburban  149 89 1.0 
(Reference) 
374 273 1.0 
(Reference) 
Urban 112 143 1.08  
(0.35 - 3.34) 
229 394 0.77  
(0.46 - 1.31) 
JHCP Specialty n       
Family Practice 64 37 1.0 
(Reference) 
205 149 1.0 
(Reference) 
IM/Peds 19 13 0.63  
(0.34 - 1.19) 
32 44 0.52  
(0.28 - 0.97) 
Internal Med 0 3 1.00  
(1.00 - 1.00) 
17 28 0.65  
(0.31 - 1.40) 
Pediatrics 178 179 0.57  
(0.30 - 1.06) 
349 446 1.07  
(0.74 - 1.54) 
All models mutually adjusted for all variables listed in the table. Results for the permissive age group are 
not shown due to limited statistical power 
Abbreviations: aOR – Adjusted Odds Ratio; CI, Confidence Interval; Asian/Pacific Is., Asian/Pacific 
Islander; IM/Peds, Internal Medicine/Pediatrics; Internal Med, Internal Medicine 
	  
	   104 
Table 3-4. Associations of Demographic and Clinical Characteristics with HPV 
Vaccine Completion by Age Group Among 702 Males Attending JHCP Clinics 
from 2012-2013 
 Target (11-12 years) Catch-Up (13-21 years) 
 HPV Vaccine 
Completion 




























(0.91 - 1.12) 
Race/Ethnicity n       
White 40 38 1.0 
(Reference) 
116 83 1.0 
(Reference) 
Black 36 60 0.63  
(0.31 - 1.29) 
87 130 0.54  
(0.25 - 1.19) 
Hispanic 4 4 1.01  
(0.38 - 2.73) 
10 11 0.57  
(0.17 - 1.88) 
Asian 3 2 1.95  
(0.17 - 23.02) 
2 6 0.24  
(0.06 - 0.99) 
Other 3 7 0.36  
(0.11 - 1.21) 
13 14 0.62  
(0.31 - 1.26) 
Insurance Type n       
Private 35 42 1.0 
(Reference) 
112 95 1.0 
(Reference) 
Public 29 45 1.10  
(0.74 - 1.63) 
55 94 0.50  
(0.25 - 1.01) 
Military 22 23 1.14  
(0.69 - 1.86) 
58 55 0.67  
(0.43 - 1.04) 
Number of Clinic 
Visits n       
1-3 Visits 29 72 1.0 
(Reference) 
78 157 1.0 
(Reference) 
>3 Visits 57 39 3.69  
(2.00 - 6.82) 
150 87 3.56  
(2.34 - 5.40) 
JHCP Clinic 
Location n       
Suburban  54 62 1.0 
(Reference) 
151 144 1.0 
(Reference) 
Urban 32 49 0.57  
(0.38 - 0.85) 
77 100 1.42  
(0.64 - 3.12) 
JHCP Specialty n       
Family Practice 18 32 1.0 
(Reference) 
82 83 1.0 
(Reference) 
IM/Peds 7 7 1.51  
(0.49 - 4.69) 
11 13 0.82  
(0.37 - 1.80) 
Internal Med 0 0 -- 
-- 
7 7 1.10  
(0.32 - 3.83) 
Pediatrics 61 72 2.15  
(0.93 - 5.00) 
128 141 1.34  
(0.81 - 2.20) 
All models mutually adjusted for all variables listed in the table. Results for the permissive age group are 
not shown due to limited statistical power 
Abbreviations: aOR – Adjusted Odds Ratio; CI, Confidence Interval; Asian/Pacific Is., Asian/Pacific 
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Introduction: The objective of this study was to determine whether perceptions of the 
home and school food environments are related to food and beverage intakes of 
postpartum teens. 
 
Methods: Our study was a baseline, cross-sectional analysis of 853 postpartum teens 
enrolled in a weight-loss intervention study across 27 states from 2007 through 2009. 
Eight-item scales assessed perceived accessibility and availability of foods and beverages 
in school and home environments.  Associations between environments and intakes were 
assessed by using χ2 and using logistic regression with generalized estimating equations 
(GEE), respectively. 
 
Results: Overall, 52% of teens perceived their school food environment as positive, and 
68% of teens perceived their home food environment as positive.  A positive school 
environment was independently associated with fruit consumption and 100% fruit juice 
consumption.  A positive home environment was independently associated with fruit, 
vegetable, and water consumption and infrequent consumption of soda and chips (χ2 P < 
.05).  Having only a positive school environment was associated with fruit consumption 
(GEE odds ratio [OR], 3.1; 95% confidence interval [CI], 1.5–6.5), and having only a 
positive home environment was associated with fruit (GEE OR, 2.9; 95% CI, 1.6–5.6), 
vegetable (GEE OR, 3.1; 95% CI, 1.5–6.2), and water (GEE OR, 2.6; 95% CI, 1.7–4.0) 




Results for positive home and school environments were similar to those for positive 
home only. 
 
Conclusion: Home and school environments are related to dietary behaviors among 








































Nearly one-third of adolescents are overweight or obese and thus are at greater 
risk for obesity and its long-term health consequences, such as diabetes, in 
adulthood251,252.  This risk is significantly heightened for postpartum, teenaged mothers 
who have sociodemographic and behavioral risk factors for overweight and obesity, such 
as low socioeconomic status and poor diet197.  Both the school and home environments 
influence dietary behaviors of teenagers, particularly in low-income and racial/ethnic 
minority populations185,253.  Aspects of food environments that may be particularly 
important include availability and accessibility of healthful foods such as fruits and 
vegetables, low-fat snacks, and low-calorie beverages254–256. 
More recent evidence suggests that school-based interventions and policies may 
not be sufficient to overcome risks posed in other settings257,258.  Reports from the 
Institute of Medicine suggest that although the school environment is a key target for 
obesity prevention programs, emphasis is also needed on the role of parents or caregivers 
in shaping dietary behaviors in the home255,259. 
Little is known about how postpartum teens perceive their food environments and 
whether those perceptions are related to their dietary behaviors185,260.  In previous work 
with high-risk, postpartum teens, we found a stronger relationship between the perceived 
home food environment (vs school) and healthful dietary behaviors261.  Here we aim to 
build on these findings by examining the associations between perceived school and 




examining whether relationships vary by body mass index (BMI) and participation in 
nutrition assistance programs.  We hypothesize that positive perceptions of food 
environments will be associated with healthful food and beverage intakes, and that these 




This cross-sectional study includes baseline data from postpartum teens enrolled 
in the Moms for a Healthy Balance Weight-loss Intervention Study (BALANCE), a 
group-randomized, nested cohort study with an intervention component designed to 
reduce postpartum weight retention in young mothers200.  BALANCE was developed in 
partnership with Parents as Teachers (PAT), a child development–parent education 
program supported by federal and state funds and delivered free of charge to over 
200,000 families in all 50 states262.  For this study, we selected 27 states on the basis of 
the number of adolescent parents expected in the state. 
Detailed methods on the BALANCE intervention have been described 
elsewhere200.  Briefly, trained PAT parent educators delivered an evidence-based 
curriculum via home visits, group activities, and online resources.  Adolescents were 
eligible to participate if they were enrolled in the PAT Teen Program, were less than 1 
year postpartum, and were not pregnant or planning to become pregnant.  We enrolled 
1,325 eligible adolescent mothers from 2007 through 2009, and the study concluded in 
2010.  A total of 141 of the 1,325 teen participants randomized did not complete the 




leaving a total of 1,139 with complete data.  For this analysis, teens who were 
underweight at baseline (n = 19) as well as those who reported they were not currently in 
school (n = 221) were excluded.  An additional 46 teen participants did not have 
information on food environments, leaving a total of 853 included in this analysis. The 
institutional review board of Saint Louis University and Washington University in St 
Louis approved this study, and informed consent was obtained from all participants. 
 
Measures 
Teen mothers self-reported characteristics including age, race/ethnicity, current 
education level, length of time since giving birth (postpartum status), breastfeeding status 
at baseline, and participation in the Supplemental Nutrition Assistance Program (SNAP) 
and the National School Lunch Program (NSLP). 
Trained staff measured height and weight at baseline in accordance with the 
National Health and Nutrition Examination Survey (NHANES) study procedures263.  
Weight, height, and age data were used to calculate age-appropriate BMI categories, 
following the Centers for Disease Control and Prevention algorithm264.  BMI was 
dichotomized as normal (<85th percentile) and overweight/obese (≥85th percentile). 
Questionnaire items measuring perceived access of 4 healthful items (fruits and 
vegetables, low-fat products, low-calorie beverages, and low-calorie snacks) were used to 
characterize the home and school food environments265,266.  For each environment, 8 
statements assessed the availability and selection of healthful items at home (eg, “it is 




purchase and selection of healthful items at school (eg, “it is easy to purchase/there is a 
large selection of low-fat products in school”).  Ratings were scored on a 5-point Likert 
scale (1 = “strongly agree” to 5 = “strongly disagree”).  A mean score of the 8 items was 
created for the school and home food environments (Cronbach’s α = 0.897 and 0.902, 
respectively) and dichotomized as less than 3.0 being a positive environment and 3.0 or 
higher being a negative environment. 
Dietary behaviors were assessed using the Snack and Beverage Food Frequency 
Questionnaire (SBFFQ) developed from our previous work267,268.  A validation study and 
pilot testing were completed with 60 teen participants. The SBFFQ examined the young 
mothers’ intake of 31 items during the prior 7 days by asking on how many days, how 
many times per week, and how much of the item she consumed.  Items that were 
consumed by less than 25% of teens were excluded.  Because of the nature and 
distribution of the data, data on the frequency of specific food and beverage items were 
collapsed into binary categories of infrequent (0–3 d/wk) and frequent (4–7 d/wk) 
consumption as a more conservative approach269. 
 
Statistical analyses 
Descriptive statistics were calculated to evaluate baseline characteristics of all 
postpartum teens and by positive and negative school and home food environments. 
Differences in baseline characteristics by environment were assessed by using Pearson χ2 
tests and t tests.  Relationships between environments and frequency of food and 




strength of association between home and school environments and dietary behaviors, we 
created the following categories: “negative school and home,” “positive school only,” 
“positive home only,” and “positive school and home.”  We used multiple logistic 
regression with generalized estimating equations (GEE) to account for clustering within a 
state.  Potential confounders including NSLP and SNAP participation, race/ethnicity, age, 
and postpartum status, were identified on the basis of a priori knowledge and assessed by 
using a backward selection procedure.  Final regression models were adjusted for 
race/ethnicity, age, and postpartum status, and results were calculated as GEE odds ratios 
(ORs) and 95% confidence intervals (CIs).  To determine whether there were any 
differences by baseline weight status or participation in nutrition assistance programs, all 
models were stratified by BMI (ie, normal weight vs overweight/obese) and NSLP or 
SNAP participation.  Data were analyzed by using Stata (Stata Intercooled, version 13; 
Stata Corp LP). 
RESULTS 
 
The mean age of the postpartum teens was 17 years (range, 12–20) and there were 
no significant age differences by perceived school or home environment (Table 4-1). 
Most teens identified as white (44%), black (29%), or Hispanic (20%).  Racial 
distribution varied significantly by home environment, with a greater proportion of white 
teens reporting a positive home environment (χ2 P < .05).  Slightly more than half of the 
teens had a normal BMI, and no significant differences were observed between home or 
school environment and BMI.  Participation in SNAP and NSLP was common (30% and 




proportion of postpartum teens reporting a negative home environment also reporting 
receiving SNAP and/or NSLP benefits (χ2 P < .05).  Most teens were from 
neighborhoods in rural or suburban settings, and neighborhood location varied 
significantly by school environment; teens living in a suburban neighborhood were more 
likely to perceive a negative school environment (χ2 P < .05).  Approximately 75% of 
teens were 3 months or more postpartum and 12% reported that they were currently 
breastfeeding. 
Overall, the item most likely to be consumed more than 3 days per week was 
chips, followed by cereal (Table 4-2). A positive school environment was significantly 
associated with eating fruit more than 3 days per week, while a positive home 
environment was significantly associated with eating cereal, fruit, and vegetables on 
more than 3 days per week and chips and chocolate on 0 to 3 days per week (χ2 P < .05). 
When we stratified by baseline BMI, the relationships between a positive home 
environment and frequency of chips and chocolate consumption were significant only 
among normal-weight teens (χ2 P < .05). When we stratified by NSLP and SNAP 
participation, patterns of frequency of intake of food items were similar to the patterns 
observed for all teens except 1) the relationship between positive school environment and 
frequency of fruit consumption was significant only for teens participating in NSLP (χ2 P 
< .01), and 2) the relationship between a positive home environment and frequency of 





Overall, the beverage item most likely to be consumed more than 3 times per 
week was water, followed by regular soda (Table 4-2).  A positive school environment 
was significantly associated with frequent consumption of 100% fruit juice as well as 2 
types of sugar-sweetened beverages: fruit punch and sports drinks (χ2 P < .05).  A 
positive home environment was significantly associated with frequent water, 100% fruit 
juice, and whole or 2% milk consumption, and infrequent regular soda consumption (χ2 P 
< .05).  We found similar results when we stratified by baseline BMI; however, the 
significant relationship between a positive home environment and whole or 2% milk 
consumption was observed only for overweight/obese teens (χ2 P < .05).  When we 
stratified by NSLP and SNAP participation, patterns of frequency of intake of beverage 
items were similar to the patterns observed for all teens except that a positive school 
environment was significantly associated only with drinking 100% fruit juice more than 3 
days per week among teens who did not participate in NSLP (χ2 P < .05). 
When compared with teens reporting negative school and home environments, a 
positive school environment only was significantly associated with increased odds of 
frequent fruit consumption (GEE OR, 3.1; 95% CI, 1.5–6.5) (Table 4-3).  Compared with 
teens reporting negative school and home environments, a positive home environment 
only was significantly associated with frequent consumption of cereal (GEE OR, 2.3; 
95% CI, 1.4–3.7), fruit (GEE OR, 2.9; 95% CI, 1.6–5.6), and vegetables (GEE OR, 3.1; 
95% CI, 1.5–6.2) and infrequent consumption of chips (GEE OR, 0.5; 95% CI, 0.3–0.8), 




frequent cereal (GEE OR, 1.7; 95% CI, 1.1–2.8), fruit (GEE OR, 2.9; 95% CI, 1.6–5.4), 
and vegetable (GEE OR, 3.2; 95% CI, 1.7–6.2) consumption. 
Reporting only a positive school environment was not significantly associated 
with frequent consumption of any beverage items.  Compared with teens reporting 
negative school and home environments, teens reporting a positive home environment 
only had increased odds of frequent water (GEE OR, 2.6; 95% CI, 1.7–4.0) and 100% 
fruit juice (GEE OR, 1.9; 95% CI, 1.2–2.9) consumption and infrequent consumption of 
regular soda (GEE OR, 0.5; 95% CI, 0.3–0.7).  Compared with teens reporting negative 
school and home environments, teens reporting both positive home and school 
environments had similar results to those reporting only a positive home environment. 
Teens reporting both a positive home and school environment had significantly greater 
odds of frequent 100% fruit juice (GEE OR, 2.3; 95% CI, 1.5–3.6) and water 
consumption (GEE OR, 1.8; 95% CI, 1.2–2.6) and infrequent consumption of regular 
soda (GEE OR, 0.7; 95% CI, 0.5–1.0) than those reporting both negative home and 
school environments.  Relative relationships between school and home food 
environments and food and beverage item consumption did not vary by baseline BMI. 
Significant associations between the positive school food environment and frequent 
consumption of healthful items such as fruit (GEE OR, 4.8; 95% CI, 1.6–14.6) and 100% 
fruit juice (GEE OR, 2.4; 95% CI, 1.1–5.6) were observed only among teens participating 
in the NSLP.  The relationships between a positive home environment and both positive 
home and school environments did not differ substantially by NSLP participation.  The 




differ by SNAP participation, but significant associations between a positive home 
environment and infrequent consumption of unhealthful items such as chips (GEE OR, 
0.4; 95% CI, 0.2–0.8) and soda (GEE OR, 0.2; 95% CI, 0.1–0.5) were observed only 
among teens who received SNAP benefits.  The same patterns were generally observed 
for both positive home and school environments. 
DISCUSSION 
 
Our findings indicate that the school and home food environments have 
differential relationships with food and beverage intakes.  Our findings were similar to 
those from other studies: we found that a perceived positive school environment was 
primarily related to healthful eating behaviors such as frequent fruit or 100% fruit juice 
intake but not unhealthful eating behaviors270,271.  In contrast, a perceived positive home 
environment was associated with frequent consumption of a wider variety of healthful 
items as well as infrequent consumption of unhealthful food and beverage items such as 
soda and chips.  Our findings regarding the impact of positive school and home food 
environments suggest that for certain items consumed by teens, the major benefit lies 
within the home environment.  This study contributes to our understanding of the 
relationship between both the home and school food environment and dietary behaviors 
of this understudied population of postpartum teens. 
Numerous studies have documented the impact of policy and behavioral 
interventions promoting healthful school food environments on positive dietary change in 
youth256,272,273.  Increased access to fruit and various juices may be a result of enhanced 




foods273,274.  In addition, school meal programs such as NSLP that promote fruit and 
vegetable intake in school environments provide opportunities for increased fruit and 
vegetable consumption among low-income teens275.  However, easy access to and 
availability of high-calorie and high-fat snacks and sugar-sweetened beverages (ie, 
“competitive foods”) that had been commonly sold in vending machines and at after-
school fundraisers may have limited the effectiveness of school food policies and the 
influence of a positive school environment on teens’ eating behaviors272,276.  Our results 
as well as findings from other studies indicate that while a positive school environment 
may be related to frequent intake of certain healthful food and beverage items, it was not 
associated with infrequent intake of unhealthful items such as sweet and salty snacks and 
sugar-sweetened beverages185,270,271,277.  These findings support the importance of recent 
changes in school food policies that limit access to unhealthful snacks by requiring 
improvements in the nutrition content of vending machine foods. 
Unlike childhood obesity interventions in the school setting, interventions 
conducted in the home have not been common.  Many of these interventions have 
focused on individual behavior change without addressing the home food environment, 
limiting their impact on dietary intake and other obesity-related outcomes255,258.  Results 
from our study are consistent with the literature suggesting the home environment has an 
important relationship with dietary intake among adolescents257,278.  The home food 
environment represents a substantial part of the full environmental context in which a 
postpartum teen grows, develops, eats, and behaves and is guided by “family policies” 




environment257,278.  Additionally, new mothers may be particularly aware of and sensitive 
to the health quality of their home setting273.  Our findings suggest the multiple and 
variable influences of a positive home environment have the added benefit of reducing 
unhealthful behaviors among postpartum teens. 
To our knowledge, ours is the first study to examine whether associations 
between the school and home environments and food and beverage intake differ by 
participation in nutrition assistance programs.  Other studies have shown mixed 
associations between SNAP and NSLP participation and dietary behaviors257,279.  Our 
findings suggest that the relationship between the food environment and frequency of 
consumption of certain items may be stronger among postpartum teens receiving 
nutrition assistance than those who did not receive assistance.  Future research is needed 
to determine whether there are differences in the relationship between the environment 
and dietary behavior among teens that do and do not participate in nutrition assistance 
programs. 
Our study has several limitations.  This was a cross-sectional analysis; thus, we 
cannot evaluate causal relationships.  Furthermore, reliance on self-reported data for 
dietary intake may be subject to recall bias and measurement error such as underreporting 
of items consumed.  We attempted to limit potential misclassification by collapsing food 
and beverage frequency into dichotomous categories, but misclassification is a concern 
when using SBFFQ data254,267.  Although we were not able to compare data on the school 
and home environments with objective measures, studies have shown that perceived 




behavior185,260.  Therefore, we consider using perceptions of the school and home food 
environments a strength of this study, particularly because we are among the first to 
address perceptions of the school and home food environments and how they are related 
to behavior.  Additional strengths of this study include a large and nationally 
representative sample of postpartum teens, an understudied population with a high risk 
for overweight and obesity. 
Our study highlights the importance of both the school and home food 
environments and their differential relationships with dietary behaviors among teens at 
high risk for obesity.  Further work targeting interventions across both home and school 
environments simultaneously are needed.  In addition, it is important to understand 
whether different subpopulations respond differently to environmental influences to tailor 
effective obesity interventions and policies.  Improving the home environment may be 
particularly important among this population of teen mothers who directly control the 
food environment of their infants.  Environmental interventions in this high-risk and 
hard-to-reach population may not only be important for reducing the risk of adult-onset 
obesity in the teenaged mother but may also have substantial impact in minimizing the 
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Table 4-1. Characteristics of 853 Postpartum Teens and Their School and Home Food Environmentsa, 
27 States, 2007-2009 
Characteristic Totalb 
School Home 
Positive Negative Positive Negative 
Total N (%) 853 (100.0) 442 (51.8) 411 (48.2) 577 (67.6) 276 (32.4) 
Age, y, mean (SD) 17.4 (1.1) 17.3 (1.1) 17.4 (1.0) 17.4 (1.0) 17.4 (1.1) 
Race/ethnicity, n (%)c 
White 379 (44.4) 193 (43.7) 186 (45.3) 264 (45.7) 115 (41.7) 
Black 247 (29.0) 131 (29.6) 116 (28.2) 151 (26.2) 96 (34.8) 
Hispanic 173 (20.3) 86 (19.5) 87 (21.2) 121 (21.0) 52 (18.8) 
Other/missing 54 (6.3) 32 (7.2) 22 (5.3) 41 (7.1) 13 (4.7) 
BMId, n (%) 
Normal 480 (56.3) 248 (56.1) 232 (56.4) 314 (54.4) 166 (60.1) 
Overweight/obese 373 (43.7) 194 (43.9) 179 (43.6) 263 (45.6) 110 (39.9) 
Education, n (%) 
9th grade 88 (10.6) 53 (12.4) 35 (8.7) 55 (9.8) 33 (12.3) 
10th grade 148 (17.9) 80 (18.7) 68 (17.0) 100 (17.9) 48 (17.9) 
11th grade 251 (30.3) 125 (29.2) 126 (31.5) 172 (30.7) 79 (29.5) 
12th grade 341 (41.2) 170 (39.7) 171 (42.8) 233 (41.6) 108 (40.3) 
SNAP benefitsc, n (%) 254 (30.0) 133 (30.3) 121 (29.6) 155 (27.1) 99 (36.0) 
NSLP benefitsc, n (%) 346 (40.8) 188 (42.8) 158 (38.6) 214 (37.4) 132 (48.0) 
Neighborhoode, n (%) 
Rural 345 (40.4) 186 (46.2) 159 (41.7) 237 (44.8) 108 (42.4) 
Suburban 260 (33.2) 116 (28.8) 144 (37.8) 176 (33.3) 84 (32.9) 
Urban 179 (22.8) 101 (25.1) 78 (20.5) 116 (21.9) 63 (24.7) 
Time since giving birth, n (%) 
<3 months 158 (25.1) 81 (25.6) 77 (24.5) 116 (27.0) 42 (20.9) 
3–6 months 193 (30.6) 107 (33.9) 86 (27.4) 130 (30.3) 63 (31.3) 
>6 months 279 (44.3) 128 (40.5) 151 (48.1) 183 (42.7) 96 (47.8) 
Breastfeedingc, n (%) 96 (11.7) 56 (13.2) 40 (10.1) 81 (14.6) 15 (5.6) 
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  Abbreviations: BMI, body mass index; NSLP, National School Lunch Program; SNAP, 
Supplemental Nutrition Assistance Program. 
a See the Methods section for a description of how positive and negative perceptions were 
determined. 
b Counts may not sum to overall total because of missing data. 
c Significantly different for home environment χ2 P < .05. 
d Weight, height, and age data were used to calculate age-appropriate BMI categories, following the 
Centers for Disease Control and Prevention algorithm. 
e Significantly different for school environment χ2 P < .05. 
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Table 4-2. Associations Between Frequency of Food and Beverage Items Consumed and 















0–3 d/wk 624 (73.2) 319 (72.2) 305 (74.2) 434 (75.2) 190 (68.8) 
4–7 d/wk 229 (26.8) 123 (27.8) 106 (25.8) 143 (24.8) 86 (31.2) 
Crackers 
0–3 d/wk 802 (94.0) 410 (92.8) 392 (95.4) 538 (93.2) 264 (95.7) 
4–7 d/wk 51 (6.0) 32 (7.2) 19 (4.6) 39 (6.8) 12 (4.3) 
Granola bars 
0–3 d/wk 812 (95.2) 417 (94.3) 395 (96.1) 545 (94.5) 267 (96.7) 
4–7 d/wk 41 (4.8) 25 (5.7) 16 (3.9) 32 (5.5) 9 (3.3) 
Cakes 
0–3 d/wk 764 (89.6) 394 (89.1) 370 (90.0) 522 (90.5) 242 (87.7) 
4–7 d/wk 89 (10.4) 48 (10.9) 41 (10.0) 55 (9.5) 34 (12.3) 
Cookies 
0–3 d/wk 785 (92.0) 402 (91.0) 383 (93.2) 531 (92.0) 254 (92.0) 
4–7 d/wk 68 (8.0) 40 (9.0) 28 (6.8) 46 (8.0) 22 (8.0) 
Chocolateb 
0–3 d/wk 750 (87.9) 389 (88.0) 361 (87.8) 520 (90.1) 230 (83.3) 
4–7 d/wk 103 (12.1) 53 (12.0) 50 (12.2) 57 (9.9) 46 (16.7) 
Hard candy 
0–3 d/wk 794 (93.1) 412 (93.2) 382 (92.9) 542 (93.9) 252 (91.3) 
4–7 d/wk 59 (6.9) 30 (6.8) 29 (7.1) 35 (6.1) 24 (8.7) 
French fries 
0–3 d/wk 738 (86.5) 381 (86.2) 357 (86.9) 505 (87.5) 233 (84.4) 
4–7 d/wk 115 (13.5) 61 (13.8) 54 (13.1) 72 (12.5) 43 (15.6) 
Pizza 
0–3 d/wk 811 (95.1) 415 (93.9) 396 (96.4) 551 (95.5) 260 (94.2) 
4–7 d/wk 42 (4.9) 27 (6.1) 15 (3.6) 26 (4.5) 16 (5.8) 
Cerealb 
0–3 d/wk 646 (75.7) 335 (75.8) 311 (75.7) 418 (72.4) 228 (82.6) 
4–7 d/wk 207 (24.3) 107 (24.2) 100 (24.3) 159 (27.6) 48 (17.4) 
Fruitb,c 
0–3 d/wk 712 (83.5) 357 (80.8) 355 (86.4) 468 (81.1) 244 (88.4) 
4–7 d/wk 141 (16.5) 85 (19.2) 56 (13.6) 109 (18.9) 32 (11.6) 
Vegetablesb 
0–3 d/wk 722 (84.6) 367 (83.0) 355 (86.4) 468 (81.1) 254 (92.0) 
4–7 d/wk 131 (15.4) 75 (17.0) 56 (13.6) 109 (18.9) 22 (8.0) 
Waterb 
0–3 d/wk 251 (29.4) 130 (29.4) 121 (29.4) 144 (25.0) 107 (38.8) 
4–7 d/wk 602 (70.6) 312 (70.6) 290 (70.6) 433 (75.0) 169 (61.2) 
Regular sodab 
0–3 d/wk 456 (53.5) 229 (51.8) 227 (55.2) 337 (58.4) 119 (43.1) 
4–7 d/wk 397 (46.5) 213 (48.2) 184 (44.8) 240 (41.6) 157 (56.9) 
100% Fruit juiceb,c 
0–3 d/wk 597 (70.0) 292 (66.1) 305 (74.2) 381 (66.0) 216 (78.3) 
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4–7 d/wk 256 (30.0) 150 (33.9) 106 (25.8) 196 (34.0) 60 (21.7) 
Fruit punchc 
0–3 d/wk 712 (83.5) 358 (81.0) 354 (86.1) 477 (82.7) 235 (85.1) 
4–7 d/wk 141 (16.5) 84 (19.0) 57 (13.9) 100 (17.3) 41 (14.9) 
Sports drinksc 
0–3 d/wk 787 (92.3) 397 (89.8) 390 (94.9) 530 (91.9) 257 (93.1) 
4–7 d/wk 66 (7.7) 45 (10.2) 21 (5.1) 47 (8.1) 19 (6.9) 
Whole or 2% milkb 
0–3 d/wk 472 (55.3) 234 (52.9) 238 (57.9) 304 (52.7) 168 (60.9) 
4–7 d/wk 381 (44.7) 208 (47.1) 173 (42.1) 273 (47.3) 108 (39.1) 
Sweet tea 
0–3 d/wk 711 (83.4) 371 (83.9) 340 (82.7) 483 (83.7) 228 (82.6) 
4–7 d/wk 142 (16.6) 71 (16.1) 71 (17.3) 94 (16.3) 48 (17.4) 
aSee the Methods section for a description of how positive and negative perceptions 
were determined. 
b Significantly different for home environment, χ2 P < .05. 
c Significantly different for school environment, χ2 P < .05. 
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Table 4-3. GEE Logistic Regressiona Analysis of Food Environments b and Frequency of 
Food and Beverage Consumption Among 853 Postpartum Teens, 27 States, 2007-2009 
Item 
Consumed 
Negative School  
and Home  
(n = 179) 
GEE OR (95% CI) 
Positive School  
Only  
(n = 97) 
Positive Home  
Only  
(n = 232) 
Positive School 
and Home  
(n = 345) 
Food 
Chips 1 [Reference] 0.8 (0.4–1.3) 0.5 (0.3–0.8)c 0.8 (0.5–1.1) 
Crackers 1 [Reference] 1.9 (0.6–6.1) 1.7 (0.6–4.7) 2.3 (0.9–5.9)d 
Granola bars 1 [Reference] 3.8 (0.9–17.0)d 3.5 (0.9–13.6)d 3.4 (0.9–12.8)d 
Cakes 1 [Reference] 1.0 (0.5–2.2) 0.6 (0.3–1.3) 0.8 (0.5–1.5) 
Cookies 1 [Reference] 1.3 (0.5–3.1) 0.9 (0.4–1.9) 1.2 (0.6–2.4) 
Chocolate 1 [Reference] 1.6 (0.9-3.1) 0.7 (0.4–1.3) 0.6 (0.3–1.0) 
Hard candy 1 [Reference] 1.1 (0.5–2.6) 0.7 (0.3–1.5) 0.7 (0.3–1.3) 
Fries 1 [Reference] 1.1 (0.5–2.1) 0.7 (0.4–1.3) 0.8 (0.5–1.4) 
Pizza 1 [Reference] 1.5 (0.5–4.1) 0.5 (0.2–1.4) 1.2 (0.5–2.5) 
Cereal 1 [Reference] 1.2 (0.7–2.4) 2.3 (1.4–3.7)e 1.7 (1.1–2.8)c 
Fruit 1 [Reference] 3.1 (1.5–6.5)e 2.9 (1.6–5.6)e 2.9 (1.6–5.4)b 
Vegetables 1 [Reference] 1.3 (0.5–3.3) 3.1 (1.5–6.2)e 3.2 (1.7–6.2)b 
Beverage 
Water 1 [Reference] 1.3 (0.8–2.1) 2.6 (1.7–4.0)e 1.8 (1.2–2.6)e 
Regular soda 1 [Reference] 1.4 (0.8–2.3) 0.5 (0.3–0.7)e 0.7 (0.5–1.0)c 
100% Fruit 
juice 
1 [Reference] 1.5 (0.8–2.6) 1.9 (1.2–2.9)e 2.3 (1.5–3.6)e 
Fruit punch 1 [Reference] 1.4 (0.7–2.7) 1.1 (0.6–1.9) 1.5 (0.9–2.6) 
Sports drinks 1 [Reference] 2.1 (0.8–5.5) 1.1 (0.4–2.6) 2.0 (1.0–4.4)d 
Whole or 2% 
milk 
1 [Reference] 1.2 (0.8–2.2) 1.5 (1.0–2.2)e 1.6 (1.1–2.3)c 
Sweet tea 1 [Reference] 0.6 (0.3–1.1) 0.7 (0.4–1.2) 0.8 (0.5–1.3) 
Abbreviations: GEE, generalized estimating equations; OR, odds ratio; CI, confidence 
interval. 
a Adjusted for race, age, and length of time since giving birth. 
b See the Methods section for a description of how positive and negative perceptions 
were determined. 
c P < .01 
d P < .1, significant for trend. 











The previous chapters suggest a number of conclusions regarding opportunities 
for cancer prevention in early-life.  For example, etiologic evidence linking gestational 
exposure to maternal obesity with altered DNA methylation patterns in offspring genes 
may provide additional insights into the in utero period as a critical window for adult 
cancer risk.  Likewise, a better understanding of how to prevent exposure to early-life 
modifiable risk factors, such as HPV infection, and unhealthy diet, have the potential to 
lead to more effective primary cancer prevention strategies.   
 
SUMMARY OF FINDINGS  
 
  In utero exposures, such as maternal adiposity, are recognized as having an 
important, yet not fully understood influence on fetal growth and later risk of obesity and 
related diseases, such as cancer.  Epigenetic mechanisms, such as DNA methylation, are 
hypothesized to play an important role in mediating this risk280.  Although some evidence 
is emerging, epidemiologic studies are relatively limited due to the inherently complex 
nature of studying the role of DNA methylation in mediating fetal programming of adult 
obesity and cancer risk.  As an essential first step, it is necessary to establish whether 
DNA methylation patterns in offspring genes vary with respect to maternal obesity and 
excess gestational weight gain280.  Our findings from Chapter 2 provide evidence 
supporting this critical first step, suggesting in utero exposure to maternal 
overweight/obesity and excess gestational weight gain may influence DNA methylation 
levels within offspring genes, some of which play a role in cell signaling and cell division 




exposures with DNA methylation levels may be different with respect to infant sex89,281.  
To our knowledge, this is the first study to evaluate the association of maternal 
overweight/obesity and gestational weight gain with offspring cord blood DNA 
methylation patterns in candidate genes using microfluidic PCR and next-generation, 
bisulfite sequencing technology.   
While promising, our findings should be interpreted with caution until replicated 
in large, independent studies.  Similar to other studies, the magnitude of the difference in 
methylation levels at several CpG sites observed in our study was small (≤5%), thus the 
biological relevance of these differences remains unclear.  Prospective cohort studies 
assessing whether differences in DNA methylation patterns persist over time and whether 
these patterns are associated with subsequent offspring BMI, will be important for 
determining the long-term functional significance of these associations.  Future studies 
investigating the influence of maternal obesity and weight gain on offspring DNA 
methylation patterns will also need to address whether patterns observed in peripheral 
blood leukocytes reflect those occurring in disease-relevant tissue, with different cellular 
compositions280.   
The identification of a persistent biomarker of early-life obesity exposure would 
be useful for epidemiologic studies of early-life exposures and cancer risk, and could 
potentially provide more meaningful endpoints for interventions designed to reduce the 
risk of offspring obesity and metabolic disease later in life.  Furthermore, early-life 
epigenetic modifications that occur in genes related to obesity and cancer may elucidate 





The critical window for HPV vaccination begins in childhood, before the onset of 
sexual activity4.  Our study of predictors of HPV vaccination in males suggests that a 
substantial proportion of age-eligible males attending primary care clinics did not receive 
the HPV vaccine during visits with their healthcare provider.  We were able to 
corroborate previous findings of higher rates of initiation, but lower rates of completion 
among non-Hispanic black and publicly insured/underinsured males compared with their 
non-Hispanic white and privately insured counterparts, respectively150,152.  Further, we 
provided novel evidence demonstrating that these disparities are as equally important for 
receipt of the second dose of the HPV vaccine.  We also observed that attending >3 clinic 
visits was positively associated with receipt of each HPV vaccine dose among all males 
and that frequent visits mitigated the inverse association between public insurance and 
receipt of subsequent doses.  In regards to provider specialty, attendance to Internal 
Medicine clinics (vs. Family Practice) was inversely associated with HPV vaccine 
initiation among older males (i.e., in catch-up and permissive age groups).   
Our findings present a number of opportunities for future investigation.  Studies 
designed to better understand barriers to receiving subsequent doses of the HPV vaccine 
will help to inform interventions among minority and publicly insured males to ensure 
HPV vaccine series completion.  Further, our study underscores the need for future 
research on provider-level factors associated with HPV vaccination in males, and 
suggests that interventions may need to be targeted by provider specialty.  Indeed, a 




vaccine uptake suggest that those conducted at the community- and practice-level may be 
more effective than individual-level educational interventions; although only two of the 
studies reviewed included males, and few focused on adolescents in the target age range 
of 11 to 12 years282.  Based on our current findings and those published in other studies, 
interventions that incorporate different strategies for increasing HPV vaccine initiation 
versus increasing rates of subsequent doses among males may be warranted. 
 
 Unhealthy dietary behaviors such as decreased fruit and vegetable intake and 
higher consumption of energy-dense foods and sugar-sweetened beverages are often 
established during adolescence, a critical period for the development of overweight and 
obesity283,284.  This risk is especially heightened for certain subgroups such as postpartum 
adolescents, who tend to gain excessive weight during pregnancy and retain more weight 
postpartum compared with their adult counterparts192–196.  Research addressing 
environmental influence on dietary patterns among this difficult to reach and high-risk 
population will be important for informing intervention strategies and preventing long-
term obesity and subsequent cancer risk.  Numerous studies have investigated the impact 
of policy and behavioral interventions promoting healthy school environments on dietary 
behaviors in adolescents.  Schools are a unique setting to promote healthy lifestyles and 
emerging evidence suggests that recent policies are having an impact on the nutritional 
content of school meals and have reduced disparities in healthy food access187.  In 
contrast to school-based interventions and policies, interventions conducted in the home 




with the literature suggesting the home environment has an important relationship with 
dietary intake among adolescents, particularly in reducing unhealthy dietary 
behaviors183,257,261,278.  The home environment is an important setting for families, 
particularly for teen mothers who are in a position to model healthy dietary behaviors for 
their infants285.   
COMMON THEMES AND IMPLICATIONS FOR CANCER PREVENTION 
 
Although each chapter represents an independent study of a discrete cancer risk 
factor, it is worth noting a few overarching themes that may be applicable to various 
aspects of cancer prevention in early-life.   
 
Pregnancy is a Critical Period for Obesity Risk 
 
The high prevalence of overweight and obesity among reproductive-aged women 
underscores the importance of pregnancy as a critical period for obesity risk for both the 
mother and infant.  Diet and other lifestyle factors during pregnancy can have profound 
effects on an infant’s weight at birth that persist into childhood and adulthood.  
Pregnancy may potentially be an optimal time for intervention, as women may be more 
receptive to making lifestyle changes as they contemplate pregnancy, and when they are 
pregnant, to increase the likelihood of having a healthy baby286.  During the postpartum 
period, many women may be willing to make substantial changes to protect the health of 
their infant.  Pregnancy also involves more frequent contact with the healthcare system, 




Preconception care interventions that provide clinical guidance, screening, and 
interventions for women of reproductive age, represent an opportunity to reduce the risk 
of adiposity and weight gain in both the mother and infant286.  Indeed, the American 
Congress of Obstetrics and Gynecologists (ACOG) emphasizes the importance of 
preconception care and strongly recommends antenatal obesity screening and the 
provision of specific information concerning maternal and fetal risk factors associated 
with obesity in pregnancy287,288.  As others and we have demonstrated, maternal pre-
pregnancy overweight and obesity can influence cord blood DNA methylation patterns in 
genes related to cell growth and differentiation, which may have potential long-term 
consequences for gene expression and disease susceptibility in offspring.  Our findings 
highlight the importance of preconception care in addressing obesity-related risk factors 
before a woman becomes pregnant.    
To reduce the risk of postpartum weight retention, ACOG also recommends 
nutrition and physical activity counseling to all overweight or obese women during 
pregnancy, through the postpartum period and before attempting another pregnancy287.  
We have shown that the availability and accessibility of foods in the home environment 
are associated with dietary patterns in postpartum teens.  As maternal dietary preferences 
and behaviors tend to shape the preferences and consumption patterns among offspring, 
dietary counseling that continues through the postpartum period is critical for mitigating 
the risk of postpartum weight retention and offspring risk of unhealthy diet and weight 




Interventions targeting the entire spectrum of pregnancy have the potential to curb 
the trajectory of weight gain throughout the life course and halt the perpetual cycle of 
obesity risk.  Increased awareness and recognition from cancer institutes and 
organizations may help to stimulate research and funding opportunities for cancer 
prevention efforts during this critical period of increased risk and opportune time for 
intervention.  
 
Cancer Prevention for Children and Adolescents Should be Integrated With Routine 
Primary Care 
 
Primary care providers should take full advantage of routine clinic visits to 
provide cancer prevention services to their pediatric and adolescent patients.  As our 
study on determinants of HPV vaccine uptake helps to illustrate, routine encounters with 
a healthcare provider can result in cancer risk reduction behaviors, such as receipt of age-
appropriate immunizations as well as early identification and reduction of modifiable 
cancer risk factors and screening for early-onset disease.  The United States Preventive 
Services Task Force (USPSTF) issues guidelines for preventive service recommendations 
for children and adolescents; however, some important topics are not included in the 
recommendations due to the strict criteria employed by the USPSTF when assessing the 
evidence.  For example, while the USPSTF recommends screening for obesity among 
children beginning at age 6, they do not find sufficient evidence to support primary care 
counseling to promote physical activity or nutrition among children and adolescents289.  
In this case, physicians should use clinical judgment and consider alternative sources for 




Futures: Guidelines for Health Supervision for Infants, Children and Adolescents is the 
primary resource for pediatricians in delivering preventive services290.  Led by the 
American Academy of Pediatrics (AAP), Bright Futures issues guidelines “to improve 
the health and well-being of all children through culturally appropriate interventions that 
address their current and emerging health promotion needs at the family, clinical practice, 
community, health system, and policy levels”.  Bright Futures covers the spectrum of 
cancer risk factors, emphasizing the promotion of healthy weight as a significant and 
growing challenge among children and adolescents, and just recently added an “HPV 
Champion Toolkit” which provides educational resources to parents and healthcare 
professionals291.   Bright Futures is a leading example of a comprehensive approach that 
integrates a wide range of preventive and health promotion services that could have real 
impact in reducing the burden of cancer risk factors in early-life.  Future studies should 
address how to best engage children and adolescents in primary care settings to achieve 
maximum benefit from these services.  Moreover, research is needed to assess how to 
best train and incentivize primary care providers and to evaluate clinical support tools 
and technology that will ensure that cancer prevention services are delivered to pediatric 
and adolescent patients.   
 
Consideration of Vulnerable Populations 
 
This dissertation focused on vulnerable populations that are typically 
understudied with respect to cancer research.  Federal regulations require additional 
human subjects’ protections for pregnant women, human fetuses, and neonates292, and 




risk293.  Developing fetuses are extremely vulnerable to maternal exposures that may 
affect organ development and programming of disease susceptibility.  As they have no 
control over their environments, developing fetuses are completely dependent on the 
mother for nutrients that are essential for normal growth and development.  This 
vulnerability may manifest as long-term obesity and cancer risk in postnatal life.  
Young males represent a population that has been significantly understudied in 
regard to HPV vaccination, particularly after the ACIP revised their recommendation in 
October 2011.  The rising incidence of HPV-associated anal and oropharyngeal cancers 
among men underscores the need to vaccinate males before they become sexually 
active144.  Relying on female vaccination alone will not provide adequate protection in 
the form of herd immunity, particularly among MSM who do not stand to benefit from 
female vaccination4.  In recognition of the importance of HPV vaccination in males, an 
objective was added to Healthy People 2020 in 2014 to increase coverage with all three 
doses for males by ages 13 to 15 years151.  
Nearly 300,000 adolescents become pregnant each year in the U.S., representing a 
significant, yet understudied population at high risk for obesity and related diseases, such 
as cancer, later in life.  Teenage mothers have unique needs and competing demands that 
limit their ability to participate in research studies.  Future studies should explore options 
for home- and school-based interventions to ensure participation200.  Furthermore, 
measurement tools that are appropriate for use in postpartum adolescents should be 
adapted and/or designed to ensure relevant content is being assessed200.  High rates of 




public health interventions targeting postpartum teens.  Addressing the physiological, 
sociodemographic, and environmental influences on dietary behaviors in this high-risk 
and understudied population is critical to interrupting the cycle of obesity risk.  
 
More Research on Early-Life Exposures and Adult Cancer Risk is Needed 
 
The purpose of this dissertation was to emphasize early-life as an important, yet 
understudied period with respect to cancer research.  Both the Centers for Disease 
Control and Prevention and the National Cancer Institute (NCI) have accentuated the 
need for more research in this area.  Recently, the NCI released a Funding Opportunity 
Announcement (PA-15-126) to simulate research with the goal of better understanding 1) 
early-life factors that are associated with later cancer development; 2) how early-life 
factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive 
markers associated with early-life exposures can be measured and developed for use in 
cancer prevention strategies.  Identifying available resources that can be utilized for 
research questions addressing early-life and cancer risk should be a priority.  The 
pressing need for more research will require innovative use of existing data from cohorts 
with relevant intermediate markers or risk factors as well as prospective studies that are 
designed to capture cancer risk factors in early-life.  In the U.S., state-based birth and 
cancer registries may also be combined to create new opportunities to investigate early-
life exposures related to cancer risk11.  Biomarker studies of early-life exposures and/or 









DNA METHYLATION QUALITY CONTROL ANALYSES  
 
Quality Control Samples: Technical Replicates 
 
 A total of 11 technical replicate samples were included for quality control (QC) 
purposes.  The replicates were amplified on separate Fluidigm Access Array chips (1, 2 
or 3) and sequenced on a single chip.  To our knowledge, there is currently no standard 
approach for quality control analyses of data generated from microfluidic PCR-based 
target enrichment and next-generation bisulfite sequencing technology1220.  Traditional 
quality control estimates such as the coefficient of variation (CV) were calculated; 
however, because the distribution of methylation values was highly right-skewed (i.e., 
methylation values were close to 0), the CVs were inflated and very sensitive to small 
changes in the mean.  As an alternative approach, we calculated the concordance 
correlation coefficient, which combines measures of both precision and accuracy to 
determine how far the observed data deviate from perfect concordance (i.e., a 45o line)294. 
Concordance correlation coefficient estimates for each pair of replicates were modestly 
high, with an average of approximately 0.70 (range 0.42 – 0.82).  To assess whether 
concordance varied by specific genes, we calculated the absolute value of the difference 
in methylation proportions between each pair of replicates for each CpG site and took the 
average across all replicates to generate a mean difference (CpG site-level mean 
difference) for each CpG site (Figure A1).  We then calculated the mean and standard 
deviation (SD) of the mean difference across CpG sites, by gene (gene-level mean 
difference and SD).  Any CpG-site level mean difference that was greater than + 2 SD’s 




identified as outliers using this approach (Table A1).  From this analysis, the degree of 





Figure A1. Box Plots of CpG Site-Level Mean Differences of Methylation Proportion by 
Gene. The absolute value of the mean difference was calculated between each pair of 
replicates for each CpG.  This value was then averaged across all replicates to generate a 









































































































Box Plots of CpG Site-Level Mean Differences of










































Quality Control Samples: Laboratory Controls 
 
Table A1. CpG Sites with Absolute Value Mean Differences 
that Exceed Gene-Level Mean Difference + 2SD 
Gene  
Symbol 
CpG Site  
Positiona 
CpG-Site Level  
Mean Differenceb 
Gene-Level Mean  
Difference (SD)c 
ADCY3 24995895 0.2878 0.0449 (0.093) 
ANAPC7 109325831 0.0643 0.0084 (0.017) 
CAB39 231285851 0.1186 0.0175 (0.032) 
 231285863 0.1122 0.0175 (0.032) 
ERBB2 35098006 0.0319 0.0062 (0.011) 
GPRC5B 19804118 0.0773 0.0149 (0.022) 
HEYL 39877608 0.5054 0.1715 (0.133) 
 39877610 0.4691 0.1715 (0.133) 
 39877725 0.5045 0.1715 (0.133) 
IGF2 2110623 0.2766 0.0769 (0.088) 
 2110642 0.3829 0.0769 (0.088) 
 2110657 0.2706 0.0769 (0.088) 
INSR 7244450 0.0770 0.0196 (0.023) 
 7244543 0.0721 0.0196 (0.023) 
ITGAE 3573467 0.1100 0.0220 (0.035) 
PPARG 12305326 0.0584 0.0198 (0.015) 
PRR16 119827784 0.0614 0.0141 (0.020) 
 119827801 0.0790 0.0141 (0.020) 
PXYLP1 142432606 0.1590 0.0296 (0.053) 
SAPCD2 139084682 0.0776 0.0152 (0.024) 
 139084741 0.1030 0.0152 (0.024) 
XRCC3 103251158 0.0819 0.0064 (0.014) 
ZCCHC10 132390109 0.0529 0.0098 (0.016) 
 132390152 0.0795 0.0098 (0.016) 
 132390195 0.0496 0.0098 (0.016) 
ZKSCAN5 98940131 0.0465 0.0138 (0.012) 
 98940249 0.0439 0.0138 (0.012) 
aBased on NCBI Build 36; bCpG site-level mean difference 
corresponds to the average mean difference across all replicates 
for a given CpG site;  cGene-level mean difference corresponds to 
the average of the CpG site-level mean differences within a given 




  Two types of laboratory control samples were also included for QC purposes, 
including water blanks containing no DNA (i.e., negative controls) and white blood cell 
DNA as a standard.  Each sample type was included on all three Fluidigm Access Array 
chips.  For the water blanks, we assessed mean coverage (i.e., the number of sequencing 
reads) levels for each gene and considered coverage of 50 reads or greater as 
contamination.  The range of coverage averaged from 0 to 39.5 reads, with a majority of 
genes having a mean coverage of less than 10 reads across all three chips (data not 
shown).  
 
Assessment of Chip (“Batch”) Effects  
 
 Several visual tools were used to assess whether there were systematic differences 
in methylation proportions according to Fluidigm Access Array chip.  First, a density plot 
was created to visualize the shape of the distribution of methylation values for each chip. 
In general, high overlap in the distribution of the curves did not suggest of batch effects by 





Figure A2. A density plot of the distribution of methylation values by chip.  The 
distribution of methylation values for each Fluidigm Access Array chip is plotted using kernel 




 Principle Component Analysis (PCA) was also employed to assess batch effects 
by chip. PCA aims to represent a large number of correlated measures (i.e., CpG sites) by 
a smaller number of uncorrelated variables to capture the majority of the variance in the 
data.  The first two principle components were graphed using a scatterplot, with each 
sample colored according to chip.  Separation of colors into distinct clusters would 
provide evidence for a batch effect, although this did not appear to be the case for our data 
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Figure A3. Principle Components Analysis by Chip.  Principle components analysis was 
performed using the methylation values from all samples. Principle component score 1 is 
plotted against principle component score 2.  Component scores are color-coded according to 
Fluidigm Access Array chip.  This plot does not suggest systematic bias with respect to chip, 
although some outliers are observed.  Abbreviations: PCA, Principle Components Analysis 
 Finally, we assessed sequencing performance according to chip by plotting the 
mean coverage values for each gene by chip in a histogram.  As shown in Figure A4, 
coverage appeared to be consistent across chips, but did vary with respect to gene, ranging 
from 341.4 (ADCY3) to 38,188.8 reads (ZKSCAN5).  In general, coverage was very high 
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Figure A4. Plot of Coverage by Gene and Chip in all Samples.  Sequencing coverage (i.e., 
the number of sequencing reads per amplicon) is plotted for each gene.  Overall, coverage is 
high (>1,000 reads) and does not appear to be systematically biased according to chip; however 





VALIDITY OF SELF-REPORTED PRE-PREGNANCY BMI IN THE 
EHUB STUDY 
 
 To assess the validity of self-reported pre-pregnancy BMI, we plotted self-reported 
pre-pregnancy BMI against BMI obtained at the first prenatal visit.  In general, there was 
a high degree of correlation between pre-pregnancy BMI and BMI at the first prenatal 




























































































































































































































Numbers Correspond to Chips 1-3
Mean Sequencing Coverage by Gene and Chip
	   147 
reported pre-pregnancy BMI.  For our analyses, we chose to use pre-pregnancy BMI 
rather than first prenatal visit BMI to be in line with other studies, and because it most 
accurately reflects a woman’s BMI prior to becoming pregnant.  
 
Figure A5. Self-Reported Pre-Pregnancy BMI vs. First Prenatal Visit BMI.  A two-way 
scatterplot of self-reported pre-pregnancy BMI and first prenatal visit BMI shows a high degree 
of linear correlation between the two values (Pearson correlation coefficient = 0.93), suggesting 
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1. Roberts JE, Clarke MA, Carter JC, Kaufmann WE. Autistic Behavior in Boys with 
Fragile X Syndrome: Social Approach and HPA-Axis Dysfunction. J Neurodevelop 
Disord 2009;1:283-291. PMCID: PMC3164009 
 
2. Kaufmann WE, Tierney E, Rhode CA, Suarez-Pedraza MC, Clarke MA, Salorio CF, 
Bibat G, Bukelis I, Naram D, Lanham DC, Naidu S. Social impairments in Rett 
syndrome: Characteristics and relationship with clinical severity. J Intellect Disabil 
Res 2012;56:223-47.  
 
3. Clarke MA, Gage JC, Olusegun AK, Wentzensen N, Akinfolarin AC, Burk RD, 
Schiffman M. A population-based cross-sectional study of age-specific risk factors 
for high risk human papillomavirus prevalence in rural Nigeria. Infect Agents Cancer. 
2011;6:12.  PMCID: PMC3162906 
4. Schiffman M, Gage JC, Clarke MA. Accepting the universal truths of global HPV 
epidemiology in pursuit of the remaining mysteries.  Sex Transm Dis 2011;38:907-8.  
5. Clarke MA, Rodriguez AC, Gage JC, Herrero R, Hildesheim A, Wacholder S, Burk 
RD, Schiffman M. A large, population-based study of age-related associations 
between vaginal pH and human papillomavirus infection. BMC Infect Dis 
2012;12:33. PMCID: PMC3292496 
 
6. Wentzensen N, Sun C, Ghosh A, Kinney W, Mirabello L, Wacholder S, Shaber R, 
LaMere B, Clarke M, Lorincz A, Castle P, Schiffman M, Burk RD.  Methylation of 
HPV18, HPV31, and HPV45 genomes is associated with cervical intraepithelial 
neoplasia grade 3. JNCI 2012;104:1738-49. PMCID: PMC3571257 
 
7. Clarke MA, Wentzensen N, Mirabello L, Ghosh A, Wacholder S, Harari A, Lorincz 
A, Schiffman M, Burk RD. Human papillomavirus DNA methylation as a potential 
biomarker for cervical cancer. Cancer Epidemiol Biomarkers Prev 2012;21:2125-37. 
PMCID: PMC3664203 
 
8. Clarke MA, Schiffman M, Wacholder S, Rodriguez AC, Hildesheim A, Quint W. A 
Prospective Study of Absolute Risk and Determinants of Human Papillomavirus 
Incidence among Young Women in Costa Rica. BMC Infect Dis 2013;13:308.  
PMCID: PMC3723935 
 
9. Clarke MA, Haire-Joshu DL, Schwarz CD, Tabak RG, Joshu CE.  Relative influence 
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of home and school environments on specific dietary behaviors among postpartum, 
high-risk teens, 2007 – 2009. 2015;12:140437. PMCID: PMC4436050 
 
10. Tabak RG, Joshu CE, Clarke MA, Schwarz CD, Haire-Joshu DL. Postpartum Teens' 
Perception of the Food Environments at Home and School. Health Educ Behav. 2015; 
epub ahead of print.  
 
11. Clarke MA, Coutinho F, Phelan-Emrick DF, Wilbur MA, Chou B, Joshu CE. 
Predictors of Human Papillomavirus Vaccination in a Large Clinical Population of 
Males Aged 11 to 26 years in Maryland, 2012 – 2013. Cancer Epidemiol Biomarkers 








1. Kaufmann WE, Capone GT, Clarke M, Budimirovic DB (2008) Autism in genetic 
intellectual disability: Insights into idiopathic autism. In Zimmerman AW (Ed). 







1. Performance of Cytology and HPV16/18 Genotyping Among a Large Cohort of HPV 
Positive Women Aged 30 Years and Older (Poster). The 2014 National STD 
Prevention Conference, Atlanta, GA. 
 
2. Sex Partner Meeting Places Reported By Newly Diagnosed HIV-Infected MSM in 
Baltimore City: Exploring Individual Characteristics and Viral Loads By Meeting 
Place (Poster). The 2014 National STD Prevention Conference, Atlanta, GA. 
 
3. Relative Influence of Home and School Environments on Dietary Behaviors Among 
Postpartum, High-Risk Teens (Poster).  AACR 2014 Frontiers in Cancer Prevention 
Conference, New Orleans, LA.  
 
4. Factors associated with HPV vaccine initiation among males aged 11-26 years 
attending outpatient clinics in the Baltimore Metro Area during 2012 – 2013 (Poster).  
Johns Hopkins Bloomberg School of Public Health’s Delta Omega Poster 
Competition, Baltimore, MD. 
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5. Factors associated with HPV vaccine initiation among males aged 11-26 years 
attending outpatient clinics in the Baltimore Metro Area during 2012 – 2013 (Poster).  
AACR 2015 Annual Meeting, Philadelphia, PA.  
 
6. Helping youth live healthy lives with character: Assessing the effectiveness of a 
multifaceted program designed for the prevention of childhood obesity in Charlotte, 
North Carolina (Poster).  APHA 2015 Annual Meeting, Chicago, IL.  
 
7. Farm to Family Obesity Initiative: A comprehensive prevention program involving 
physical activity, nutrition education and a food access program in Louisville, KY 
(Presentation). APHA 2015 Annual Meeting, Chicago, IL.  
 
TEACHING AND MENTORING 
 
Lead Teaching Assistant 
Johns Hopkins School of Public Health 
 
2014-present  Principles of Epidemiology (340.601.01) 
   290 graduate students  
    
   Etiology, Prevention, and Control of Cancer (340.624.01) 
   20 graduate students 
 
Teaching Assistant 
Johns Hopkins School of Public Health 
  
2013-2014  Epidemiologic Methods 3 (340.753.01)  
60-75 graduate students (lab section) 
 
2013   Epidemiologic Methods 2 (340.752.01) 
60-75 graduate students (lab section) 
 
2013   Principles of Epidemiology (340.601.01) 
   25 graduate students (lead, lab section) 
 
Johns Hopkins University 
 
2013               Fundamentals of Epidemiology (280.350) 
   Grading TA 
 
Mentoring 
Johns Hopkins School of Public Health 
 
2013-2015                    Peer Mentor, Department of Epidemiology Public Health 
 
National Cancer Institute  
2010-2011    High school student intern 
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Professional Societies 
2014-present  American Association for Cancer Research 
   Women in Cancer Research 
   American Public Health Association 
	  
